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ABSTRACT
Brain energy metabolism is vital for many cellular processes including 
homeostasis and thus disturbances to metabolism can be the cause or 
consequence of neurodegeneration. Metabolic discrepancies have been 
hypothesized to be involved but less frequently demonstrated to be manipulated 
by acute and chronic neurodegenerative disorders such as stroke, traumatic 
brain injury, and epilepsy. I hypothesized that cerebral energy levels are 
decreased in my model systems for Alzheimer’s disease, Autism, Down 
syndrome, and HIV-1 dementia and that dietary treatments could enhance 
energy reserves and protect against neurodegenerative disease. For rodent 
studies, I utlilized a high-energy head focused microwave irradiation system to 
kill animals but most importantly to snap-inactivate all cerebral enzymes, 
including those that contribute to the rapid degradation of high-energy phosphate 
compounds. I found that energy levels are diminished in a high-cholesterol diet 
model for Alzheimer’s disease in rabbit, a trisomic mouse model for Down 
syndrome (Ts65Dn), and following administration of Tat to primary mouse 
cortical cultures as a model for HIV-1 dementia. My experiments also examined 
the extent to which protection is provided by creatine supplementation and the 
ketogenic diet in models of HIV-1 dementia and epilepsy, respectively. Creatine 
bioenergetically protected against Tat-induced decreases in cellular levels of 
ATP, Tat-induced mitochondrial hypopolarization, and Tat-induced
xvii
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mitochondrial permeability transition pore opening. My calorie restricted 
ketogenic diet studies demonstrated this diet’s ability to protect against 
chemically induced seizures. As well, I observed a coordinated upregulation of all 
differentially regulated transcripts encoding energy metabolism enzymes, 
increased numbers of mitochondrial profiles, and ultimately augmented high- 
energy phosphate levels in seizure na'ive rats. My studies demonstrate 
compromised brain energy levels in the aforementioned neurodegenerative 
disorders and that dietary treatments such as creatine supplementation for HIV-1 
dementia and the ketogenic diet for epilepsy, may protect cerebral function by 
enhancing neuroenergetics.
xviii




The brain uses a disproportionately large amount of energy for its size and 
it is of utmost importance that this organ is able to maintain its proper energy.
The brain uses approximately 20% of the body’s energy even though it only 
comprises approximately 2% of the body’s mass (Clarke & Sokoloff, 1999). The 
brain has a high priority for glucose. Energy is responsible for all the active 
processes that occur. For example, adenosine triphosphate (ATP) is used for 
transcription, translation, lipid production, and for channels and transport proteins 
(Clarke & Sokoloff, 1999). Large amounts of brain energy are needed to drive the 
Na+/K+ ATPase; transport proteins that exchange 2 extracellular K+ ions for 3 
intracellular Na+ ions. The NaVK+ ATPases are directly responsible for 
maintaining ion gradients across the plasma membrane in neurons and thus 
readying neurons for action potential generation.
Mitochondrial oxidative phosphorylation is regulated by three metabolites; 
adenosine diphosphate (ADP), O2, and nitric oxide (Wallace, 2001). The rate of 
ATP synthesis and that of respiration are set by cellular energy needs, which are 
represented by the concentration of cytosolic ADP or as phosphorylation 
potential ([ATP]/[ADP][Pi]), where the ratio of [ATP]/[ADP] is the fundamental 
component (Navarro & Boveris, 2007). ATP metabolizes to ADP and inorganic
iroduced with permission of the copyright owner. Further reproduction prohibited without permission.
phosphate (Pi), and these products increase when cellular energy demand is 
elevated, thus lowering the phosphorylation potential. Increased availability of 
ADP raises the rate of respiration and this regenerates ATP. The phosphorylation 
potential is finely regulated and only minimally fluctuates between tissues 
(Navarro & Boveris, 2007).
Mitochondria contribute approximately 90% of the required energy for 
cellular functions (Wallace, 1997) by two metabolic processes; the citric acid 
cycle (TCA; anaerobic) and the electron transport chain (ETC; aerobic). 
Bioenergetic homeostasis requires the production and deliverance of 
phosphoryls and nicotinamide adenine dinucleotide (NAD+) oxidizing power 
(Dzeja et al., 2000; Saks et al., 1994). During aerobic conditions, the majority of 
ATP generated by the oxidation of the glycolytic product pyruvate is used to 
maintain cellular homeostasis (Figure 1). Under anaerobic conditions, glycolysis 
results in lactate as the product. ATP generating systems, including glucose 
uptake, glycolysis, NADH, and fatty acid oxidation (Vannucci & Hawkins, 1983), 
are stimulated by an elevated ratio of AMP to ATP and thus activation of AMP- 
activated protein kinase (Carling, 2004; Hardie et al., 2003). However, this 
process is inadequate to satisfy all cellular energetic demands (Dzeja et al.,
2000) and therefore, other processes including adenylate kinase, creatine 
kinase, and glycolytic enzymes contribute to maintenance of ATP-generating and 
ATP-consuming processes (Dzeja & Terzic, 1998; Saks et al., 1994; Wallace, 
1999).
2
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glucose
acetaldehyde
Figure 1: Glycolysis. Glycolysis links the metabolism of sugars to that of organic 
acids in the Citric acid cycle. Glycolysis has three key functions: (1) to generate 
high-energy molecules such as ATP and NADH as energy sources for either 
aerobic or anaerobic respiration; (2) to produce pyruvate for the citric acid cycle; 
and (3 ) to produce various three and six carbon intermediate products that can 
be removed and utilized for other cellular purposes.
3
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Figure 2: The Citric Acid Cycle. Two carbons are oxidized to C02 and energy 
from these reactions is transferred to other metabolic processes by either GTP or 
ATP, and as electrons in ubiquinol (QH2) and nicotinamide adenine dinucleotide 
(NADH). The NADH generated in the citric acid cycle will donate its electrons in 
oxidative phosphorylation to drive ATP synthesis. Flavin adenine dinucleotide 
(FADH2) is covalently attached to succinate dehydrogenase, an enzyme 
functioning both in the citric acid cycle and the ETC in oxidative phosphorylation. 
FADH2 facilitates transfer of electrons to coenzyme Q, the final electron acceptor 
of the reaction.
Cerebral cells create most of their energy as ATP, through the 
mitochondrial ETC coupled to oxidative phosphorylation from the oxidation of 
NADH, a substrate for complex I, and FADH2, a substrate for complex II. NADH 
and FADH2 function as electron carriers by transferring glycolytic-derived 
electrons (Figure 1) and/or those resulting from the citric acid (TCA) or Kreb’s 
cycle (Figure 2) into the ETC (Figure 3) through NADH; ubiquinone
4
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oxidoreductase (complex I) and succinate:ubiquinone oxidoreductase (complex 
II). Ubiquinone:cytochrome c-oxidoreductase (complex III) couples the oxidation 
of ubiquinol to cytochrome c reduction (Rieske, 1976), whereas cytochrome 
c:oxygen oxidoreductase (complex IV) catalyzes the oxidation of cytochrome c, 
ultimately reducing molecular oxygen to water (Capaldi, 1990; Higgins & 
Greenamyre,1996). The course of redox cycling, releases potential energy that 
drives extrusion of protons across the inner mitochondrial membrane at 
complexes I, III, and IV. The generated electrochemical gradient from proton 
translocation powers ATP synthesis by the activity of FiF0 ATP synthase 
(Complex V; Love et al., 1999).
Mitochondrial Electron Transport Chain
Figure 3: The Electron Transport Chain. Enzymatic complexes couple a chemical 
reaction between an electron donor (such as NADH) and an electron acceptor 
(such as O2) to the transfer of H+ ions across a membrane, through a set of 
mediating biochemical reactions. These H+ ions generate an electrochemical 
gradient that drives ATP synthase and thus produces ATP.
5
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Glycogen represents the principal store of glucose equivalents in brain, 
with its equivalent concentration far exceeding physiological glucose 
concentration. Glycogen is essential for normal brain function, however its 
acceptance as a reserve has been discounted based on its low concentration 
compared to liver and muscle. This limited amount of glycogen, taken together 
with a metabolic rate of 1.4 pmol/g/min glucose in rodents, has led to an 
argument that 3 pmol/g of glycogen can merely sustain glycolysis for 10 min and 
therefore glycogen must not serve as a significant energy store (Siegel & 
Agranoff, 1999). However, there are indeed substantial brain glycogen levels, 
that are further elevated following hypoglycemia (Choi et al., 2003), sleep 
deprivation (Kong et al., 2002), and ischemia (Brucklacher et al., 2002). Brain 
glycogen is a significant store of glucose equivalents and can protect brain during 
episodes of diminished glucose or insult (Gruetter, 2003).
The basal rate of glucose utilization of astrocytes is higher than that 
observed for neurons (Magistretti & Pellerin, 1996). A metabolic 
compartmentation exists whereby astrocytic glucose is glycolytically metabolized 
to lactate, which is then released to the extracellular space to be utilized by 
neurons. Lactate can act as an energy source, i.e. sustain synaptic activity, 
through pyruvate by being enzymatically metabolized by lactate dehydrogenase 
(Bittar et al., 1996). Pyruvate is therefore an important energetic substrate that is 
distributed abundantly in brain synapses (Nicklas et al., 1971). Both lactate and 
pyruvate have limited permeability to the blood-brain barrier and thus cannot
6
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replace plasma glucose to maintain then normal function of brain (Pardridge & 
Oldendorf, 1977) however they remain useful metabolic substrates for neurons if 
formed inside brain parenchyma (Ide et al., 1969; Teller et al., 1977).
Glucose is the brain’s essential energy substrate (Edvinsson et al, 1993), but 
fatty acids are also used (Ebert et al., 2003). However, fatty acid oxidation is 
limited by the low activity of mitochondrial 3-ketoacyl-CoA thiolase (Yang et al., 
1987). As an alternative substrate, brain cells can metabolize ketones during 
fasting-induced reductions to blood glucose (Cahill, 1970; Greene et al., 2003). 
Ketone bodies are derived from hepatic fat metabolism and are transported into 
brain across the blood-brain barrier via monocarboxylic transporters (Koehler- 
Stec et al., 1998; Pellerin et al., 1998). The ketones consist of p-hydroxybutyrate, 
acetoacetate, and acetone and are important metabolites in our ketogenic diet 
studies described later.
Creatine (N-[aminoiminomethyl]-N-methyl glycine) is an amino acid that is 
produced endogenously (Figure 4) as well as being ingested in meat-based 
diets. Though creatine is not a direct brain energetic substrate, it does serve an 
intimate role for maintaining energy levels. Creatine is stored mainly in the 
muscle with the remainder found in brain, liver, kidneys and testes (Mujika & 
Padilla, 1997). In a typical western diet, approximately 1g of creatine is 
consumed per day from protein containing foods (Jacobs, 1999). Endogenous 
creatine is primarily produced from the amino acids arginine, glycine and 
methionine in liver, with a minor contribution from the kidneys, pancreas and 
testes. The average human body will synthesize approximately 1g of creatine per
7
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day. The kidneys excrete creatine in the form of creatinine at the rate of 
approximately 2 grams per day (Thorell et al., 1999).
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Figure 4: Creatine Biosynthesis. Endogenous formation of creatine occurs 
primarily in liver from arginine, glycine and methionine. Removal of creatine from 
the body results from nonenzymatic degradation to creatinine through glomerular 
filtration within kidneys.
Greater than 95% of creatine is stored in muscle where it appears to 
enhance muscle performance; however creatine can be taken up into brain 
where evidence suggests that it is neuroprotective (Sullivan et al., 2000). 
Transport of creatine across the blood brain barrier is limited as there is an 
absence of creatine transporter expression on astrocytes in contact with capillary
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endothelial cells. The brain relies instead on de novo synthesis of creatine 
(Figure 4; Braissant et al., 2001).
Creatine enters target tissue cells via sodium dependent transport through 
creatine transporters (CreaT; Snow & Murphy, 2001) that are down-regulated in 
some myopathies (Persky & Brazeau, 2001). CreaT regulates tissue levels in 
response to low dietary intake or high endogenous creatine levels (Guerrero- 
Ontiveros & Wallimann, 1998). Reverse enzymatic phosphorylation of creatine by 
mitochondrial creatine kinase, in the presence of ATP, thereby forms 
phosphocreatine (creatine phosphate) and ADP in the mitochondrial 
intermembrane space. Phosphocreatine is then transported into the cytosol 
where creatine kinase can enzymatically catalyze high-energy phosphate 
donation from phosphocreatine to ADP and thus yield the products creatine and 
ATP (Greenhaff et al., 1994). This process in which creatine accepts and 
donates a high-energy phosphate to ATP is termed the creatine-phosphocreatine 
energy shuttle (Figure 5). This mechanism permits phosphocreatine to act as a 
cytosolic energy store.
9
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ATPas* AMPK
Figure 5: Creatine-Phosphocreatine Energy Shuttle. Creatine enters the cell 
through its plasma membrane transporter and passes into mitochondria via the 
outer mitochondrial membrane creatine transporter. Mitochondrial creatine 
kinase reversibly phosphorylates creatine in the presence of adenosine 
triphosphate (ATP) thus forming phosphocreatine. Phosphocreatine, after leaving 
a mitochondrion, donates a high-energy phosphate group to adenosine 
diphosphate (ADP) by cytosolic creatine kinase to form ATP and creatine.
The creatine-phosphocreatine energy shuttle and adenylate kinase 
systems facilitate processes in the brain that would otherwise depend entirely on 
the diffusion of ATP and ADP. Creatine kinase is a major phosphotransfer 
system in cells specifically located at places of energy metabolism (Wallimann et 
al., 1992) and acts in concert with other enzymatic systems to facilitate
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intracellular energetic communication (Dzeja & Terzic, 2003; Joubert et al., 2002; 
Neumann et al., 2003) and enhancement of cytoplasmic high-energy phosphates 
(Brustovetsky et al., 2001). Due to its location at the adenine nucleotide 
transporter on the mitochondrial membrane, intramitochondrial ATP is released 
from mitochondria by interconversion to phosphocreatine (Schlattner et al.,
2006). Phosphocreatine has an important role in protection from heart attacks 
(Saks et al., 2006) and as a result of creatine treatment for brain insult (e.g. 
traumatic brain injury (Sullivan et al., 2000), and other acute and chronic 
neurological disorders (Klein & Ferrante, 2007). Both mitochondrial and cytosolic 
creatine kinase isozymes are active in brain cells with high and variable ATP 
metabolic rates (Holtzman et al., 1997). The importance of phosphocreatine to 
energetic homeostasis is indicated by promotion of hypoxic seizures (Holtzman 
et al., 1999).
Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
characterized primarily by deteriorating cognitive function with memory loss, 
reduced self-care, behavioral and psychological symptoms, and emotional 
troubles (Mimura, 2008). The most vulnerable regions of brain in AD include the 
basal forebrain, amygdale, hippocampus, cerebral cortex, and discrete brain 
stem nuclei (Auld et al., 2002; Selkoe, 2001). For the most part, AD cases are 
sporadic without known genetic linkage, however approximately 5% of cases are 
caused by known genetic abnormalities. There have been many documented 
pathogenic pathways that lead to neurodegeneration observed in AD patients;
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these include accumulation of misfolded proteins, excitotoxic reactions, oxidative 
stress, mitochondrial injury, ubiquitin-proteasome system dysfunction, synaptic 
failure, altered metal homeostasis, dysfunction of axonal and dendritic transport, 
and misoperation of chaperones (Cacabelos et al., 2005; Kayed et al., 2003).
The hallmark pathologies of disease for both sporadic and genetic (familial) AD 
are the presence of extracellular neuritic plaques containing amyloid-p (AP) 
peptide, intracellular neurofibrillary tangles consisting of hyperphosphorylated 
microtubule associated protein (Tau), and loss of specific cerebral synapses. Ap 
plaque deposition is composed of a 39- to 42-amino acid peptide, the proteolytic 
product of the amyloid precursor protein (APR; Miller et al., 1993). The underlying 
root for selective neuronal loss is unknown, however evidence suggests that Ap 
accumulation may initiate and / or advance neurodegeneration in brain 
(Clippingdale et al., 2001; Yankner, 1996). Fernandez-Vizarra and colleagues 
(2004) hypothesized that Ap may be inhibiting mitochondrial function and thus 
contributing to bioenergetic failure. A loss of mitochondrial metabolism regulation, 
combined with plausible oxidative abnormalities, may be an underlying link to the 
known pathological events (Zhu et al., 2004c).
Brain hypoperfusion and heart disease are two important risk factors that 
have been linked to AD (de la Torre, 2006). Evidence from an assortment of 
clinical and basic studies (Alves & Busatto, 2006; Breteler, 2000; Korf et al.,
2004) have suggested that AD is a vasocognopathy (a vascular-related, cognitive 
disorder; de la Torre, 2004). Hypoperfusion-induced oxidative stress contributes 
to the pathogenesis of AD (de la Torre, 2002; de la Torre, 1997). AD patients
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also collect a larger fraction of oxygen from the vasculature (Fukuyama et al., 
1994; Hoyer, 1993; Galle et al., 1995). It is possible that low cerebrovascular 
blood flow could be one of the chief initiating factors of mitochondrial 
abnormalities during AD progression (Risberg, 1980). De la Torre (2000) 
predicted that aging in the presence of a comorbid condition, such as a vascular 
risk factor, promotes a critically attained threshold of chronic cerebral 
hypoperfusion and over time induces degeneration of brain capillaries and 
hindered delivery of energy substrates to neurons (de la Torre, 2000).
Diminished metabolism occurs with age in frontal areas, temporal and 
parietal cortices, as measured by high-resolution positron emission tomography 
(PET) Loessner et al., 1995). Impaired cerebral energy metabolism can facilitate 
neuronal damage or the deleterious effects of some excitotoxic agents such as 
glutamate (Schinder et al., 1996). The most direct evidence of abnormal 
metabolism was demonstrated from in vivo PET (Benson et al., 1983;
Frackowiak et al., 1981; Rhee, 1999) and diagnosis of AD using PET are roughly 
equivalent to those using diagnostic criteria. Decreases in the metabolic rate for 
glucose in cortex have been demonstrated (Vander Borght et al., 1997) appear 
early in the disease, perhaps even earlier than the onset of clinical symptoms in 
some patients (Kennedy et al., 1995; Small et al., 2000), and increase in 
magnitude as AD becomes more severe (Smith et al., 1992).
Since brain cells thrive on glucose as a principal fuel, its impaired delivery 
and poor delivery of oxygen compromises neuronal stability as aerobic glycolysis’ 
supply does not adequately satisfy the brain's requirements. Most importantly,
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cerebral metabolic rate abnormalities precede evidence for functional impairment 
by neuropsychological testing or of brain atrophy by neuroimaging (Baloyannis et 
al., 2004). Metabolic derangements comparable to those observed in AD, such 
as hypoxia, hypoglycemia, vitamin deficiency, are sufficient to provoke mental 
and neurological deficits as is evident in neuropsychiatric disorders associated 
with oxidative metabolism abnormalities (Blass & Gibson, 1999). Overall, chronic 
cerebral hypoperfusion is a metabolic cascade involving mitochondrial 
dysfunction, elevated oxidative stress, and diminished production of ATP and 
phosphocreatine (Pettegrew et al., 1994) that likely contributes to the progressive 
cognitive decline characteristic of AD. Chronic cerebral hypoperfusion also 
results in anatomic pathology common to AD, such as synaptic loss, senile 
plaques, and neurofibrillary tangles.
Since impaired energy metabolism greatly precedes clinical symptoms 
and oxidative stress is one of the initial features of the disease (Nunomura et al., 
2000; Nunomura et al., 2001), it is likely that mitochondria play a critical role in 
the pathogenesis of the disease. Mitochondria, the powerhouses of the cell, are 
located within dendrites, axons and synaptic terminals and generate ATP, 
oxidizing power, and calcium buffering (Mattson & Liu, 2003). These subcellular 
regions have greater metabolic demands from mitochondria, compared to other 
subcellular neuronal regions, and therefore are endowed with superior oxidative 
and calcium burdens. Indirect evidence for this enhanced burden can be 
extrapolated from the location of early neurodegeneration in AD, the synapse 
(Coleman et al., 2004). For example, synapses are missing within dense A(B
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cores of classic senile plaques (Lassmann et al., 1993) and synapse 
degeneration correlates strongly with cognitive decline (DeKosky et al., 1996). 
Synaptic compartments have high concentrations of glutamate receptors and 
calcium channels. Following depolarization with calcium influx there is increased 
oxidative stress and ATP demand, and possible apoptosis (Bergles & Jahr, 1998; 
Guo, 1999). Considerable evidence suggesting that synapses are primary sites 
of calcium deregulation in AD (LaFerla, 2002). As well, apoptosis has been 
demonstrated to occur in vulnerable AD neuronal populations and may be 
activated locally in synaptic compartments following exposure to A(3 (Mattson et 
al., 1998). Synaptic loss associated with downstream processes may elicit 
neurodegeneration through reduction in metabolic activity, regional cerebral 
blood flow (Liu et al., 1999), and activation of microglia (Ji et al., 2001).
The most dependable defect in mitochondrial components in AD has been 
a deficit in key enzymes of oxidative metabolism, including alpha-ketoglutarate 
dehydrogenase complex and pyruvate dehydrogenase complex, two enzymes in 
the rate-limiting step of the tricarboxylic acid cycle, and cytochrome oxidase, 
complex IV of the mitochondrial respiratory chain that reduces molecular oxygen 
to water (Cottrell et al., 2001; Gibson et al., 1998). Reductions in alpha- 
ketoglutarate dehydrogenase complex activity correlates much better to the 
extent of dementia than can senile plaques and neurofibrillary tangles in the 
brains of ApoE4-positive AD patients (Gibson et al., 2000). Upon reductions to 
enzymatic activity there is a substantial increase in aberrant production of 
reactive oxygen species and this has been demonstrated in mitochondrial DNA
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isolated from AD (Coskun et al., 2004; Hirai et al., 2001; Mecocci et al., 1993; 
Mecocci et al., 1994).
Changes to mitochondrial function are well documented in AD and can 
have a significant impact on neurons. Recently, Liang and colleagues (2008) 
performed analyses of nuclear genes influencing mitochondrial energy 
metabolism and demonstrated that they have a significantly lowered expression 
in AD brain. The majority of these nuclear genes encode electron transport chain 
subunits while the remaining examined genes encode mitochondrial translocases 
that are responsible for the entry of electron transport chain subunits into 
mitochondria. The largest percentage of underexpressed genes was found in the 
posterior cingulate cortex, where up to 70% of genes were underexpressed, this 
region has been shown to be metabolically affected in the earliest stages of AD 
(Liang et al., 2008). The regional underexpression of genes encoding ETC 
subunits correspond to the regional pattern of cerebral metabolic rate of glucose 
reductions observed in PET studies of AD patients (Mielke et al., 1994; 
Minoshima et al., 1994; Minoshima et al., 1997; Pietrini et al., 1993; Smith et al., 
1992)
Findings of abnormal brain energy metabolism in AD patients have come 
from imaging studies laregely of patients with the sporadic form of the disease. 
However, there exist alternative strategies to help elucidate these metabolic 
changes. For example, direct biochemical measurements from animal models 
may better define disease etiology. Cholesterol has been suggested to be a risk 
factor for AD (Pappolla et al., 2003; Wolozin 2004) and has been demonstrated
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in both animal (Refolo et al., 2000; Sparks et al., 1994) and cellular (Racchi et al., 
1997) models to promote production of A[3, a major pathological hallmark of AD. 
Examination of brain energy levels in this AD model system may provide better 
insight into the universality of altered energetics in AD and our work was aimed 
to determine whether changes in brain bioenergetics was associated with this 
disease.
Autism
Autism is a syndrome of early childhood characterized by abnormal social 
relationships, language, impaired understanding, echolalia, and pronominal 
reversal. Individuals with autism may perform ritual and compulsive behaviors 
and typically display an uneven intellectual development (State et al., 2000). 
Affecting approximately 1 in 2000 individuals (Wassink & Piven, 2000), the 
syndrome emerges prior to three years of age and affects approximately three 
times more boys than girls. However, girls with the disorder are often more 
severely affected (Wassink & Piven, 2000). Extreme environmental deprivation is 
one means to cause an autism-like syndrome however the relatively constant 
rate of occurrence across cultures suggests a strong biological component. A 
biological factor has been demonstrated by family studies (Wassink & Piven, 
2000). The recurrence rate among siblings of an affected proband is 
approximately 5% and therefore the risk for siblings is 100-200 times higher than 
that for the general population. The concordance of between monozygotic and 
dizygotic twins is 60% versus 0% in the general population. These findings taken 
together argue for a strong genetic component to autism. Unfortunately, of the
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three large genome-wide scans of autism groups none were successful in 
identifing a significant linkage.
It is generally agreed that there is a large genetic component to autism 
however no single gene has been found to be responsible; although 
chromosomal regions possibly containing susceptibility genes have been 
identified and account for approximately 10-20% of cases. However, no single 
identified cause accounts for greater than 1-2% of cases. Regardless of this 
heterogeneity, hypotheses have been generated to link genetic changes with 
altered biological function, including faulty synaptic function, irregular brain 
connectivity (Geschwind & Levitt, 2007), changes to mitochondrial reactive 
oxygen species and the purine synthetic pathway (Spiegel et al., 2006). Several 
parallel approaches are essential to progress our understanding of the genetic 
factors causal of the ASDs. These approaches comprise whole-genome and 
pathway-based association experiments, dense resequencing to discover 
mutations, and sustained gathering of large well characterized patient cohorts 
and their relatives for genotype-phenotype studies (Abrahams & Geschwind, 
2008). One genetic disease, adenylosuccinate lyase (ADSL) deficiency, causes a 
syndrome of profound developmental delay wherein approximately 30% of those 
affected develop autistic features (Jaeken & Van den Berghe, 1984). Over 20 
different genetic mutations causing ADSL deficiency are recognized while little is 
known about how this deficiency leads to the syndrome. In fact, this is not an 
isolated example of disruption to the purine synthetic pathway as defects are
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known to cause other neurodevelopmental abnormalities, including Lesch-Nyhan 
syndrome (Baumeister & Frye, 1985).
If there is a biological component to autism then one would expect there to 
be a biochemical correlate and indeed there is; approximately 20 to 30% of 
individuals have significantly elevated levels of the end product of purine 
metabolism in humans, uric acid, as well as significant increases in de novo 
purine synthesis (Page, 2000; Page & Coleman, 2000). These or other purine 
synthesis abnormalities may be important for the development of autistic 
features. Specifically, fault in the purine biosynthetic pathway, the enzyme ADSL, 
has been associated with a high incidence of autistic features (Jaeken et al., 
1984).
An infantile autistic syndrome has been described that is characterized by 
the presence of succinylpurines in bodily fluids (Jaeken & Van den Berghe,
1984). These findings are likely attributable to significantly reduced activity of 
ADSL in liver and its absence in kidney from one patient. This enzyme is 
responsible for both the eighth step of de novo purine biosynthesis as well as the 
second step of conversion from IMP to AMP (Figure 6). Both reactions involve 
the release of a fumarate molecule from the succinylpurine substrate, in the first 
case from phosphoribosylsuccinylaminoimidazole carboxamide (SAICAR) and in 
the second case from adenylosuccinate . As a result of the deficiency in ADSL, 
the nucleoside derivatives of the precursor compounds SAICA and succinyl- 
adenosine accumulate in the bodily fluids, including cerebrospinal fluid, of 
affected individuals.
19








Figure 6: Pathways of Purine Metabolism. The first 7 steps of the de novo 
synthetic pathway are represented by a broken line. The ADSL defect is 
indicated by solid bars. PRPP, phosphoribosyl pyrophosphate; SAICAR, 
succinylaminoimidazolecarboxamide ribotide; AICAR, 
aminoimidazolecarboxamide ribotide; IMP, inosine monophosphate; S-AMP, 
adenylosuccinate; S-Ado, succinyladenosine; XMP, xanthosine monophosphate. 
1, adenylosuccinate lyase; 2, adenylosuccinate synthetase; 3, AMP deaminase; 
4, cytosolic 5'-nucleotidase; 5, adenosine deaminase; 6, purine nucleoside 
phosphorylase; 7, xanthine oxidase; 8, hypoxanthine-guanine 
phosphoribosyltransferase; 9, adenine phosphoribosyltransferase.
Mutations in ADSL are single base pair substitutions that translate into 
changed ADSL protein (Baron-Cohen et al., 2000; Kmoch et al., 2000; Marie et 
al., 1999; Valik et al., 1997; van den Berghe et al., 1998). In 1999, Kohler et al., 
reported a patient with a single base substitution that had especially severe 
autism together with severe early infantile epileptic encephalopathy amid 
reduced myelination (Kohler et al., 1999). There have not been any reported
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cases where enzymatic activity is completely missing; all affected individuals 
have been compound heterozygotes (Van den Berghe et al., 1993a).
Our collaborator, Dr. David Patterson, and his group mapped the gene 
encoding ADSL to human chromosome 22, a location that was later confirmed by 
the DNA sequence of this chromosome (Dunham et al., 1999; Van Keuren et al., 
1987). The ADSL gene and cDNA have been cloned as well as their structures 
determined (Kmoch et al., 2000). The mouse gene has also been cloned and 
characterized and is located on mouse chromosome 15 (Wong & O'Brien, 1995). 
The clinical presentation of ADSL deficiencies is quite varied, but commonly 
includes severe psychomotor delay, epileptic seizures, and autism features 
(Jaeken et al., 1984; Kohler et al., 1999; Maaswinkel-Mooij et al., 1997; Race et 
al., 2000; Valik et al., 1997; Van den Berghe et al., 1998). Other characteristics 
noted include profound hypotonia, atypical brain glucose utilization, and muscle 
energy metabolism malfunction (Salerno et al., 1997; Salerno et al., 1999; Valik 
et al., 1997). Some individuals with mutations to ADSL are only mildly 
developmentally delayed.
Residual ADSL activity is observed to some extent in tissues of ADSL- 
deficient individuals (Kmoch et al., 2000; Marie et al., 1999; Van Den Bergh et 
al., 1993b). However, the severity of clinical features manifest by these mutations 
does not correlate well with decreased purine levels and altered patterns of 
purine metabolism and stability. Because of this, researchers have divided the 
disorder into two groups; ADSL type I & II. For ADSL type I, individuals are 
severely affected and contain a ratio of S-ado/SAICA of roughly 1:1 in bodily
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fluids. Whereas for ADSL type II, the ratio spans from four to five to one (Van 
Den Berge et al., 1993) and individuals are not severely affected. It is possible 
that it is not the lack of purines that leads to this pathology, but rather an 
accumulation of SAICA, the precursor to SAICAR. Some investigators have 
proposed that accumulation of S-ado may even be protective (Van Den Bergh, 
1993b) against the damaging effects of SAICA (Stone et al., 1998).
Approximately 30% of individuals with autism appear to have elevated 
serum levels of urate. This increase is associated with greater rates of de novo 
purine biosynthesis in fibroblasts originating from these individuals (Page & 
Coleman, 2000). This condition, hyperuricemia, has an incidence of 
approximately 5 to 8% among adult American males and appears to have no 
clinical significance for these individuals (Becker & Roessler, 1995). Thus, 30% 
of individuals with autism having elevated de novo purine synthesis are strongly 
suggestive of a relationship between the purine biosynthetic pathway and autism. 
A large percentage of individuals with autism have elevated serum urate and 
many have an elevated auditory startle response (Page & Coleman, 2000). For 
these individuals with hyperuricosuric autism, a low purine diet has been reported 
to improve symptoms (Page, 2000).
ADSL also contributes to the purine nucleotide cycle with AMP deaminase 
and adenylosuccinate synthetase by controlling the levels of fumarate and free 
AMP, which influences the concentration of ATP (Van den Berghe et al., 1992). 
Furthermore in muscle, the purine nucleotide cycle is essential to preserve the 
ratio of ATP/AMP (Van den Berghe et al., 1992). An ADSL deficient patient has
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been reported with impaired energy metabolism and a low energy reserve in 
muscle. This patient’s ATP levels were rapidly depleted from mild exercise 
(Salerno et al., 1997). Thus, ADSL deficiency may contribute to muscle wasting 
and growth retardation observed in some patients.
In a 1999 study by Kent and colleagues, the comorbidity of autism 
spectrum disorders and Down syndrome (DS or trisomy 21) was calculated (Kent 
et al., 1999). A comorbidity rate of at least 7% was determined, meaning that 
individuals with DS are at least 100-times more likely to have autism than 
persons without DS. Remarkably, people with DS have increased serum urate 
levels (Pant et al., 1968). Dr. Patterson’s group has produced transgenic mice 
that express the human GART gene (steps 2, 3, 5 of Figure 6) that resides on 
human chromosome 21 (Daubner et al., 1985), and these mice do have elevated 
auditory startle responses (Page & Coleman, 2000). Koch & Schnitzler (1997) 
predicted on the basis of increased purine production. Thus, abnormalities in the 
purine pathway may influence auditory startle response systems.
Animal models of chemically-induced autism have been generated, for 
example, by treating rats with ibotenic acid or with valproic acid during gestation 
in an attempt to mimic the prenatal teratogenic effects generated by compounds 
such as thalidomide (Ingram et al., 2000; Rodier et al., 1997; Wolterink et al., 
2001). These animals have neuronal abnormalities in the amygdale and/or 
cerebellum and in cranial nerve motor nuclei associated with autism (Ingram et 
al., 2000; Rodier et al., 1997; Wolterink et al., 2001). A major focus among
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researchers continues to be generating transgenic mouse models of autism that 
compare favorably with rodent models generated through chemical treatment.
Down Syndrome
Down syndrome (DS), or trisomy 21, is the most common genetic cause of 
cognitive disability, affecting approximately 1 in every 1000 births (Collins et al., 
2002). DS can be detected prenatally, through a tri- or quad-screening or a 
maternal blood screening test, and the incidence of the syndrome is increasing 
(Alexander, 2000). The most pervasive and considerable characteristic of DS is 
cognitive impairment as it not only encompasses lifelong cognitive impairment, 
but also a cognitive decline with age. The life expectancy of persons with DS 
continues to increase and this increases the significance of cognitive decline for 
these individuals.
Improving the cognitive abilities of persons with DS would provide a major 
benefit to persons with DS, their families, and society as a whole. The IQ for 
people with DS ranges from 30 to 70, with an average of 50 (Chapman &
Hesketh, 2000). The American Association of Mental Retardation (AAMR) 
regards individuals with an IQ less than 70 as having mental retardation. 
Therefore an improvement of 20 IQ points would imply that the average IQ of 
people with DS would be close to normal. An improvement of 20 points was 
obtained for persons home-reared rather than institutionalized (Wishart, 1995).
The predominance of experimental and clinical support suggests that DS 
results from altered expression of several genes. Chromosome analyses 
occasionally reveal that only a segment of human chromosome 21 (HSA21) is
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trisomic for some individuals, and these findings led to attempts to identify a 
small region of the chromosome responsible for DS (Delabar et al., 1993; 
Korenberg et al., 1994). This strategy has some success as some aspects of DS 
have been regionally mapped (Barlow et al., 2001); however regional mapping of 
the cognitive phenotype of the syndrome has not been successful (Shapiro,
1999). To date, about 430 genes have been identified on HSA21 with about 45% 
of these genes having an unknown function (Kahlem, 2006). The sequence of 
HSA21 has exposed the complexity of genome structure and in gene regulation 
that will have profound implications for understanding genotype/ phenotype 
relationships. The trisomic region reaches from Mrp139 to Znf295 and contains 
approximately 136 genes that are orthologous to genes on HSA21. Partial 
trisomy 21 often manifests a mild to moderate DS phenotype (Habedank & 
Rodewald, 1982; Miyazaki et al., 1987). These observations indicate that there 
are genes in particular regions of chromosome 21 that are not trisomic in the mild 
or moderate cases of DS. Partial trisomy also suggests that there are genes in 
the trisomic region that lead to a clinical diagnosis of DS for the individual. Mice 
have been developed with segmental trisomies that offer a similar situation to the 
human condition. Three trisomic mouse lines exists, including Ts65Dn, TsICje, 
and Ms1Ts65 and all three lines have trisomy to different regions of chromosome 
16 (equivalent to human chromosome 21).
All three trisomic mouse lines have cognitive and behavioral impairment 
(Sago et al., 2000), although the phenotypes vary between lines. The Ts65Dn 
mice have a trisomic region that is the summation of the TsICje and Ms1Ts65.
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Notably, the Ts65Dn mouse does not have all of the cognitive features of DS and 
this signifies that there are genes essential for cognition on chromosome 21 that 
are not trisomic in the Ts65Dn mouse. The Ts65Dn mouse is the most robust 
and commonly used model for DS. These mice contain an additional 
chromosome, spanning most of the region of MMU16 that is homologous to 
HSA21, translocated to a MMU17 centromere. This model system has several 
physical, behavioral, and neurological features observed in persons with DS. 
These features include craniofacial dysmorphogenesis, loss of age-related 
cholinergic markers in the basal forebrain, and prominent learning and memory 
deficits (Cataldo et al., 2003; Holtzman et al., 1996; Hyde et al., 2001; Olson et 
al., 2004; Reeves et al., 1995).
Mice have also been developed to be transgenic for a single gene on 
chromosome. For example, mice transgenic for DyrklA (Altafaj et al., 2001;
Smith & Rubin, 1997) Sim2 (Ema et al., 1999; Chrast et al., 2000), SOD1 
(Avraham et al., 1988; Rando et al., 1998), APP (Cairns, 2001; Koistinaho et al., 
2001), and S100beta (Wincour et al., 2001) all demonstrate neurocognitive 
abnormalities. These genes map to different locations on chromosome 21, 
however none of these alone cause all of the features linked with DS. Thus, 
results argue that a different approach may be more advantageous. We 
hypothesized that examining consequences of the trisomy, involving numerous 
genes (not all on chromosome 21), may explain the neurocognitive impairments 
observed in DS 21 and this argues against any individual gene causing DS. The 
effects of modifying gene expression, protein levels, or even enzyme activities
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should have quantifiable metabolic, anatomic, and/or physiological 
consequences if the change affects cognitive ability.
Depending on tissue or cell type, the expression of single HSA21 genes 
appeared to be different (Li et al., 2006). This situation is present in the Ts65Dn 
mouse model of DS where expression of GABPA protein is prominent only in 
brain and skeletal muscle (O’Leary et al., 2004). It is important to determine 
HSA21 gene expression levels, the tissues that specific genes are expressed in 
and at what developmental stage expression occurs as functions of homologous 
genes are not identical in mice and humans and even their regulation can differ 
between the two species. An example is folate/one-carbon/trans-sulfuration; the 
tissue specificity of expression of critical genes in this biological system is 
different in mice and in humans (Whetstine et al., 2002; Liu et al., 2005; Butler et 
al., 2006) and may mean that these pathways provide somewhat different 
functions in humans and mice. The purine metabolic pathway is another example 
of gene differences between the species. The end product of purine catabolism 
in humans is urate, whereas mice metabolize urate to allantoin. Pant and 
colleagues (1968) observed dramatically increased urate levels in AD patients 
(Pant et al., 1968). In particular the GART (phosphoribosylglycineamide 
transformylase) gene is on HSA21, and trisomy of this gene may be guilty of 
causing excessive urate accumulation in people with DS (Brodsky et al., 1997). 
Therefore, data arising from mouse studies have to ultimately be confirmed for 
their significance to humans.
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According to gene dosage in DS, many genes are expressed at high 
levels ; yet tissue and temporal specificity has been observed (Antonarakis & 
Epstein, 2006; Butler et at., 2006; Li et al., 2006; O’Leary et al., 2004; Rachidi et 
al., 2005; Reymond et al., 2002b; Roper & Reeves, 2006). Overexpression of a 
gene may have varying consequences depending on an individual’s 
developmental stage. For instance, overexpression of a particular gene may 
cause developmental abnormalities at a particular stage of development while 
the same gene’s overexpression at another developmental stage could 
compensate for developmental irregularities that are associated with the 
syndrome (Head et al., 2007). It is possible that a gene’s overexpression may 
only occur at a specific timepoint and to specific cells or tissues yet still manifest 
a permanent phenotypic effect. Conversely, there may also be genes that require 
continual overexpression to preserve their phenotypic effect (Patterson, 2007).
Trisomy of particular genes may generate functional consequences 
through alterations to protein levels in cells. For instance, many proteins interact 
with other proteins in their immediate environment, such as enzymes. Enzymes 
are highly regulated proteins through events such as phosphorylation and 
endproduct inhibition among other mechanisms. Thus, increased levels of an 
enzyme may not correctly reveal the same increases to enzyme activity and 
therefore may not predict disturbed metabolism (Cornish-Bowden & Cardenas,
2000).
The majority of genes on chromosome 21 contribute to either metabolic or 
developmental pathways, and this increases the difficulty in predicting how
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altering expression of one gene in a multi-step pathway will ultimately affect the 
whole pathway. For example mitochondrial reactive oxygen species pathways, 
many genes are located on chromosome 21 that are vital for the pathways 
(Hattori et al., 2000; see table 6 in the Appendices). All 18 genes listed in Table 6 
are expressed in mouse with the first 14 being trisomic in the Ts65Dn mouse 
(Akeson et al., 2001; Gardiner et al., 2002; Gitton et al., 2002; Reymond et al., 
2002a; Reymond et al., 2002b). Because the enzymes themselves are subject to 
biochemical or metabolic regulation, this complicates the extraction of definite 
conclusions based solely on increased gene or protein expression. It is widely 
hypothesized that mitochondrial reactive oxygen species and one-carbon 
metabolism play a role in many cognitive disabilities and neurodegenerative 
diseases including DS. Preliminary findings by our collaborator, Dr. David 
Patterson as well as by others, demonstrate that similar to persons with DS 
having trouble performing tasks that involves hippocampal function (Pennington 
et al., 2003) Ts65Dn mice exhibit deficits in hippocampal tasks (Hyde et al.,
2001; Hyde & Cynic, 2001; Granholm et al., 2000). The observed deficits entail 
both failure of appropriate development of the brain as well as age-related loss of 
functional cholinergic neurons of the basal forebrain, reminiscent of what occurs 
in persons with DS (Granholm et al., 2000), and this cognitive loss can be 
reversed in old Ts65Dn mice (Granholm et al., 2002).
Mitochondrial oxidative phosphorylation is accountable for the majority of 
ATP generation in cells as well as production of the bulk of reactive oxygen 
species (Halliwell & Gutteridge, 1985; Wallace, 2001). The collapse of the
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mitochondrial transmembrane potential can initiate apoptosis. Mitochondrial 
energy metabolism is carried out by five multienzyme complexes and mutations 
in several of the mitochondrial reactive oxygen species genes lead to human 
disorders, including mental retardation, developmental abnormalities, and 
neuromuscular and neurodegenerative disorders (Wallace, 2001). Altered 
mitochondrial function and reactive oxygen species metabolism have been 
hypothesized to play a significant role in DS, Alzheimer disease, other 
neurodegenerative diseases, and aging (Busciglio et al., 2002; Butterfield et al., 
2002; Capone et al., 2002; Cecchi et al., 2002; Floyd & Hensley, 2002; lannello 
et al., 1999; Prince et al., 1994; Rao & Balachandran, 2002; Schon et al., 2000). 
For example in DS and AD there are decreased levels of Complex I subunits, 
Complex III core protein 1, and Complex V subunits (Kim et al., 2000; Kim et al.,
2001). Abnormal expression of these genes may affect the stoichiometry of these 
complexes and could result in diminished function or stability. These changes 
could lead to impaired energy metabolism in DS and could also promote 
generation of reactive oxygen species and therefore enhance neuronal cell 
death. Another well-known gene on chromosome 21 is amyloid precursor protein 
(APP). Trisomy of APP may elicit mitochondrial dysfunction in DS (Busciglio et 
al., 2002) and thus provides a link between AD and DS. Defective mitochondrial 
energy metabolism is consistent with the finding that individuals with DS have a 
low resting metabolic rate (Roizen & Patterson, 2003) with an elevated threat for 
obesity (Luke et al., 1996; Prasher, 1995).
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The GART gene, trisomic in the Ts65Dn mouse, encodes a trifunctional 
protein carrying out steps 2 (GARS), 3 (GART), and 5 (AIRS) of de novo purine 
synthesis (see figure 6). These three activities are performed by distinct domains 
of the protein ordered GARS-AIRS-GART from the N-terminal end. In DS 
cerebellum, the production of the petite GARS protein declines slower than the 
entire GARS-AIRS-GART protein (Brodsky et al., 1997). Though the function of 
the small GARS protein is unknown we hypothesize that it may contribute to the 
regulation of purine synthesis. Therefore, intron 11 was deleted from the GART 
P1 clone, P8E5, via the method of Yu et al (2000) as customized by 
Swaminathan et al (2001) and Lee et al (2001) to produce a GART gene that can 
solely fabricate the GARS-AIRS-GART protein but not the single GARS protein. 
Since GART gene overexpression affects the de novo purine synthesis pathway, 
it is likely to have effects on both DS and autism and could possibly be a link 
between the high comorbidity between the disorders.
Mitochondria have gained attention in aging biology due to their vital role 
in generating ATP to satisfy cellular energy demands. Aging leads to a decline in 
basal metabolic rate and to physical performance in energy-requiring tasks 
(McCarter, 1995). Mitochondrial function is impaired with age and may 
encompass slower rates of electron transfer, increased inner membrane H+ 
permeability, and H+-driven ATP synthesis impairment (Navarro & Boveris,
2007). An underlying concept for the mitochondrial hypothesis of aging is that 
oxidative damage accumulates in the organs and tissues of aged animals as 
mitochondrial ATP production declines. This age-dependent diminished capacity
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to generate ATP is not due to a reduced mitochondrial mass in brain nor to the 
phosphorylating capacity of ATP synthase (Navarro et al., 2004; Navarro et al., 
2005; Navarro & Boveris, 2004) but this mitochondrial dysfunction has been 
attributed to abnormal electron transfer (Navarro et al., 2002; Navarro et al.,
2004; Navarro et al., 2005; Navarro & Boveris, 2004). Upon further investigation, 
Navarro & Boveris demonstrated that the activities of mitochondrial complexes I 
and IV decrease by approximately 30% with age and are therefore effective 
markers of aging (Navarro & Boveris, 2007). Diminished complex I activity 
predisposes to excitotoxicity by changing levels of ATP and by altering calcium 
homeostasis (Dauer & Przedborski, 2003). Reductions to the levels of ATP 
negatively affect the activity of plasma membrane Na+/K+-ATPase, resulting in 
partial neuronal depolarization. Under these circumstances, even physiological 
levels of extracellular glutamate can cause excitotoxicity through the activation of 
N-methyl-D-aspartate (NMDA) receptors and elevations to intracellular calcium, 
and complex I defects disturb normal calcium signaling in neurons (Giasson & 
Lee, 2003). Even under ideal conditions mitochondrial electron transfer is not 
perfect; some electrons escape from the ETC and subsequently interact with 
oxygen to produce superoxide anion among other reactive oxygen-nitrogen 
species. This electron leakage increases significantly upon mitochondrial 
dysfunction as a function of age.
Individuals with DS have a lifelong cognitive impairment that worsens with 
age. Biochemical studies are difficult, if not impossible, to perform on these 
individuals but we do have transgenic animal models in which to perform these
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studies, namely Ts65Dn mice and GART overexpressing mice. We hypothesize 
that the features of DS are partially due to changes to de novo purine synthesis 
resulting from mitochondrial dysfunction that result in decreased brain energy 
levels in these animals and likely the human population.
HIV-1 Dementia
Human immunodeficiency virus type 1 (HIV-1) infection can lead to HIV-1 
associated dementia characterized clinically by memory loss, and cognitive, 
motor and behavioral abnormalities, and pathologically by neuronal loss, 
dendritic pruning, astrogliosis, demyelination, neuroinflammation, and the 
presence of multinucleated giant cells (Everall et al., 1999; Masliah et al., 1992; 
Navia et al., 1986; Rappaport et al., 1999; Zhou et al., 2004). With the advent of 
highly active antiretroviral therapeutics the incidence but not the prevalence of 
HIV-1 associated dementia has decreased (Bouwman et al., 1998). Neuronal cell 
dysfunction and death, as a result of HIV-1 infection, appears to be caused by 
the release of soluble factors secreted from infected non-neuronal cells including 
macrophages, microglia and astrocytes because HIV-1 only rarely infects 
neurons (Giulian et al., 1990). One such soluble factor is HIV-1 Tat, a 
nonstructural viral protein essential for viral replication that is actively released 
from cells infected with HIV-1 and that can be taken up by non-infected cells 
(Cheng et al., 1998).
HIV-1 Tat, composed of 72 amino acids in the first exon and up to an 
additional 32 amino acids in the second exon, is present in brain of HIV-1 
infected patients (Hofman etal., 1994; Kruman et al., 1999; Nath et al., 1998).
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Neuronal cell death can be induced by Tat (Aksenov et al., 2006; Gavriil et al., 
2000; Kruman et al., 1998; Langford et al., 2004; Nath & Geiger, 1998; New et 
al., 1997; Perry et al., 2005; Shi et al., 1998; Singh et al., 2005), as it depolarizes 
neurons through the activation of glutamate receptors (Cheng et al., 1998; 
Chandra et al., 2005; Haughey et al., 2001; Longordo et al., 2006; Magnuson et 
al., 1995; Self et al., 2004; Song et al., 2003), increases levels of intracellular 
calcium at least in part through the release of calcium from intracellular stores 
(Haughey et al., 1999; Lipton, 1994; Nath & Geiger, 1998), and leads to 
mitochondrial dysfunction as indicated by changes to the levels of reactive 
oxygen species, levels of ATP, and/or mitochondrial membrane polarization 
(Kruman et al., 1998; Nath et al., 2000; Perry et al., 2005; Price et al., 2005; 
Rappaport et al., 1999).
Creatine, a normal component of meat-based diets that is produced 
endogenously and may be ingested as a dietary supplement is present at high 
levels in brain (Mujika & Padilla, 1997). Creatine is an effective neuroprotectant 
against a number of acute and chronic neurodegenerative conditions including 
traumatic brain and spinal cord injuries (Rabchevsky et al., 2003; Scheff & 
Dhillon, 2004; Sullivan et al., 2000), ischemia and hypoxia (Adcock et al., 2002; 
Zhu et al., 2004a), Huntington’s disease (Bender et al., 2005; Dedeoglu et al., 
2003; Matthews et al., 1998; Ryu et al., 2005), Alzheimer’s disease (Brewer & 
Wallimann, 2000), amyotrophic lateral sclerosis (Dupuis et al., 2004; Ferrante et 
al., 2000; Klivenyi et al., 2004; Pena-Altamira et al., 2005), and Parkinson’s 
disease (Beal, 2003; Matthews et al., 1999).
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Mechanistically, the neuroprotective properties of creatine appear to be 
related mostly to stabilizing mitochondrial bioenergetics and preventing 
mitochondrial redox catastrophe. In terms of stabilizing mitochondrial 
bioenergetics, creatine is phosphorylated by mitochondrial creatine kinase to 
phosphocreatine that is then transported to the cytoplasm where cytoplasmic 
creatine kinase catalyzes the transfer of high-energy phosphate from 
phosphocreatine to ADP thus yielding ATP. For the prevention of redox 
catastrophe, creatine can reduce the production of reactive oxygen species by 
various actions including acting as a free-radical scavenger (Lawler et al., 2002) 
and prevention of mitochondrial permeability transition pore opening (Dolder et 
al., 2003; O’Gorman et al., 1997; Sullivan et al., 2000).
Ketogenic Diet & Epilepsy
Epilepsy is a brain disorder that is characterized by a predisposition to 
generate epileptic seizures. In the general population, the incidence of epilepsy is 
around 50 cases per 100,000 people per year, with higher proportions for infants 
and elderly people (Duncan et al., 2006; Forsgren et al., 2005; Patel, 2004). The 
disorder is poorly classified as it has many known and unknown causes, 
manifestations, seizure types, and identifiable syndromes. Epilepsy associated 
with head trauma, central nervous system infections, and tumors may occur at 
any age whereas cerebrovascular disease is the most common risk factor in 
people older than 60 years (Duncan et al., 2006).
Seizures are transient occurrences of signs or symptoms that are due to 
abnormally excessive or synchronous neuronal activity in brain (Fisher et al.,
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2005). During a seizure, groups of neurons undergo a prolonged depolarization 
that may last for seconds. The prolonged depolarization of a neuron increases 
the probability that an inadequate stimulus can elicit an action potential and this 
can result in neurons firing at a very high rate (Walker et al., 1990). Excessive 
neuronal activity causes a large flux of ions across the plasma membrane and 
will lead to the intracellular accumulation of sodium and calcium ions. Each of 
these ions’ influx generates a predicament for cellular homeostasis in that the cell 
expends large amounts of energy in order to maintain low intracellular sodium 
and calcium concentrations. The fate for sodium is active transport from the cell, 
via sodium-potassium-ATPase, whereas calcium may accumulate within the 
mitochondria, endoplasmic reticulum, or be extruded from the cell. These ion 
movement processes directly impact a neuron’s bioenergetics and may lead to 
redox catastrophe. ATP is necessary to maintain the resting membrane potential. 
During seizure activity the resting membrane potential depolarizes, as the 
sodium-potassium-ATPase is unable to exchange sufficient amounts of 
intracellular sodium for extracellular potassium. A decreased electrical potential 
across the neuronal membrane increases the probability of a subsequent action 
potential train occurring and further sodium and calcium influx.
The mitochondrion is commonly termed the powerhouse of the cell as it 
converts dietary calories, through oxidative phosphorylation by the ETC, into 
ATP. The rate of ATP production is augmented as ATP is consumed by cellular 
processes such as via the sodium-potassium-ATPase to ADP (Wallace et al., 
2005). Under basal conditions, estimations are that this ATPase consumes 25-
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40% of the brain’s energy (Albers & Siegel, 1999) furthermore, after seizure 
activity it is probable that this ATPase consumes an even greater percentage of 
brain energy to restore the resting membrane potential. The ETC not only 
creates useable ATP energy for the cell but also produces most of the cell’s 
endogenous reactive oxygen species, as a toxic byproduct of energy production 
(Wallace, 2005).
Antiepileptic drugs as well as non-pharmacological treatments are 
available for the treatment of epilepsy (Duncan et al., 2006). The aim of 
antiepileptic drug treatment is to control seizures without adverse effects; 
unfortunately antiepileptic drugs are effective for only 60-70% of epileptic 
individuals. Findings that epileptic seizures were reduced in frequency and 
intensity lead to the hypothesis that ketosis effectively decreases seizure 
disorders (Freeman & Vining, 1998; Schwartzkroin, 1999). The ketogenic diet 
(KD) induces ketosis and is a common non-pharmacological treatment for 
individuals with epilepsy that do not respond well to traditional AEDs.
R.M. Wilder, at the Mayo Clinic, first proposed the KD in 1921 to mimic the 
biochemical changes such as acidosis, dehydration, and ketosis that occur 
during fasting (Schwartzkroin, 1999). The KD is a high fat and low carbohydrate 
diet that can be expressed as a ratio of fat to protein (plus carbohydrate) of 4:1 
(fat: protein + carbohydrates). Approximately 90% of dietary calories are derived 
from fat whereas only 2-3% comes from carbohydrates (Freeman et al., 2000). 
Proteins are added to the diet to meet requirements for the individual’s age and 
size. In order to maintain ketosis in the patient, fluids and calories are restricted
37
roduced with permission of the copyright owner. Further reproduction prohibited without permission.
and total caloric intake is targeted to 75% of recommendations for the individual’s 
age (Sinha & Kossoff, 2005). The diet reduces seizure frequency by more than 
90% for a third of children and by greater than 50% for an additional third of 
children (Thiele, 2003). It appears that the KD is more or less as effective in 
adults as it is in children however there have been few studies on adults 
(Barborka, 1930; Sirven et al., 1999). Most patients that respond well to the KD 
are weaned from the diet after two years as the anticonvulsant effect achieved 
becomes permanent (Edelstein & Chrisholm, 1996). The KD may even be more 
efficient in the management of childhood seizures than all other currently 
available AEDs (Freeman et al., 2006). The KD might also slow the progression 
of this disorder (Bough et al., 2003; Su et al., 2000). Unfortunately the 
mechanism(s) by which the KD provides protection remains uncertain.
There are many hypothesizes for the protective effects of the KD. Investigators 
have attributed the diet's protection to; alterations in neurotransmitter levels, 
circulating factors that function as neuromodulators, modifications to the 
extracellular milieu, decreased neuronal excitability, and transformations of 
cerebral energy metabolism (Schwartzkroin, 1999). We hypothesize that 
changes to gene expression and ultimately altered energy metabolism are the 
strongest candidates.
Because the KD may require several days and weeks to become 
maximally effective (Appleton & DeVivo, 1974), we in collaboration with Drs. 
Raymond Dingledine and Kristopher Bough at Emory University in Atlanta 
hypothesized that alterations in gene expression and ultimately altered energy
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metabolism were responsible for its anticonvulsant actions. Microarrays were 
used to identify functional groups of genes induced or repressed in rat 
hippocampus after KD. Although microarray analysis of brain regions is 
complicated by massive heterogeneneity of cell types, global changes in gene 
expression have provided important insights into underlying mechanisms of 
neurological disease. For example, transcriptional profiling has yielded insights 
into epilepsy, schizophrenia, Alzheimer’s disease, and multiple sclerosis (Arion et 
al., 2006; Glanzer et al., 2004; Mimics & Pevsner, 2004; Pierce & Small, 2004). 
The hippocampus was chosen for microarray, electron micrographic, 
biochemical, and electrophysiological studies because of previous findings 
showing that KD affects several hippocampal processes associated with 
diminished neuronal excitability and altered epileptogenesis (Bough et al., 2003; 
Cheng et al., 2003, Muller-Schwarze et al., 1999; Noh et al., 2003; Su et al.,
2000; Sullivan et al., 2004; Ziegler et al., 2003). Normal animals were studied 
rather than ‘epileptic’ animals because a KD-induced change in seizure 
frequency would itself change gene expression that would cloud interpretation. 
We selected adolescent rats (37-41 d; Stansfield et al., 2004) rather than very 
young rats to circumvent ontogenetic profiles that would be superimposed on 
diet-induced changes. Age at diet onset is only moderately linked with 
anticonvulsant efficacy either experimentally (Appleton & DeVivo, 1974; Bough et 
al., 1999b) or clinically (Freeman et al., 1998; Sirven et al., 1999; Vining et al., 
1998). Indeed, in a prospective trial of 150 children and adolescents age less 
than 2 to greater than 12 years, there was no age-related difference in outcome
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(Freeman et al., 1998). The KD is effective in infants (Nordli et al., 2001), 
adolescents, (Coppola et al., 2002; Mady et al., 2003) and adults with 
generalized and partial epilepsy (Sirven et al., 1999). Experimental studies in 
adult rats support this notion (Appleton & DeVivo, 1974). Although the KD is 
primarily used for pediatric epilepsy, we chose to study adolescent rats (e.g. 
Stansfield et al., 2004), an age group in which KD has documented effect 
(Coppola et al., 2002; Mady et al., 2003). Key variables associated with KD 
efficacy have been identified in rats (Bough et al., 1999a; Bough et al., 1999b; 
Bough & Eagles, 1999; Bough et al., 2000a; Bough et al., 2000b).
Reports have suggested that KD-fed brain has increased ATP levels (DeVivo et 
al., 1978) and phosphocreatine to yATP ratio (Pan et al., 1999). During our 
studies, in collaboration with Drs. Raymond Dingledine & Kristopher Bough, we 
observed a significantly elevated energetic capacity from KD-fed brain (data 
presented in results section; Bough et al., 2006). Specifically, we fed young 
Sprague-Dawley rats a calorie-restricted KD for three weeks prior to sacrifice by 
high-energy head focused microwave irradiation. In order to accurately determine 
brain energy levels it is critical to kill the animals by microwave irradiation as it 
snap-inactivates all brain enzymes and thus prevents the rapid post-mortem 
degradation of high-energy molecules (Delaney & Geiger, 1996). We found an 
increased ratio of phosphocreatine to creatine in hippocampus (Bough et al., 
2006). This elevation indicates that KD-fed brain has a greater ability to maintain 
cellular ATP levels. We believe that these animals will also have reduced
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mitochondrial free radical production and oxidative damage following seizures 
however this hypothesis has not been tested.
Adenosine is the brain’s endogenous anticonvulsant and an endogenous 
neuromodulator that is released during seizures, ischemia, and hypoxia (Berman 
et al., 2000; Fredholm et al., 1984; Olsson et a!., 2004). The brain is the tissue by 
far with the greatest density of the most abundant adenosine Ai receptors (AiR), 
which play key roles in controlling neuronal excitability and in particular 
neurotransmitter release (Cunha, 2005). It exerts both anticonvulsant and 
neuroprotective effects (Fredholm, 1997; Fredholm et al., 2005a; Ribeiro et al., 
2003) that are mediated by adenosine receptors, of which the inhibitory AiR is 
the most abundant in seizure prone regions, such as the hippocampus (Fredholm 
et al., 2001; Fredholm et al., 2005b). Excitotoxicity and ischemia studies have 
demonstrated that Ai activation is neuroprotective (Fredholm, 1997; Fredholm et 
al., 2005a; Lee et al., 2004; de Mendonca et al., 2000; Sweeney, 1997; Vianna et 
al., 2005). Adenosine is released during seizures and is believed to contribute to 
the termination of seizures (Dunwiddie et al., 1981; During & Spencer, 1992; 
Ribeiro et al., 2003) by reducing neuronal excitability via activation of AiRs.
A-iR activation inhibits excitatory synaptic transmission, mainly by inhibiting 
presynaptic glutamate release (Thompson et al., 1992). Postsynaptically, AiR 
activation inhibits potassium conductances which lead to hyperpolarization of the 
neuron (Greene & Haas, 1991). This latter effect is of chief importance to 
manage neuronal firing (Cunha, 2005). The post-synaptic density contains high 
numbers of AiRs and could implicate adenosine in the control of signal
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integration at the post-synaptic level. For instance, tonic activation of AiRs 
affects synaptic plasticity (de Mendonca & Ribeiro, 1997) and this could be due 
to AiRs modulating NMDA receptors (Klishin et al., 1995) as well as post- 
synaptically located voltage-sensitive calcium channels. Hence, the dominant 
anticonvulsant role of endogenous and tonic adenosine occurs through the 
actions of the A ^  (Etherington & Frenquelli, 2004) where seizure activity can be 
suppressed (Anschel et al., 2004; Boison, 2005; Huber et al., 2001). 
Furthermore, adenosine agonists have been demonstrated to suppress 
pharmacoresistant epilepsy through A-iRs (Gouder et al., 2003).
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Analysis of Cerebral Energetics
Frozen brain tissue samples were weighed in 1.5 ml centrifuge tubes and 
the total volume of ice-cold H20  necessary to generate a concentration of 50 mg 
of tissue per ml was calculated and added. Samples were kept ice-cold while 
being homogenized with a Polytron (Speed “3”) in short bursts to ensure the 
samples remained cold. From each sample, 50 pi of homogenate was removed 
and stored at -20°C until being taken for protein analysis by DC method (Bio- 
Rad, Hercules, CA). The remaining homogenate volume was calculated and 
100% trichloroacetic acid (TCA; Supelco, Bellefonte, PA) was added to yield a 2% 
final concentration of TCA. Samples were rigorously vortexed for 10s at the 
highest setting to allow ample opportunity for the acid to interact and precipitate 
proteins in the tubes prior to centrifugation for 15 min at 4°C at 16,000 x g. The 
supernatant containing adenine nucleotides, phosphocreatine, creatine and 
adenosine were analyzed using high pressure liquid chromatography (HPLC)- 
based method (Delaney & Geiger, 1996). The supernatant was added on ice to a 
mixture of tri-n-octylamine (TOA) and dichloromethane (DCM) in order to 
neutralize the TCA (225:775, respectively). The tubes were then vortexed for
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15 s and centrifuged at 4°C for 4 min at 16,000 x g to promote separation of the 
organic and aqueous layers. The organic layer was discarded while the aqueous 
layer was collected and re-introduced to the same ratio of our TOA/DCM mixture 
prior to a 15 s vortex and 4 min centrifugation at 16,000 x g. Following the 
second phase separation, the aqueous layer was collected and placed into 
polyspring inserts residing in transparent HPLC vials. The contents of the vials 
were analyzed using a Gemini 3 pm C18 column (4.6 x 150 mm, Phenomenex, 
Torrance, CA) using a mobile phase consisting of 0.1 M KH2PO4, pH 6.0 run 
isocratically at 1.0 ml/min. Metabolites were detected by a photodiode array 168 
detector (Beckman Coulter) at 210 nm for phosphocreatine and creatine, and at 
254 nm for adenine nucleotides. Each sample run was analyzed for 60 min, even 
though all compounds of interest were eluted in less than 15 min, to ensure no 
other compounds from a previous run would contaminate a subsequent sample. 
We then quantified nucleotide levels according to sample spiking and by injecting 
known amounts of standards to determine peak heights and areas under the 
peaks. AMP, ADP, ATP, creatine, and phosphocreatine peaks will be identified 
by retention time of standards. Adenylate energy charge was calculated using 
the formula ([ATP] + 1/2 [ADP]) / ([ATP] + [ADP]+[AMP]).
For adenosine, brain samples were homogenized and neutralized in the 
same fashion as for the adenine nucleotides. Following collection of the second 
supernatant, we added an equal volume of Ba(OH)2 and samples were mixed 
rigorously for 10 s -  this resulted in a milk-like solution that was mixed with an 
equal volume of ZnSC>3. The resulting solution was vortexed for 10 s and
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centrifuged at 4°C for 4 min at 16,000 x g. The supernatant (150 pi) was then 
added to 25 pi of 5% chloroacetaldehyde and samples were vortex mixed for 10 
s prior to being heated for 2h at 85°C to produce adenosine’s fluorescent 
derivative N6-ethenoadenosine (Zhang et al., 1991). After heating, samples and 
adenosine standards were removed from the block, vortexed for 2 s, and 
centrifuged at room temperature for 2 min at 16,000 x g. The samples and 
adenosine standards were then injected onto a Gemini 3 pm C18 column (4.6 x 
150 mm) using a mobile phase of 0.01 M NH4H2PO4, 17% methanol, pH 5.4 run 
isocratically at 1 ml/min. The excitation wavelength for fluorescent detection was 
set at 275 nm and the emission wavelength at 407 nm. Adenosine levels were 
quantified according to sample spiking and by injecting a known amount of 
standard to determine peak heights & areas under the peaks.
The resulting HPLC data were analyzed using 32Karat software (Beckman 
Coulter) to determine quantitatively levels of adenine nucleotides, creatines, and 
adenosine. Data were expressed either as moles per mg wet weight or per mg 
protein and analyzed statistically using GraphPad software (La Jolla, CA). A 
student’s t-test was used to determine statistical significance between 
experimental groups within discrete brain regions; error bars are standard 
deviation unless mentioned otherwise, p values were set at 0.05.
Cholesterol Fed Rabbits as a Model for Alzheimer's Disease 
Animals and Dietary Treatment
New Zealand white male rabbits (Charles River Laboratories, Wilmington, 
MA), were obtained between 1.5 to 2 years of age (initial weights 3-5 kg).
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Rabbits were assigned randomly to either control diet (n=6) or 2% (w:w) 
cholesterol-enriched diet (n=6; Harlan-Teklad, Madison, Wl) groups and were fed 
their respective diets for 12 weeks before death. The animals were killed by 
anesthetic and were perfused with 37°C Dulbecco’s phosphate-buffered saline. 
Brains were rapidly removed, dissected for olfactory bulbs, hippocampus, and 
cerebral cortex, and were frozen on a liquid nitrogen cooled surface before 
storage at -80°C. All experiments were performed in accordance with NIH 
guidelines for the care and use of laboratory animals and approved by the 
University of North Dakota’s Animal Care and Use Committee.
Analysis of Cerebral Energetics
Frozen cerebral cortex and hippocampal samples were analyzed for 
adenine nucleotides, phosphocreatine, and creatine (see General method).
ADSL Transgenic Mice as a Model for Autism 
Animals and Dietary Treatment
As a model for Autism, we received genetically modified mice from Dr. 
David Patterson’s laboratory at the Eleanor Roosevelt Institute at the University 
of Denver. Mice ranging in age from 3 to 18 months were communally housed 
and fed a standard diet ad libitum (#2018, Harlan-Teklad, Madison, Wl). A 
detailed description of the constituents of the diet is provided in Table 1 of the 
Appendix. Control and genetically modified mice were killed with a 6 kW head- 
focused high-energy microwave irradiation system (Cober Electronics, Norwalk, 
CT) set to 35% of maximal power for a duration of 0.3 s. Mouse brains were 
taken and cerebral cortex and cerebellum were dissected and frozen on dry ice.
46
roduced with permission of the copyright owner. Further reproduction prohibited without permission.
Brain tissue was stored at -80°C. All experiments were performed in accordance 
with NIH guidelines for the care and use of laboratory animals and approved by 
Institutional Animal Care and Use Committees.
Analysis of Cerebral Energetics
In addition to phosphocreatine and creatine detected at 210 nm and 
adenine nucleotides detected at 254 nm (see General method), SAICAR and 
adenylosuccinate were detected at 254 nm from from cerebral cortex and 
cerebellum.
Ts65Dn and GART Transgenic Mice as Models for Down Syndrome 
Animals and Dietary Treatment
As a model for Down syndrome, we obtained trisomic (Ts65Dn) and 
standard FVB mice from Dr. David Patterson’s laboratory at the Eleanor 
Roosevelt Institute at the University of Denver. The Ts65Dn mouse strain 
originated from Jackson Laboratory (Bar Harbor, ME) and contains triplications of 
partially overlapping segments in the Down syndrome region and covers the 
majority of the triplicated region observed in humans (Epstein et al., 1985). Mice 
ranged in age from 3 to 18 months, were housed communally, and were fed a 
standard diet ad libitum (#2018, Harlan-Teklad, Madison, Wl). A detailed 
description of the constituents of the diet is provided in Table 1 of the Appendix. 
Control and genetically modified mice were killed with a 6 kW head-focused high- 
energy microwave irradiation system (Cober Electronics, Norwalk, CT) set to 
35% of maximal power for a duration of 0.3 s. Mouse brains were taken and 
cerebral cortex and cerebellum were dissected and frozen on dry ice. Brain
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tissue was stored at -80°C. All experiments were performed in accordance with 
NIH guidelines for the care and use of laboratory animals and approved by 
Institutional Animal Care and Use Committees.
Analysis of Cerebral Energetics
Frozen cerebral cortex and cerebellum samples were analyzed for 
adenine nucleotides, phosphocreatine, creatine, and adenosine (see General 
method).
Treatment of Rat Cerebral Cortical Neurons with HIV-1 Protein Tat as a Model
for HIV-1 Dementia
Preparation of Primary Cortical Neuron Culture 
Primary cultures of mouse cerebral cortical neurons were prepared as 
follows. E-16 pups were removed aseptically from pregnant C57BL/6 mice 
(Charles River Laboratories), brains were isolated and placed into ice-cold sterile 
PBS containing 5.5 mM glucose, 1 pM EDTA and 1 pM EGTA, and meninges 
were removed. Cerebral cortices were dissected, placed in fresh ice-cold buffer, 
minced and incubated for 15 minutes at 37°C with 5 ml of trypsin-EDTA (Gibco). 
Trypsin was de-activated by adding cells to 5 ml of heat-inactivated fetal bovine 
serum (Atlanta Biologicals) for 1 min at room temperature. Cells were added to 
10 ml of Neurobasal media (Gibco) containing B-27 supplement (Gibco), 0.5 mM 
L-glutamine, and antibiotic antimycotic (Sigma) containing penicillin (100 units), 
streptomycin (0.10 mg) and amphotericin B (0.25 pg) and were triturated through 
a 5 ml pipette. Cells were seeded onto uncoated 96-well plates (Nunc, Roskilde, 
Denmark) or glass bottom 35 mm culture dishes (Matek, Ashland, MA, USA)
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coated previously with poly-D-lysine. After 10-14 days in culture, cells were found 
typically to be >95% neurons and were taken for experimentation as determined 
by staining and morphology.
HIV-1 Tat
Purified (>95%) recombinant Tati.72 protein was produced from the tat 
gene encoding for the first exon as described (Ma & Nath, 1997). A deletion 
mutant (Gurwell et al., 2001; Prendergast et al., 2002) was produced by deleting 
the sequence encoding amino acids 31-61 of Tat (mutant Tat) previously shown 
to contain the neurotoxic epitope (Nath et al., 1996). Both Tati-72 and mutant Tati- 
72 were obtained as gifts from Dr. Avindra Nath. Low retention pipette tips and 
micro-centrifuge tubes were used to reduce the loss of Tat due to its adherent 
properties. At the time of experimental treatments, Neurobasal media was 
replaced with Locke’s buffer containing 156 mM NaCI, 5.6 mM KCI, 2 mM CaCI2,
1 mM MgCI2, 3.6 mM NaHCC>3, 5 mM glucose, and 5 mM HEPES in double- 
distilled sterile water (pH 7.2). Thawed Tat was never re-frozen for later use due 
to freeze/thaw degradation. Care was taken not to mix vigorously or oxygenate 
Tat so as to minimize inactivation.
Analysis of Cerebral Energetics
Four h after experimental treatments were applied, buffer was removed, 
cultures were washed three-times with ice-cold PBS, and cells were lysed by 
three freeze/thaw cycles and proteins were precipitated with 2% trichloroacetic 
acid (TCA; Supelco, Bellefonte, PA). A small amount of the lysate was removed 
for protein analysis (Bio-Rad). Lysate was added to an equal amount of
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dichloromethane and tri-octylamine (775:225 v:v) and samples were mixed 
vigorously. Aliquots (30 pi) of the aqueous phase were injected onto a LC-18-T 
HPLC column (Supelco, Bellefonte, PA) and adenine nucleotides, 
phosphocreatine, and creatine were analyzed as described in General method.
Cell Viability Assays
Trypan blue exclusion assays were conducted in 96-well plates to 
determine neuronal cell death (Mattson et al., 1995; Wang et al., 2002). Media 
was removed from cell cultures 24 h after treatments, 50 pi trypan blue (0.2%) 
diluted in PBS was added, and after 5 min at room temperature the total number 
of cells and the number of cells lacking trypan blue were counted; data for dead 
cells were expressed as a percentage of total cells. Each experiment was 
conducted in triplicate and experiments were repeated at least four times using 
different dishes of cultured cells.
Measurement of Mitochondrial Membrane Potential 
Mitochondrial membrane potential was determined 4 h after treatments in 
cells grown on glass bottom 35 mm culture dishes by removing culture media, 
replacing the media with 2 ml PBS containing 1.0 pg/ml of the cationic dual 
emission dye JC-1 (Molecular Probes), and incubating cells at 37°C and 5% C 02 
for 25 minutes. After incubation, cells were washed two-times with media at 37°C 
and fluorescence was measured using a Zeiss Axiovert 200M microscope 
system at excitation/emission wavelengths of 485/530nm for the monomer and 
535/570nm for the J-aggregate. Fluorescence was quantified for each cell using 
average pixel intensity of both J-aggregate and JC-1 monomers using Image-J
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software (NIH). Data were normalized to the ratio of J-aggregate (average pixel 
intensity)/J-monomer (average pixel intensity) in untreated control cultures 
(untreated ratios were changed to a value of 1). Each experiment was conducted 
in duplicate and experiments were repeated four-times using different batches of 
neurons.
Measurements of Mitochondrial Permeability Transition Pore Status
Mitochondrial permeability transition pore opening was determined 
fluorometrically (Petronilli et al., 1999). Following treatment of cells for 4 h, 
cultures were washed in 2 ml Locke’s buffer and incubated in 2 ml Locke’s buffer 
containing calcein-AM (1 pM) and cobalt chloride (1 mM) for 20 minutes at 37°C. 
Cells were washed with 2 ml Locke’s buffer and fluorescence was measured with 
a Zeiss Axiovert 200M microscope at an excitation wavelength of 488 nm and an 
emission wavelength of 525 nm. Following de-esterification, calcein fluorescence 
was visible in mitochondria, and cobalt chloride that quenches the fluorescence 
only enters intact mitochondria with opening of the mitochondrial permeability 
transition pore. Fluorescence was quantified using average pixel intensity using 
Image-J software (NIH) and data were expressed as cells with open pores as a 
percentage of total cells. Each experiment was conducted in duplicate 35 mm 
glass-bottomed plates and repeated four-times using different batches of cultured 
cells.
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Analysis of Reactive Oxygen Species
Levels of reactive oxygen species were measured in 96-well plates using 
the fluorescent dye dichloro-dihydrofluorecein diacetate (H2DCFDA), a cell 
membrane permeable dye that fluoresces in the presence of hydrogen peroxide, 
peroxyl radicals, peroxynitrite anions, and nitric oxide. Following treatment of 
cells for 4 h, culture media was replaced with 50 pi PBS containing 20 pM 
FI2DCFDA and cells were incubated at 37°C and 5% C 02 for 45 minutes. Cells 
were washed once with 50 pi PBS and fluorescence was determined using a 
SpectraMax Plus 384 plate-reader (Molecular Devices). Each experiment was 
conducted in triplicate and experiments were repeated at least 4-times using 
different batches of cultured cells.
Statistical Analyses
All data were reported as means ± SEM. Statistical comparisons were 
made using one-way analysis of variance (ANOVA) followed by Tukey-Kramer 
multiple comparison post hoc test, unless indicated otherwise. Significant 
differences were set at p < 0.05.
Ketogenic Diet as Treatment for Epilepsy 
Animals and Dietary Treatment
For these experiments conducted at Emory University, male Sprague- 
Dawley rats (Harlan, Indianapolis, IN) were housed individually and fed either a 
calorie-restricted ketogenic (KD) or an isocaloric normal diet ad libitum (CON) 
beginning on post-natal day 37-41 (initial body weights 135-175 g). A detailed 
description of the constituents of the normal (Purina 5001) and ketogenic (Bio-
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Serv #F-3666, Frenchtown, NJ) diets is provided (Bough & Eagles, 1999). All 
experiments were performed in accordance with NIH guidelines for the care and 
use of laboratory animals and approved by Institutional Animal Care and Use 
Committees. Seizure threshold was measured every 3 to 4 days via timed 
venous infusion of pentylenetetrazole (PTZ; Pollack & Shen, 1985). In separate 
experiments seizure threshold was measured only once, after three weeks on a 
control or KD, via timed exposure to PTZ (n = 25) or flurothyl (n = 20). A 
threshold dose of PTZ or flurothyl (mg/kg) was calculated from the time at which 
the rat first exhibited a bilateral forelimb clonic jerk (Bough et al., 2000a).
Seizures were induced between 13:00 and 17:00 prior to feeding to minimize 
possible effects of circadian rhythms and postprandial hormonal fluctuations. 
Plasma levels of p-hydroxybutyrate (BHB) and glucose were measured using a 
Keto-Site (GDS Technologies, Elkhart, IN) or Precision Xtra (Abbott Labs, 
Alameda, CA) meter, respectively.
Microarray Analysis
Seizure-naive male rats (n = 24) were maintained on the diet for 22 days, 
lightly anesthetized with isoflorane, and decapitated. Their brains were rapidly 
removed and placed in ice-cold phosphate-buffered saline solution for 10-15 s, 
and then hippocampi were dissected over ice and frozen. To minimize biologic 
variability, left hippocampi from either two KD or two control animals were pooled 
together and stored at -80°C to produce six pooled samples from each treatment 
group of 12 rats. The right hippocampi (n = 12 per group) were stored individually 
at -80°C for corroborative analyses. All tissue samples were sent to the NINDS-
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NIMH Affymetrix Microarray Consortium (TGEN, Phoenix, AZ) for total RNA 
isolation, quality control assessment, probe generation, hybridization to rat 230A 
GeneChips (Affymetrix, Santa Clara, CA), and GeneChip scanning. Total RNA 
was inadequately isolated from one of the ketogenic samples, thus only 11 total 
samples were used for array testing (5 KD, 6 CON). Image data from each chip 
were normalized to a mean target intensity value of 150.
The relative abundance of each probe set and an evaluation of whether a 
particular transcript was expressed above background were calculated using 
Microarray suite (MAS 5.0, Affymetrix). The assignment of each probe pair on the 
rat 230A GeneChip to a gene was originally based by Affymetrix on the 
sequences available in Unigene build #99, whereas the most recent build is 
#144. The probe pair assignments were not updated by Affymetrix, and 
approximately 11% of the original accession numbers assigned to probe sets on 
the RAE 230A chip either match fewer than half of the probe pairs in the 
corresponding set or are retired from current databases (Dai et al., 2005). Dai 
and colleagues (2005) created a custom CDF file (http://brainarray.mbni.med. 
umich.edu/Brainarray/Database/CustomCDF/genomic_curated_CDF.asp) that 
was readable by the MAS 5.0 program to assign signal intensities of each probe 
pair to genes. All probe pairs for a particular transcript were pooled into a single 
probe set, which eliminated duplicate or triplicate instances of genes on the Chip. 
Moreover, probes hybridizing to the non-coding strand of a transcript were 
deleted from analysis, which greatly reduced the number of expressed sequence 
tags (ESTs) called. Discrimination scores of the signal intensities for each spot
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on an individual chip were determined to be significantly different from 
background (i.e., present, marginally present, or absent calls) using a one-sided 
Wilcoxon’s Sign Ranked test. We selected genes for subsequent statistical 
analysis if signal intensities were significantly above background (i.e., called 
“present”) in at least 5 of the 11 arrays tested. The Significance Analysis of 
Microarrays (SAM) program (http://www.stat.stanford/edu/~tibs/SAM; Tusher et 
al., 2001) was used to determine differences in patterns of gene expression 
between groups at a 1% false discovery rate (FDR). Functional categories were 
ascribed to differentially-expressed genes using NetAffx Analysis Center 
(www.affymetrix.com), and explore Gene Ontology (eGOn; http://nova2.idi.ntnu. 
no/egon/). Because not all named genes were associated with a GO biological 
process, functions for the remaining named genes were identified by manual 
searching through EntrezGene (NIH), the Rat Genome Database, and 
GeneCards. To determine whether the ratio of induced-to-repressed genes in a 
particular category was significantly different from the ratio of all induced-to- 
repressed genes, two-sided Fisher’s exact tests for each of the eight categories 
were performed.
Analysis of Cerebral Metabolites, Enzyme Activities and Nucleotides
Cohorts of KD (n = 29) and CON (n = 28) animals were maintained on diet 
treatment for 20-28 days. A cohort of KD (n = 10) and CON (n = 10) animals 
was maintained on diet treatment for 28 days, then lightly anesthetized with 
isoflorane and decapitated. The head was immediately cooled in ice-cold 
phosphate-buffered saline for 10 to 15 s to minimize the post-mortem
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accumulation of GABA (Hassel et al., 2001) and the brain was rapidly removed. 
Hippocampi were dissected rapidly over ice, frozen on dry ice, and weighed. For 
BHB, citrate and amino acid determinations, freshly-frozen hippocampi were 
homogenized in a 1:20 weight-to-volume ratio of a 7% perchloric acid (v:v) 
solution that included 100 pM a-aminoadipate as an internal standard. BHB was 
measured fluorometrically according to the principles of Lowry and Passonneau 
(1972) in a buffer containing Tris-potassium, 0.1 M, hydrazine, 0.1 M, NAD, 0.2 
mM, and BHB dehydrogenase, 1 U/ml. Citrate was analyzed as described by 
Lowry and Passonneau (1972). Amino acid levels were measured by HPLC and 
fluorescence detection after precolumn derivatization with o-phthaldialdehyde 
(Hassel et al., 1997).
For enzyme determinations, frozen hippocampi were homogenized in ice- 
cold 0.32 M sucrose. Hexokinase was measured fluorometrically according to 
Knull et al (1973) with an ATP concentration of 1 mM; glucose-6-phosphate 
dehydrogenase was measured with the buffers used for hexokinase, substituting 
10 mM glucose-6-phosphate for glucose and ATP. Lactate dehydrogenase was 
analyzed fluorometrically in Tris-HCI, 0.1 M, hydrazine 0.1 M, pH 8, MgC^, 5 mM, 
lactate, 30 mM, and NAD, 1 mM; BHB dehydrogenase was analyzed in Tris-HCI, 
0.1 M without hydrazine, pH 8, MgCh, 3 mM, p-mercaptoethanol, 10 mM, BHB,
30 mM, and NAD, 1 mM. Citrate synthase and malate dehydrogenase were 
analyzed spectrophotometrically according to Srere (1969) and Kitto (1969), 
respectively. a-Ketoglutarate dehydrogenase was analyzed fluorometrically 
according to Mastrogiacomo et al. (1993). All enzyme reactions were verified to
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be linear with time and concentration of tissue. Protein was measured according 
to Lowry et al (1951).
For cerebral nucleotides and glycogen a separate cohort of KD (n = 9) and 
control (n = 8) rats were maintained on their respective diets for 20 days and 
killed with a 6 kW head-focused high-energy microwave irradiation system 
(Cober Electronics, Norwalk, CT) set to 70% of maxima! power for a duration of 
1.3 s (Delaney & Geiger, 1996). Hippocampus was dissected and then frozen on 
dry ice. The left hippocampus was used to measure AMP, ADP, ATP, creatine, 
and phosphocreatine levels as described in General method, whereas 
hippocampal tissue from the right hemisphere was used to measure glycogen. 
Glycogen levels were determined biochemically using an enzyme-linked assay 
as described (Kong et al., 2002). Glycogen was hydrolyzed to glucose in aliquots 
(100 pi) of homogenate that were incubated overnight (16 h) at room temperature 
with 1 ml of 0.2 M sodium acetate, 20 pi of 1.0 M KHCO3, and 20 U/ml of 
amyloglucosidase. Following incubation, we added 0.5 ml of a perchloric acid 
solution containing 6% perchloric acid and 1 mM ethylenediaminetetraacetic acid 
(EDTA) that stopped the reaction. The tubes were centrifuged at 25,000 X g for 
10 min at 4°C before supernatants were neutralized with a KOH solution 
consisting of 3 M KOH, 0.3 M imidazole, and 0.4 M KCI and then centrifuged at 
14,000 X g for 10 min at 4°C, and utilized for glucose content assays. 
Endogenous glucose levels were determined from nonhydrolyzed samples that 
we obtained by centrifuging homogenates as described above and a pH 
adjustment to a final pH 6-8 via KOH solution. Neutralized samples were
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vortexed, centrifuged at 25,000 X g for 10 min at 4°C and assayed for 
background glucose levels. To each well of the 96-well plate 200 pi of a reaction 
solution containing 50 mM Tris-HCI, pH 8.1, 0.5 mM ATP, 0.5 mM NADP+, 5 mM 
MgS04, and 0.1 U/ml glucose-6-phosphate dehydrogenase was added. The 
plates were then placed in a SpectraMax Gemini fluorescence plate reader 
(Molecular Devices, Sunnyvale, CA), shaken, and measurements of formed 
NADPH were executed at 355 nm excitation, 480 nm emission, and 420 nm 
cutoff wavelengths. Hexokinase (0.3 U) was added to each well, plates were 
shaken, and after a 30 min incubation period, measurements were collected. 
Glycogen levels, indicated as glucose units, were calculated by subtracting the 
final pM concentration of glucose per g of wet weight of the nonhydrolyzed tissue 
sample from the pM concentration of glucose per g of wet weight of the 
hydrolyzed tissue sample. Resulting numbers were transposed to GraphPad 
software (La Jolla, CA) for statistical analyses as well as graphing of data. A 
student’s t-test was used to determine significance of between experimental 
groups within discrete brain regions; the p value was set at 0.05.
Electron Microscopy
Nine animals (4 KD, 5 CON) were maintained on diet treatment as above 
for at least four weeks. After deep anesthesia with halothane, animals were 
perfused transcardially with 4% paraformaldehyde and 0.1% glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4). Brains were post-fixed in the same mixture for 8- 
12 h at 4-8°C. Coronal sections (60 pm) were cut with a vibratome, dehydrated 
and embedded in Durcupan resin (Electron Microscopy Sciences, Fort
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Washington, PA). Regions of the dentate and hilus (-2 mm2) were 
microdissected, mounted on blocks, and 60 nm sections were collected onto 
Pioloform-coated slot grids, then counterstained with uranyl acetate and lead 
citrate.
Sections were examined using a Zeiss EM10C electron microscope. 
Electron micrographs were randomly taken at 20,000 x magnification through the 
dentate-hilus region. Data from 4 KD-fed animals (160 micrographs representing 
2680 pm2) and 5 controls (184 micrographs representing 3080 pm2) were 
examined for mitochondrial counts. Images were captured on a Leica DMRBE 
microscope with a Spot RT color digital camera (Diagnostic Instruments, Inc., 
Sterling Heights, Ml), saved in a jpg-file format, and printed using a Kodak 8660 
Thermal printer. Identification of dendrites, terminals, spines, and axons was 
based on ultrastructural characteristics and size, as described previously (Peters 
& Palay, 1996). Mitochondria were identified by their localization within identified 
processes, dual outer membranes, and presence of internal cristae.
Electrophysiology
Six pairs of animals were fed either a ketogenic or CON diet for & 20 days 
as above, anesthetized with halothane, and decapitated. Brains were rapidly 
removed and chilled in an ice-cold, bubbled with 95% 0 2/5% C 02 cutting ACSF 
containing the following (in mM); NaCI 130, KCI 3.5, Na2HP04 1.25, NaHC03 24, 
MgS04 4, CaCI2 1, glucose 10, and osmolarity 300 ± 5 mOsm. For each 
experiment, transverse entorhinal-hippocampal slices (500-550 pM thick) were 
cut using a vibratome from each pair of animals (1 KD and 1 control)
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simultaneously. Slices were transferred to a carbogenated holding chamber in 
ACSF containing 2 mM each of MgS04 and CaCI2, where they were maintained 
for approximately 30 min at 25°C until recordings were begun. Slice recordings 
from pairs of animals were conducted concurrently in a submerged chamber, 
where slices were continuously perfused with carbogenated bathing medium at a 
rate of 2-3 ml/min. With our chamber dead volume of 2.2 ml, this allowed for fluid 
exchange within a few minutes. All experiments were performed at 32-34°C. 
Extracellular field excitatory post-synaptic potentials (fEPSPs) were recorded 
from the dentate molecular layer using glass micropipettes (5-10 M£2) filled with 
artificial cerebrospinal fluid (ACSF) and an aliquot (~25 pi) of India ink to 
visualize recording electrode placement. Slices from the middle hippocampus 
were used preferentially. Responses were evoked by stimulation of the medial 
perforant path (MPP, located in the middle third of the molecular layer of the 
dentate gyrus) using a Teflon-coated, Pt/I monopolar microelectrode (~1 MQ 
impedance). Electrode placements in the MPP were corroborated by observing 
paired-pulse depression (~15%) at a 50 ms interpulse interval (McNaughton, 
1980). Responses that did not exhibit consistent paired-pulse depression were 
not used. Stimulus intensity (0.1 ms duration, <70 pA) was adjusted to evoke 
fEPSPs of approximately 50% maximum amplitude. A solution containing low (2 
mM) glucose supplemented with 8 mM mannitol to maintain osmolarity was bath 
applied for 7 min.
Electrophysiological recordings were performed on cerebral tissue from 
male Sprague-Dawley rats fed control or KD for 21-35 days at Trinity College.
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Animals were decapitated, the hippocampus was dissected from whole brain, 
after rapid decapitation and cooling, hippocampal slices (400 mm) were 
prepared. At least 1 hr after surgery, brain slices were maintained at a constant 
temperature of 31-33°C in a submersion chamber and constantly superfused (2 
ml/min) with gassed (95% 02, 5% C 02) artificial cerebrospinal fluid containing 
126 mM NaCI, 3 mM KCI, 1.5 mM MgCI2, 2.4 mM CaCI2, 1.2 mM NaH2P04, 11 
mM glucose, and 26 mM NaHCOs (Sigma-Aldrich, St. Louis, MO). For recordings 
of field excitatory postsynaptic potential (fEPSP) responses, the recording 
electrode was placed in stratum radiatum of the CA1 region and the stimulation 
electrode in stratum radiatum near the border of the CA1 and CA2 regions at 
33°C; stimuli were delivered at 15 s intervals (Masino et al., 2002). Adenosine 
(50 mM) was added at least 15 min prior to recording and all recordings were 
performed within 3.5 h of slicing. Responses were recorded using an AC 
amplifier, and a computer was used to digitize and store the responses for further 
analysis (Dunwiddie & Diao, 1994). A student’s t-test was used to determine 
significance between experimental groups, p was set at 0.05.
QRT-PCR of Laser Captured Neurons 
Brains from KD (n=5) and CON (n = 5) fed rats were fresh frozen and 
sectioned via cryostat into 8-12 p,m thick sections for laser-capture microscopy 
(LCM). Dentate granule and CA1 pyramidal cells were harvested with an 
Arcturus Pixcell lie system (Arcturus, CA) using the following parameters: power 
= 90-100 W, Duration = 800-1500 ps, and spot size = 7.5 ^m (Greene et al., 
2005). cDNA was transcribed from random hexamer amplified total RNA
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(Invitrogen, Carlsbad, CA) and quantitative PCR (qPCR) was performed using 
Applied Biosystems SybrGreen Master Mix [Applied Biosystems, Foster City,
CA],
Eight metabolic genes showing some degree of regulation on the 
microarray were examined by qPCR. These genes were Rieske (similar to 
Ubiquinol cytochrome reductase transmembrane 1 (Uqcrfsl), NADH 
dehydrogenase (ubiquinone) 1 beta subcomplex 9 (Ndufb9), the delta and O 
subunits of ATP synthase, H+ transporting and mitochondrial F1 complex (Atp5d 
and ATP5o), succinate dehydrogenase complex (Sdhal), both soluble and 
mitochondrial forms of malate dehydrogenase, and cytochrome c oxidase subunit 
Via polypeptide 1 (Cox6a1). Hypoxanthine guanine phosphoribosyl transferase 
(HPRT), a gene showing no significant change related to KD, was used to 
standardize the level of expression of each transcript.
Changes in transcript levels of the genes of interest (GOI) were measured 
in duplicate and calculated as [(the average cycle threshold (CT) for transcript -  
average CT for HPRT (standard gene) for a KD-fed animal] -  [(average CT for 
transcript -  the average CT for HPRT for a control-fed animal], resulting in a 
AACT value for each sample (Greene et al., 2005). The mean DG and CA1 AACT 
values were compared with a 2 tailed -test for significance, p was set at 0.05.
Analysis of Cerebral Energetics
For these experiments conducted at University of North Dakota, male 
Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed individually and fed 
either a calorie-restricted KD or an ad libitum standard rodent diet beginning on
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post-natal day 35 (initial weights 135-175 g). A detailed description of the 
constituents of the control (Harlan-Teklad #2018) and ketogenic (Bio-Serv #F- 
3666, Frenchtown, NJ) diets is provided in Table 2 of the Appendix. Animals 
were individually housed at the University of North Dakota in the Center for 
Biomedical Research for five days prior to a daily monitoring of each animal’s 
weight and caloric intake. Rats were weight-matched and evenly split into 
experimental (KD) and control groups. Caloric intake data was used to calculate 
daily food allowance for all animals with an increase of 1.6% of their previous 
day’s calories to allow for their normal growth. Ketogenic animals received 90% 
of their normal daily caloric intake in the form of a frozen 8% ketogenic paste 
smeared on one side of a 35 mm culture dish that was placed atop of the 
bedding in their cage. Control animals received an isocaloric amount of their 
normal daily caloric intake in the form of chow pellets that were placed on the 
hopper of each cage. All rats were fed at approximately 5:00 pm each day. After 
21 days of diet treatment, a cohort of KD and control rats were killed with a 6kW 
head-focused high-energy microwave irradiation system (Cober Electronics, 
Norwalk, CT) set to 70% of maximal power for a duration of 1.3 s. Animals were 
killed at 5pm ±2h as to minimize circadian and feeding effects. Discrete rat brain 
regions were dissected and then fresh frozen over dry ice. Samples were stored 
at -80°C until taken for analyses. All experiments were performed in accordance 
with NIH guidelines for the care and use of laboratory animals and approved by 
University of North Dakota’s Animal Care and Use Committees.
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Frozen cerebral cortex, cerebellum, hippocampal, hypothalamus, and 
striatum samples were analyzed for adenine nucleotides, phosphocreatine, 
creatine, and adenosine (see General method).
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CHAPTER III
RESULTS
Cholesterol Fed Rabbits as a Model for Alzheimer’s Disease 
Pathological hallmarks of Alzheimer’s disease (AD) include abnormal 
accumulations of A£ and Tau. These pathological observations may be 
associated with changes in brain energy metabolism that could occur as a result 
of dysregulation of mitochondrial metabolism (Zhu et al., 2004b) and/or altered 
glucose metabolism that has been observed in patients with AD (Pettegrew et al., 
1994). Accordingly, using high-cholesterol diet fed rabbits as a model for the 
sporadic form of Alzheimer’s disease (Ghribi et al., 2006) we tested the 
hypothesis that rabbits fed a high cholesterol diet for 12 weeks have decreased 
levels of high-energy brain metabolites in cerebral cortex and hippocampus. 
Compared to a standard diet, 2% cholesterol fed rabbits exhibited decreased 
phosphocreatine levels (ns, Figure 7A), significantly diminished levels of creatine 
(Figure 7B, p < 0.05), and significantly elevated phosphocreatine/creatine ratio 
(Figure 7C, p < 0.05).
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Figure 7: Effects of Administration of a High Cholesterol Diet on Levels of 
Creatine and Phosphocreatine in Rabbit Cerebral Cortex. (A) Compared with 
controls, levels of phosphocreatine in cholesterol-fed rabbits were not 
significantly decreased. (B) Levels of creatine were decreased significantly (p < 
0.05) in cerebral cortex compared to control animals. (C) Statistically significant 
increases (p < 0.01) were observed for the ratio of phosphocreatine/creatine 
compared to control rabbits. * p < 0.05 versus control, ** p < 0.01 versus control. 
Values are mean ± SD. Sample sizes are indicated on respective bars.
Adenine nucleotides represent an important energy and demands for 
energy are particularly high at neuronal synapses; sites where 
neurodegenerative processes occur early in the disease state (Coleman et al., 
2004). We hypothesized that levels of ATP would be diminished in our 
hypercholesterol model for AD. In cerebral cortex, levels of ATP were reduced 
significantly (p < 0.05) in cholesterol-fed rabbits (Figure 8A). The levels of ADP 
(Figure 8B) and AMP (Figure 8C) were also reduced significantly (p < 0.05) as a
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result of the diet. These findings suggest that energy stores in the form of 



















Figure 8: Effects of Administration of Cholesterol-Enriched Diet on Levels of 
Adenine Nucleotides in Rabbit Cerebral Cortex. (A) Compared with controls, 
levels of ATP were decreased significantly (p < 0.05) in cerebral cortexof rabbits 
fed cholesterol-enriched diet for 12 weeks. ADP (B) and AMP (C) were also 
significantly (p < 0.05) lower in cerebral cortex compared to control animals (p < 
0.05). * p < 0.05 versus control, Values are mean ± SD. Sample sizes are 
indicated on respective bars.
From the data on adenine nucleotide levels, we calculated the ratio of 
ATP/ADP and the adenylate energy charge. The ratio of ATP/ADP was 
increased significantly (p < 0.05) in cholesterol-fed rabbits (Figure 9A) indicating 
an increased energetic status of the cerebral cortical tissue. However, adenylate 
energy charge ratios were not significantly different (Figure 9B). However,
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adenylate energy charge values were very much lower than the theoretical 
maximum ratio of 1 because these animals were killed such that post-mortem 
decreases in bioenergetic: environment was unavoidable.
Figure 9: Effects of Administration of Cholesterol-Enriched Diet on Energetic 
Ratios in Rabbit Cerebral Cortex. (A) Statistically significant (p < 0.05) elevations 
were observed for the ratio of ATP/ADP in rabbits fed cholesterol-enriched diet 
for 12 weeks. (B) No statistically significant differences were observed for 
adenylate energy charge ((ATP + (/4ADP) / (ATP + ADP + AMP)). * p < 0.05 
versus control. Values are mean ± SD. Sample sizes are indicated on respective 
bars.
ADSL Transgenic Mice as a Model for Autism 
For autism, a group of pervasive neurodevelopmental disorders, genetic 
mutations and de novo copy number variations have been described (Abrahams 
& Geschwind, 2008). Here, we examined brain energy levels in mice with 
genetically modified ADSL, a gene associated with a sub-population of 
individuals with autism. Using mice genetically modified for D87E, a novel 
genetic mutation to the ADSL gene that results in severe autism (Spiegel et al., 
2006), and ADSL, a deficiency of which causes defects in purine metabolism and 
severe neurological and physiological symptoms (Spiegel et al., 2006) we
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measured levels of phosphocreatine and creatine. Because of limited sample 
size, we “forced” the statistical program to ignore sample size and generate 
approximate p values; this applies to data in Figures 10, 13, 16, & 19. For 
phosphocreatine, we observed significantly (p < 0.05) reduced levels for D87E 
and ADSL_P9383 transgenic mice (Figure 10A). Levels of creatine were reduced 
significantly (p < 0.01) for D87E as well (Figure 10B). However, 
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Figure 10: Effects of ADSL Genetic Modification on Levels of Creatine and 
Phosphocreatine in Mouse Cerebral Cortex. (A) Compared to wildtype founder 
mice, levels of phosphocreatine were decreased significantly (p < 0.05) in the 
D87E_M347 and ADSL_P9383 (p < 0.05) transgenic mice. (B) Levels of creatine 
were decreased significantly (p < 0.01) in cerebral cortex for the D87E M347 
transgenic mice. (C) No statistically significant changes were observed for the 
ratio of phosphocreatine/creatine ratios. * p < 0.05 versus control, ** p < 0.01
69
roduced with permission of the copyright owner. Further reproduction prohibited without permission.
versus control. Values are mean ± SD. Sample sizes are indicated on respective 
bars.
In a second shipment of mice from our collaborators in Denver we 
receieved D87E, ADSL, and R426H animals. The amino acid change of R426H 
is an ADSL mutation that results in moderate to severe autism (Spiegel et al., 
2006). With increased sizes within each group, normal statistical analyses were 
performed; this applies to Figures 11, 12, 14, 15, 17, 18, 20 & 21. Levels of 
phosphocreatine were reduced significantly (p < 0.05) in cerebral cortex in the 
transgenic ADSL_P9383 group (Figure 11 A) while levels of creatine were 
elevated significantly (p < 0.05) in transgenic ADSL_P365 mice (Figure 11B). No 
statistically significant changes were observed to phosphocreatine/creatine ratios 
(Figure 11C). No statistically significant changes in metabolite levels were noted 
in cerebellum (Figure 12).
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Figure 11: Effects of ADSL Genetic Modification on Levels of Creatine and 
Phosphocreatine in Mouse Cerebral Cortex. (A) Compared to wildtype founder 
mice, levels of phosphocreatine were decreased significantly (p < 0.05) for 
ADSL P9383 transgenic mice. (B) Levels of creatine were increased significantly 
(p < 0.05) in cerebral cortex for ADSL P9365 transgenic mice. (C) No statistically 
significant changes were observed for phosphocreatine/creatine ratios. * p < 0.05 
versus control. Values are mean + SD. Sample sizes are indicated on respective 
bars.
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Figure 12: Effects of ADSL Genetic Modification on Levels of Creatine and 
Phosphocreatine in Mouse Cerebellum. (A) Compared to wildtype founder mice, 
levels of phosphocreatine were decreased significantly (p < 0.05) in 
ADSL P9383 transgenic mice. (B) Levels of creatine were increased significantly 
(p < 0.05) in cerebellum for ADSL_P9365 transgenic mice. (C) No statistically 
significant changes were observed for phosphocreatine/creatine ratios. * p < 0.05 
versus control. Values are mean ± SD. Sample sizes are indicated on respective 
bars.
Next, we measured levels of adenine nucleotides. Levels of ATP (Figure 
13A, p < 0.01) and ADP (Figure 13B, p < 0.05) were significantly reduced in 
ADSL P9383 transgenic mice but remained unchanged for all other transcripts. 
Levels of AMP were not altered significantly in cerebral cortex for any group 
(Figure 13C).
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Figure 13: Effects of ADSL Genetic Modification on Levels of Adenine 
Nucleotides in Mouse Cerebral Cortex. (A) Compared to wildtype founder mice, 
levels of ATP were decreased significantly (p < 0.01) in the ADSL_P9383 
transgenic mice. (B) Levels of ADP were decreased significantly (p < 0.05) in 
cerebral cortex for ADSL_P9383 transgenic mice. (C) No statistically significant 
changes were observed for levels of AMP. * p < 0.05 versus control, ** p < 0.01 
versus control. Values are mean ± SD. Sample sizes are indicated on respective 
bars.
In ADSL_P9383 transgenic mice we observed a non-statistically 
significant decrease in levels of ATP cerebral cortex (Figure 14A) and increase in 
cerebellum (Figure 15A. The large standard deviations likely accounted for the 
lack of statistical significance. In R426H M1036 transgenic mice, levels of ATP in 
cerebral cortex (Figure 14A, p < 0.05) and ADP in cerebral cortex and cerebellum 
(Figure 14B & 15B p < 0.05) were elevated significantly whereas levels of AMP 
were decreased significantly (Figure 14C, p < 0.01) in cerebral cortex and
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displayed a non-significant trend toward a decrease in cerebellum (Figure 15C, p 
> 0.05). These findings of increased ADP and ATP were unexpected in R426H 
transgenic mice, but may caused by developmental changes (Alexiou & Leese, 
1992) or by other as yet unexplained technical reasons.
Figure 14: Effects of ADSL Genetic Modification on Levels of Adenine 
Nucleotides in Mouse Cerebral Cortex. (A) Compared to wildtype founder mice, 
levels of ATP were increased significantly (p < 0.05) in R426HJVI1036 transgenic 
mice. (B) Levels of ADP were increased significantly (p < 0.05) in cerebral cortex 
for R426H_M1036 transgenic mice. (C) Levels of AMP were decreased 
significantly (p < 0.05) for R426H M1036 transgenic mice. * p < 0.05 versus 
control. Values are mean ± SD. Sample sizes are indicated on respective bars.
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Figure 15: Effects of ADSL Genetic Modification on Levels of Adenine 
Nucleotides in Mouse Cerebellum. (A) Compared to wildtype founder mice, levels 
of ATP were increased significantly (p < 0.05) in R426H_M1036 transgenic mice. 
(B) Levels of ADP were increased significantly (p < 0.05) in ADSL_P9383 
transgenic mice. (C) Levels of AMP were decreased significantly (p < 0.05) in 
R426H_M1036 transgenic mice. * p < 0.05 versus control. Values are mean ±
SD. Sample sizes are indicated on respective bars.
Decreased levels of adenine nucleotides were noted for some transgenic 
groups born to founder mouse ADSL_P9383 whereas unexpected elevations 
were found when examining mice with the R426H transcript. To examine further 
potential differences, we calculated two energetic ratios; ATP/ADP and adenylate 
energy charge. In cerebral cortex from our first group of ADSL animals, we noted 
a significantly lower level of ATP from the group born to founder mouse P9383 
(Figure 13A), and this effect was confirmed with decreased ATP/ADP ratios 
(Figure 16A, p < 0.05) and adenylate energy charges (Figure 16B, p < 0.05).
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Figure 16: Effects of ADSL Genetic Modification on Energetic Ratios in Mouse 
Cerebral Cortex. (A) Compared to wildtype founder mouse, the ratio of ATP/ADP 
was decreased significantly (p < 0.05) in ADSL_P9383 transgenic mice. (B) 
Adenylate energy charge was decreased significantly (p < 0.05) for ADSL_P9383 
transgenic mice. * p < 0.05 versus control. Values are mean ± SD. Sample sizes 
are indicated on respective bars.
In the second group of genetically modified ADSL mice, animals born to 
founder ADSL_P9383 had non-statistically significant decreases in levels of ATP 
in cerebral cortex (Figure 14A), a significantly lower (p < 0.05) amount of ATP 
compared to ADP (Figure 17A), and no change in adenylate energy charge 
(Figure 17B). For cerebral cortex of mice from founder R426H_M1036’s litters, 
ATP and ADP increased significantly (Figure 14A & B) and the ATP/ADP ratios 
and adenylate energy charges were elevated significantly (Figure 17A & B).
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Figure 17: Effects of ADSL Genetic Modification on Energetic Ratios in Mouse 
Cerebral Cortex. (A) Compared to wildtype founder mice, ATP/ADP ratios were 
decreased significantly (p < 0.05) for ADSL_P9383 and increased significantly (p 
< 0.05) in the R426H_M1036 transgenic mice. (B) Adenylate energy charge was 
increased significantly (p < 0.05) for R426H_M1036 transgenic mice. * p < 0.05 
versus control. Values are mean ± SD. Sample sizes are indicated on respective 
bars.
For cerebellum, we observed a non-significant trend toward elevated ATP 
levels in mice bred from founder ADSL_P9383 (Figure 15A). The ATP/ADP ratios 
were not increased significantly (Figure 18A) and no change was observed for 
adenylate energy charge (Figure 18B). For cerebellum of transgenic mice born to 
founder R426H_M1036, ATP was non-significantly elevated (Figure 15A), ADP 
was increased significantly (Figure 15B), AMP was not significantly decreased 
(Figure 15C). ATP/ADP ratios were reduced significantly (Figure 18A, p < 0.05) 
whereas no change was demonstrated for adenylate energy charge (Figure 
18B).
77
•oduced with permission of the copyright owner. Further reproduction prohibited without permission.
ATP / ADP Ratio Adenylate Energy Charge
Figure 18: Effects of ADSL Genetic Modification on Energetic Ratios in Mouse 
Cerebellum. (A) Compared to wildtype founder mice, ATP/ADP ratios were 
decreased significantly (p < 0.05) in ADSL P9383 transgenic mice whereas this 
ratio was increased significantly (p < 0.05) in R426H_M1036 transgenic mice. (B) 
Adenylate energy charge was decreased significantly (p < 0.05) for 
R426H_M1036 transgenic mice. * p < 0.05 versus control. Values are mean ±
SD. Sample sizes are indicated on respective bars.
Next, we attempted to quantify levels of SAICAR and adenylosuccinate 
using HPLC-based techniques. Since these animals have genetically altered 
ADSL genes, it was expected that we would find levels of both our compounds of 
interest elevated significantly in cortex and cerebellum. We developed an 
accurate and reliable means to determine these compounds via photo-diode 
array HPLC and relatively pure SAICAR and adenylosuccinate standards were 
received and used. Surprisingly, SAICAR was not elevated in brain samples of 
transgenic mice as was expected and were even decreased significantly (p < 
0.05) in ADSL_P9383 (Figure 19).
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Figure 19: Effects of ADSL Genetic Modification on SAICAR Levels in Mouse 
Cerebral Cortex. Compared to the wildtype founder mice, levels of SAICAR were 
significantly (p < 0.05) lower for ADSL_P9383 transgenic mice. * p < 0.05 versus 
control. Values are mean ± SD. Sample sizes are indicated on respective bars.
We then analyzed cerebral cortex and cerebellum from our second set of 
ADSL animals for SAICAR and adenylosuccinate. We found that in cerebral 
cortex SAICAR levels were not changed significantly as a result of modifying the 
ADSL gene (Figure 20A). For adenylosuccinate levels, only R426H_M1036 mice 
exhibited stastically significant decreases (Figure 20B, p < 0.05). In cerebellum, 
we observed significantly (p < 0.05) elevated levels of SAICAR in D87E_M347 
mice (Figure 21A) however no significant changes were noted for 
adenylosuccinate levels (Figure 20B & Figure 21B).
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Figure 20: Effects of ADSL Genetic Modification on SAICAR and 
Adenylosuccinate Levels in Mouse Cerebral Cortex. (A) Compared to wildtype 
founder mice, levels of SAICAR were not significantly altered for any of the 
tested groups. (B) Levels of adenylosuccinate were significantly decreased (p < 
0.05) in R426H_M1036 transgenic mice. * p < 0.05 versus control. Values are 
mean ± SD. Sample sizes are indicated on respective bars.
S A IC A R  A d e n y lo su cc in a te
Figure 21: Effects of ADSL Genetic Modification on SAICAR and 
Adenylosuccinate Levels in Mouse Cerebellum. (A) Compared to the wildtype 
founder mice, levels of SAICAR were not significantly altered for any of the 
tested groups. (B) Levels of adenylosuccinate were decreased significantly (p < 
0.05) in R426HJVI1036 transgenic mice. * p < 0.05 versus control. Values are 
mean ± SD. Sample sizes are indicated on respective bars.
In an attempt to confirm that the SAICAR and adenylosuccinate peaks 
observed using HPLC techniques were indeed the compounds of interest we 
applied additional analytical techniques. Having collected fractions containing the
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apparent SAICAR peak, samples were lyophilized and analyzed by Dr. Erin 
Spiegel using the Bratton-Marshall assay method (Laikind et al., 1986). SAICAR 
was undetectable in our brain samples. We then collaborated with Dr. Alena 
Kubatova of the Mass Spectrometry Core at the University of North Dakota to 
apply electro-spray ionization mass spectrometer as well as through an HPLC- 
coupled tandem mass spectrometer. Although we detected SAICAR from spiked 
samples, we could not measure definitively SAICAR in our brain samples. 
Therefore, we remain uncertain as to the validity of the results illustrated in 
Figures 19-21.
Ts65Dn and GART Transgenic Mice as Models for Down Syndrome
The Ts65Dn mouse model of Down syndrome (Reeves et al., 1995) has 
trisomic genes important for mitochondrial metabolism (see Table 5). With these 
mice we tested the hypothesis that trisomy leads to increased energy production 
In 3 month old trisomic mice, phosphocreatine levels were decreased 
significantly (Figure 22A, p < 0.05) and were increased significantly (p < 0.05) in 
old animals (Figure 22A); levels of creatine and phosphocreatine/creatine ratios 
were not significantly changed (Figure 22B & C).
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Figure 22: Effects of Trisomy 21 on Levels of Creatine and Phosphocreatine in 
Mouse Cerebral Cortex. (A) Compared to 3 month old wildtype mice, levels of 
phosphocreatine were decreased significantly (p < 0.05) in 3 month old Ts65Dn 
mice. Levels of phosphocreatine were elevated significantly (p < 0.05) in old 
Ts65Dn animals. (B & C) There were no statistically significant changes in 
creatine levels or to ratios of phosphocreatine/creatine. * p < 0.05 versus control, 
** p < 0.01 versus control. Values are mean ± SD. Sample sizes are indicated on 
respective bars.
We next examined levels of adenine nucleotides between trisomic and 
normal mice for differing ages. Similar to preliminary data obtained at the 
University of Manitoba, we observed that levels of ATP were reduced 
significantly (p < 0.05) in trisomic mice 6 months of age compared to wildtype 
controls (Figure 23A). In addition, we found levels of ATP were increased 
significantly (p < 0.05) in old trisomic mice (Figure 23A) and that levels of ADP
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were reduced significantly (p < 0.05) at 6 months in trisomic mice (Figure 23B); 
ADP levels were not changed in old animals and no changes were observed for 
AMP.
AD P
Figure 23: Effects of Trisomy 21 on Levels of Adenine Nucleotides in Mouse 
Cerebral Cortex. (A) Compared to 6 month old wildtype mice, levels of ATP were 
decreased significantly (p < 0.05) at 6 months in Ts65Dn mice. Levels of ATP 
were elevated significantly (p < 0.05) in old Ts65Dn animals compared to age- 
matched controls. (B) Levels of ADP were decreased significantly (p < 0.05) at 6 
months in Ts65Dn mice compared to 6 month control mice. (C) Levels of AMP 
were not statistically different at any age between groups. * p < 0.05 versus 
control. Values are mean ± SD. Sample sizes are indicated on respective bars.
Next we calculated the ratios of ATP/ADP and adenylate energy charge 
as a function of each age from these groups. This ratio was reduced significantly 
in 3 (Figure 24A, p < 0.05) and 6 month old (Figure 24A, p < 0.001) animals, but 
was altered in old mice. Adenylate energy charge ratios were decreased
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significantly (p < 0.01) in 6 month old Ts65Dn mice compared to wildtypes 
(Figure 24B).
A T P  /  A D P R a tio  A d en y la te  E n e rg y  C harge
Figure 24: Effects of Trisomy 21 on Energetic Ratios in Mouse Cerebral Cortex.
(A) The ratio of ATP/ADP was decreased significantly in 3 month old (p < 0.05) 
and 6 month old (p < 0.001) Ts65Dn mice compared to age-matched controls.
(B) Adenylate energy charge was decreased significantly (p < 0.01) in 6 month 
old Ts65Dn mice. * p < 0.05 versus control. ** p < 0.01 versus control. *** p < 
0.001 versus control. Values are mean ± SD. Sample sizes are indicated on 
respective bars.
In Ts65Dn mice, adenosine levels were elevated significantly (p < 0.05) in 
3 and 6 month old mice (Figure 25); in old animals the levels were similar to 
those in control.
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Figure 25: Effects of Trisomy 21 on Levels of Adenosine in Mouse Cerebral 
Cortex. Adenosine levels were elevated significantly (p < 0.05) in 3 and 6 month 
old Ts65Dn mice compared to age-matched controls. * p < 0.05 versus control. 
Values are mean ± SD. Sample sizes are indicated on respective bars
Using wildtype control animal data from the Ts65Dn experiments, we 
analyzed energy measurements as a function of age. Aging decreases basal 
metabolic rates, decreases efficiency of the ETC, increases production of 
reactive oxygen species, and diminishes energy levels. Therefore, we 
hypothesized that aged wildtype animals would have lower energy levels in 
cerebral cortex compared to young and middle-aged adult mice. Levels of 
phosphocreatine were elevated significantly in old wildtype mice compared to 3 
(Figure 26A, p < 0.05) and 6 month old animals (Figure 26A, p < 0.001) whereas 
levels of creatine (Figure 26B) and the ratio of phosphocreatine/creatine were 
unchanged as a function of age (Figure 26C).
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Figure 26: Levels of Creatine and Phosphocreatine in Wildtype Mouse Cerebral 
Cortex as a Function of Age. (A) Compared to old wildtype mice, the levels of 
phosphocreatine were decreased significantly at 3 (p < 0.05) and 6 (p < 0.001) 
months of age. (B) There were no statistically significant changes in creatine 
levels and the ratio of phosphocreatine/creatine (C) between different age 
groups. * p < 0.05 versus control, *** p < 0.001 versus control. Values are mean 
+ SD. Sample sizes are indicated on respective bars.
We next analyzed the extent to which levels of adenine nucleotides and 
their energetic ratios were affected by aging. Levels of ATP (Figure 27A), ADP 
(Figure 27B), and AMP (Figure 27C) were unchanged across the various ages. 
We did however observe that the ratio of ATP/ADP increased significantly in old 
animals compared to 3 month (Figure 28A, p < 0.01) and 6 month (Figure 28A, 
p<0.05) old animals. Adenylate energy charge values (Figure 28B) were not 
affected by adenosine levels (Figure 29).
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Figure 27: Levels of Adenine Nucleotides in Wildtype Mouse Cerebral Cortex as 
a Function of Age. No statistically significant differences were observed for ATP 
levels (A), ADP levels (B), and AMP levels (C) as a function of age. Values are 
mean ± SD. Sample sizes are indicated on respective bars.
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Figure 28: Energetic Ratios in Wildtype Mouse Cerebral Cortex as a Function of 
Age. (A) The ratio of ATP/ADP was decreased significantly at 3 months (p <
0.01) and 6 months (p < 0.05) compared to old mice. (B) We did not observe any 
statistically significant changes for adenylate energy charge ((ATP + (1/4ADP) / 
(ATP + ADP + AMP)) between any age group. * p < 0.05 versus control. ** p <
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0.01 versus control. Values are mean ± SD. Sample sizes are indicated on 
respective bars.
Adenosine
Figure 29: Levels of Adenosine in Wildtype Mouse Cerebral Cortex as a Function 
of Age. Adenosine levels were not significantly different between any of the age 
groups. Values are mean ± SD. Sample sizes are indicated on respective bars
We next examined each energy measurement from the trisomic Ts65Dn 
mice as a function of age. We hypothesized that energy levels would be 
increased in aged animals due to compensatory responses. People with DS have 
an elevated cerebral metabolic rate for glucose and this could possibly facilitate 
increased energy levels in aged humans and mice prior to or in parallel to 
dementia. Levels of phosphocreatine were elevated significantly in old Ts65Dn 
mice compared to three (Figure 30A, p < 0.001) and six month old animals 
(Figure 30A, p < 0.001) whereas levels of creatine were unchanged (Figure 30B). 
The ratio of phosphocreatine/creatine was increased significantly in 6 month old 
mice from the levels observed in both 3 month (Figure 30C, p < 0.05) and old 
mice (Figure 30C, p < 0.05).
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Figure 30: Levels of Creatine and Phosphocreatine in Ts65Dn Mouse Cerebral 
Cortex as a Function of Age. (A) Compared to old Ts65Dn mice, the levels of 
phosphocreatine were decreased significantly at 3 (p < 0.001) and 6 (p < 0.001) 
months of age. (B) There were no statistically significant changes in creatine 
levels. (C) The ratio of phosphocreatine/creatine was significantly decreased in 3 
month old (p < 0.05) and old mice (p < 0.05) compared against 6 month old mice. 
* p < 0.05 versus control, *** p < 0.001 versus control. Values are mean ± SD. 
Sample sizes are indicated on respective bars.
We next analyzed the extent to which levels of adenine nucleotides and 
their energetic ratios were affected by aging in Ts65Dn mice. Levels of ATP were 
elevated significantly in aged animals compared to 3 month (Figure 31 A, p < 
0.05) and 6 month old mice (Figure 31 A, p < 0.01) whereas the levels of ADP 
were elevated significantly (p < 0.05) only in 3 month old mice compared to 6 
month old mice (Figure 31B). We did not find any significant changes to the 
levels of AMP across the age groupings (Figure 31C). The ratio of ATP/ADP and
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adenylate energy charge values increased significantly in aged animals 
compared to 3 month (Figure 32A, p < 0.001; Figure 32B, p < 0.01) and 6 month 
(Figure 32A, p<0.001; Figure 32B, p < 0.01) old animals. Adenosine levels did 
not exhibit age-related differences (Figure 33).
AM P
Figure 31: Levels of Adenine Nucleotides in Ts65Dn Mouse Cerebral Cortex as a 
Function of Age. (A) Compared to old Ts65Dn mice, levels of ATP were 
significantly lower in 3 month (p < 0.05) and 6 month (p < 0.01) old animals. (B) 
Levels of ADP are decreased significantly at 6 month compared to 3 month (p < 
0.05) trisomic mice. (C) No statistically significant differences were observed for 
the levels of AMP in Ts65Dn mice. * p < 0.05 versus control, ** p < 0.01 versus 
control. Values are mean ± SD. Sample sizes are indicated on respective bars.
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Figure 32: Energetic Ratios in Ts65Dn Mouse Cerebral Cortex as a Function of 
Age. (A) The ratio of ATP/ADP was decreased significantly in 3 month (p < 
0.001) and 6 month old (p < 0.001) compared to old trisomic mice. (B) Adenylate 
energy charge values were significantly (p < 0.01) lower in 3 month and 6 month 
old Ts65Dn mice. ** p < 0.01 versus control. *** p < 0.001 versus control. Values 
are mean ± SD. Sample sizes are indicated on respective bars.
Adenosine
Figure 33: Levels of Adenosine in Ts65Dn Mouse Cerebral Cortex as a Function 
of Age. Adenosine levels were not significantly different between any of the age 
groups. Values are mean ± SD. Sample sizes are indicated on respective bars
In our studies we examined the effects of genetically modifying a 
candidate gene of the purine biosynthetic pathway, GART, on brain energy 
levels. GART modifications occur in the enzymatic steps preceding production of 
SAICAR whereas ADSL mutations are performed in the steps proceeding 
SAICAR (Figure 6). Phosphocreatine and creatine levels were not significantly
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different in cerebral cortex (Figure 34A & B, respectively) and cerebellum (Figure 
35A & B, respectively). Phosphocreatine/creatine ratios were not significantly 
different in P8E5 P7293 cerebral cortex (Figure 34C) or cerebellum (Figure 
35C), however, were significantly (p < 0.001) reduced ratio in cerebellum of 
P8E5 P7139 mice (Figure 35C).
P h o s p h o c re a t in e C re a tin e
Figure 34: Effects of GART Genetic Modification on Levels of Creatine and 
Phosphocreatine in Mouse Cerebral Cortex. No statistically significant changes 
were observed for levels of phosphocreatine (A), creatine, (B), or 
phosphocreatine/creatine ratios. Values are mean ± SD. Sample sizes are 
indicated on respective bars.
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Figure 35: Effects of GART Genetic Modification on Levels of Creatine and 
Phosphocreatine in Mouse Cerebellum. No statistically significant changes were 
observed for levels of phosphocreatine (A), creatine, (B), or 
phosphocreatine/creatine ratios. Values are mean ± SD. Sample sizes are 
indicated on respective bars.
The GART gene codes for 3 enzymes, phosphoribosylglycineamide 
synthase (GARS), phosphoribosylglycineamide transformylase (GART), AIR 
synthase (a trifunctional protein; Spiegel et al., 2006). Because all of these 
enzymes catalyze reactions upstream from SAICAR in the purine de novo 
biosynthetic pathway we hypothesized that altering the GART gene would lead to 
decreased levels of adenine nucleotides in cortex and cerebellum. The levels of 
ATP were unchanged in cerebral cortex of genetically modified GART mice
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(Figure 36A) however were increased significantly (p < 0.05) in cerebellum of 
animals born to founder mouse P7293 (Figure 37A). This finding was unexpected 
because presumably these transgenic animals should have elevated SAICAR 
levels and therefore a lesser ability to generate and/or maintain ATP levels. Upon 
examination of ADP levels from these animals, we noted that these levels were 
elevated significantly (p < 0.05) as a result of the transgene in cortex from P7139 
litters (Figure 36B). There was no change in levels of ADP in cerebellum for 
either group (Figure 37B, p > 0.05). Levels of AMP were unchanged in cerebral 
cortex from GART mice (Figure 36C), however were significantly (p < 0.05) 
reduced from animals born from founder P7293 (Figure 37C). These elevations 
in ADP and ATP, like in ADSL, may be due to this GART modification having 
more profound effects developmentally than it does in adult animals with this 
increase in ATP resulting as a compensatory mechanism to previously 
diminished nucleotides.
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Figure 36: Effects of GART Genetic Modification on Levels of Adenine 
Nucleotides in Mouse Cerebral Cortex. (A) No statistically significant changes 
were observed for levels of ATP compared to wildtype founder mice. (B) Levels 
of ADP were increased significantly (p < 0.05) for P8E5_P7139 transgenic mice 
compared to its wildtype founder control. (C) Levels of AMP were not altered 
significantly for any transgenic group compared to its wildtype founder. * p < 0.05 
versus control. Values are mean ± SD. Sample sizes are indicated on respective 
bars.
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Figure 37: Effects of GART Genetic Modification on Levels of Adenine 
Nucleotides in Mouse Cerebellum. (A) Levels of ATP in P8E5P7293 were 
increased significantly (p < 0.05) compared to its wildtype control. (B) Levels of 
ADP were not altered significantly for either transgenic group compared to its 
respective wildtype control. (C) Levels of AMP were decreased significantly (p < 
0.05) in P8E5P7293 transgenic mice compared to its wildtype control. * p < 0.05 
versus control. Values are mean ± SD. Sample sizes are indicated on respective 
bars.
We calculated ATP/ADP ratios and adenylate energy charge values for 
GART mice and found that adenylate energy charge was elevated significantly (p 
< 0.05) in cerebral cortex from wildtype P8E5_P7293 mice (Figure 38B) and in 
cerebellum ATP/ADP ratios (Figure 39A, p < 0.01), adenylate energy charge 
(Figure 39B, p < 0.001).
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A T P /A D P  Ratio Adenylate Energy Charge
Figure 38: Effects of GART Genetic Modification on Energetic Ratios in Mouse 
Cerebral Cortex. (A) Compared to wildtype founder mice, ATP/ADP ratios were 
not significantly changed for either of the transgenic groups. (B) Adenylate 
energy charge values were increased significantly (p < 0.05) for P8E5_P7293 
transgenic mice compared to its wildtype founder mice. * p < 0.05 versus control 
Values are mean ± SD. Sample sizes are indicated on respective bars.
A T P  / A D P  R a tio A d e n y la te  E n e rgy  C ha rg e
Figure 39: Effects of GART Genetic Modification on Energetic Ratios in Mouse 
Cerebellum. Compared to wildtype founder mice, ATP/ADP ratios (A) and 
adenylate energy charge values (B) were increased significantly for P8E5_P7293 
transgenic mice compared to its wildtype control (p < 0.01 & p < 0.001, 
respectively). No statistically significant changes were observed for P8E5_P7139 
transgenic versus control animals. * p < 0.05 versus control. Values are mean ± 
SD. Sample sizes are indicated on respective bars.
In P8E5_P7293 transgenic animals we noted significantly lower levels of 
adenosine compared to wildtype controls in cerebral cortex (Figure 40, p < 0.001)
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and cerebellum (Figure 41, p < 0.05). This effect was not observed in 
P8E5 P7139 mice.
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Figure 40: Effects of GART Genetic Modification on Adenosine Levels in Mouse 
Cerebral Cortex. (A) Compared to the wildtype founder mice, levels of adenosine 
were decreased significantly (p < 0.001) for P8E5_P7293 compared to its 
wildtype founder control. *** p < 0.001 versus control. Values are mean ± SD. 
Sample sizes are indicated on respective bars.
A denosine
Figure 41: Effects of GART Genetic Modification on Adenosine Levels in Mouse 
Cerebellum. (A) Compared to the wildtype founder mice, levels of adenosine 
were decreased significantly (p < 0.05) for P8E5_P7293) compared to its 
wildtype founder control. * p < 0.05 versus control. Values are mean ± SD. 
Sample sizes are indicated on respective bars.
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Treatment of Rat Cerebral Cortical Neurons with HIV-1 Protein Tat as a Model
for HIV-1 Dementia
The HIV-1 protein Tat, but not mutant-Tat missing amino acids 31-61, 
causes neuronal cell death. To control for possible non-specific effects of Tat, 
parallel experiments were performed throughout these studies with equivalent 
concentrations of Tati.72 and mutant-Tat. Primary cultures of mouse cerebral 
cortical neurons treated for 24 h with concentrations of Tati.72 and mutant-Tat 
ranging from 10 pM to 400 nM (results for effects of 10 to 400 nM were illustrated 
in Fig. 42A) showed statistically significant decreases in the percentage of viable 
neurons with 100 nM (84.0% ± 12.1; p < 0.05) and 400 nM Tati.72 (60.4% ± 8.6; p 
< 0.001) but not mutant-Tat as determined by trypan blue exclusion (Figure 42B) 
and MTT assay (data not shown). Because of findings that Tat affects 
mitochondrial function and MTT assays reflect cell viability and mitochondrial 
function all subsequent experiments for determination of cell viability used trypan 
blue exclusion. Time profile studies for Tat-induced neuronal death established 
that Tati.72 at 100 nM increased significantly (p < 0.01) levels of neuronal cell 
death to comparable levels at incubations intervals of 24 and 48 h (Figure 42B). 
Accordingly, all subsequent studies on cell viability used Tat at a concentration of 
100 nM and incubations of 24 h.
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Time (h)
Figure 42: Tati-72 Concentration- and Time-Dependently Decreases Cortical 
Neuron Viability. (A) Treatment of neurons with Tati-72, but not mutant-Tab.72, at 
concentrations of 100 and 400 nM significantly reduced (p < 0.05 and p < 0.001, 
respectively) neuronal viability as determined with trypan blue exclusion (n=12). 
(B) Tat at a concentration of 100 nM produced time dependent increases in 
neuronal cell death as determined by trypan blue exclusion assay; statistically 
significant (p < 0.01) increases were observed with 24 h and 48 h incubations, (n 
= 5 for control, n = 6 for treatment groups) Results are expressed as the number 
of non-viable cells relative to total cell number. * p < 0.05, ** p < 0.01, *** p < 
0.001 versus untreated controls
Creatine Protection Against Tati.72-lnduced Neuronal Cell Death 
To test for creatine protection against Tati-72-induced neuronal cell death, 
neurons were treated with Tati.72 (100 nM) for 24 h in the absence or presence of 
creatine at concentrations of 1,3, 5, and 20 mM. Creatine, at a concentration of 3 
mM, significantly (p < 0.05) reduced levels of Tat-induced neurotoxicity from 12.6 
± 4.5 % to 6.5 ± 2.2 % (Figure 43).
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Figure 43: Creatine Concentration-Dependently Protects Against Tat-lnduced 
Neuronal Cell Death. Statistically significant (p < 0.01) increases in neuronal cell 
death were observed with treatments of 100 nM Tat at 24 h as determined by 
trypan blue exclusion assay. Statistically significant (p < 0.05) protection against 
Tat-induced neuronal cell death was observed with 3 mM creatine (n = 4). 
Results are expressed as the number of non-viable cells relative to total cell 
number. ** p ^ 0.01 Tat versus control.
Effects of Tat and Creatine on Levels of Adenine Nucleotides and
Phosphocreatine
To determine underlying mechanism(s) responsible for the neurotoxic 
actions of Tati-72 and the neuroprotective effects of creatine we measured, at a 
time period (4 h) that precedes the neurotoxic effects, levels of adenine 
nucleotides, creatine and phosphocreatine. Creatine (3 mM) treatment of 
neurons for 4 h significantly (p < 0.01) increased levels of ATP from control levels 
of 10.3 ± 0.3 to 13.6 ± 0.6 nmol/mg protein (Fig. 44A). After treatment with T a t ^  
(100 nM, 4h), ATP levels were significantly (p < 0.05) decreased to 7.3 ± 0.6 
nmol/mg protein. Co-application of 3 mM creatine with 100 nM Tati-72 for 4 h 
protected against Tat-induced decreases in ATP levels and returned levels to 
near control values of 10.0 ± 0.8 nmol/mg protein. Similar, but statistically non-
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significant, changes to levels of ADP (Figure 44B) and AMP (Figure 44C) were 
observed for the same treatment groups. When the data were calculated to 
determine adenylate energy charges (Figure 45B) or ATP/ADP ratios (Figure 
45A), no statistically significant differences were observed between controls and 
treated cells.
Figure 44: Effects of Tat, Mutant-Tat and Creatine on Levels of Adenine 
Nucleotides. (A) Compared with controls, creatine (Cr, 3 mM) increased 
significantly (p < 0.01), and Tat (100 nM) but not mutant-Tat (mTat, 100 nM) 
decreased significantly (p < 0.05) levels of ATP in cortical neurons. Creatine (3 
mM) co-applied with Tat (100 nM) significantly (p < 0.05) protected against Tat- 
induced decreases in levels of ATP. (B, C) Similar, but statistically non­
significant, changes to ADP (B) and AMP (C) were observed for treatments with 
Tat, mutant-Tat and creatine. (D, E) No statistically significant differences were 
observed for treatments with Tat, mutant-Tat and creatine on (D) adenylate 
energy charge or (E) levels of ATP/ADP (n = 5 for control, creatine, Tat, and
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creatine with Tat experiments, n=4 for mTat). * p ^ 0.05, ** p ^ 0.01 versus 
control.
Adenylate Energy Charge
Figure 45: Effects of Tat, Mutant-Tat and Creatine on Energetic Ratios. No 
statistically significant differences were observed for treatments with Tat, mutant- 
Tat and creatine on (A) adenylate energy charge or (B) levels of ATP/ADP (n=5 
for control, creatine, Tat, and creatine with Tat experiments, n=4 for mTat). * p s 
0.05, ** p < 0.01 versus control.
We next determined the effects of Tat and/or creatine on cellular levels of 
creatine and its associated source of tissue energetics, phosphocreatine. 
Incubation of cells with 3 mM creatine for 4 h resulted in statistically significant (p 
< 0.01) increases in cellular levels of creatine from control levels of 62.3 ± 3.2 
nmol/mg protein to 86.2 ± 5.0 nmol/mg protein (Figure 46A). Tissue levels of 
creatine were not significantly changed when cells were treated with 100 nM Tat 
(64.9 ± 3.4 nmol/mg protein) or with 100 nM mutant-Tat (60.0 ± 4.8 nmol/mg 
protein). Tat co-applied with creatine resulted in statistically significant (p <
0.001) increases in levels of creatine to 98.0 ± 4.4 nmol/mg protein (Figure 46A). 
Levels of phosphocreatine were not affected significantly by any of the 
treatments (Figure 47B). The ratio of phosphocreatine to creatine (Figure 46C) of 
1.2 ± 0.1 in controls was decreased significantly to 1.0 ± 0.04 by Tat (p < 0.05),
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to 0.8 ± 0.02 by creatine (p < 0.01) and to 0.7 ± 0.07 by creatine plus Tat (p < 
0.001). Co-applicatiori of creatine and Tat decreased significantly (p < 0.001) the 
ratio of phosphocreatine to creatine to a level significantly (p < 0.05) less than 
that observed with Tat alone.
Phosphocreatine
Phosphocreatine / Creatine Ratio
Creatine
Figure 46: Effects of Tat, Mutant-Tat and Creatine on Levels of Creatine and 
Phosphocreatine in Primary Rat Cortical Neurons. (A) Treatment of neurons with 
creatine, Tat, creatine plus Tat, and mTat did not significantly alter levels of 
phosphocreatine (B) Treatment of neurons with creatine (3 mM) increased 
significantly levels of creatine whether applied alone (p < 0.01) or concomitantly 
with Tat (p < 0.001). (C) Ratios of phosphocreatine to creatine were decreased 
significantly following treatment with either creatine (p < 0.01) or Tat (p < 0.05). * 
p < 0.05 versus control. Values are mean ± SD. Sample sizes are indicated on 
respective bars.
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Potential
Because HIV-1 Tat has been shown to affect mitochondrial function 
(Kruman et al., 1998; Langford et al., 2004; Perry et al., 2005) and creatine has 
been shown to have neuroprotective actions through mitochondrial mechanisms 
we next examined mitochondrial mechanisms related to redox catastrophe. Tat 
(100 nM, 4h) decreased significantly (p < 0.001) the ratio of JC-1 aggregate to 
monomer by about 36 % (Figure 47). This Tat-induced hypopolarization of 
mitochondria was blocked completely (p < 0.001) with co-application of creatine 
(Figure 47). Creatine and mutant-Tat alone had no significant effects on 
mitochondrial membrane potential.
p<  0.001
Creatine Protects Against Tat-lnduced Decreases in Mitochondrial Membrane
Figure 47: Effects of Tat, Mutant-Tat and Creatine on Mitochondrial Membrane 
Potential as Determined with the Fluorescent Dye JC-1. Tat (100 nM), but not 
mutant-Tat (mTat, 100 nM), decreased significantly (p < 0.001) mitochondrial 
membrane potential. Creatine (Cr, 3 mM) did not affect mitochondrial membrane 
potential, but creatine (3 nnM) co-applied with Tat (100 nM) significantly (p < 
0.001) blocked Tat-induced mitochondrial hypopolarization (n = 4). *** p < 0.001 
versus control.
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Permeability Transition Pores
Treatment of cultured neurons with 100 nM Tat caused a significant (p < 
0.01) increase in the number of cells with open mitochondrial permeability 
transition pores (Figure 48). Co-application of 3 mM creatine with Tat resulted in 
a statistically significant (p < 0.05) decrease in the number of cells with 
mitochondrial permeability transition pore opening compared to Tat treatment 
alone (Figure 48). Mutant-Tat and creatine alone had no significant effects on 
mitochondrial permeability transition pore opening.
Creatine Protects Against Tat-lnduced Increases in the Opening of Mitochondrial
p < 0.05
Figure 48: Effects of Tat, Mutant-Tat and Creatine on Opening of Mitochondrial 
Permeability Transition Pores as Determined with Calcein-AM Fluorescence and 
Cobalt Chloride Quenching. Tat (100 nM), but not mutant Tat (mTat, 100 nM), 
increased significantly (p < 0.01) the percentage of cells with open mitochondrial 
permeability transition pores. Creatine (Cr, 3 mM) did not affect pore opening but 
creatine (3 mM) when co-applied with Tat (100 nM) significantly (p < 0.05) 
blocked Tat-induced mitochondrial permeability transition pore opening (n = 5 for 
control, n = 4 for all treatment groups). ** p < 0.01 versus control
Effects of Tat and Creatine on Levels of Reactive Oxygen Species 
Tat (100 nM) increased significantly (p < 0.01) reactive oxygen species to 
a level similar to that observed with the positive control used, hydrogen peroxide
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(Figure 49). Creatine (3 mM) did not significantly reduce Tat-induced increases in 
levels of reactive oxygen species. Mutant-Tat (100 nM) produced statistically 
significant (p < 0.05) increases in levels of reactive oxygen species similar to 
those of cells treated with Tati.72.
***
Figure 49: Effects of Tat, Mutant-Tat and Creatine on Formation of Reactive 
Oxygen Species as Determined with the Fluorescent Dye H2DCFDA. Tat (100 
nM), creatine (3 mM) plus Tat (100 nM), mutant-Tat (100 nM) and the positive 
control hydrogen peroxide (H2O2, 500 pM) significantly increased reactive 
oxygen species. Creatine (3 mM) did not block Tat-induced increases in levels of 
reactive oxygen species (n=8 for all groups except creatine where n=9). * p s 
0.05, ** p < 0.01, *** p < 0.001 versus control.
Ketogenic Diet as a Treatment for Epilepsy 
KD Treatment Induces Rapid Ketonemia but Delayed Seizure Protection 
When effective, KD produces sustained ketonemia and increased seizure 
resistance to a variety of proconvulsant challenges (Appleton & DeVivo, 1974, 
Bough & Eagles, 1999, Rho et al., 1999). To determine how long the diet must 
be administered to achieve an anticonvulsant effect in adolescent rats, we 
monitored seizure threshold repeatedly in the same cohort of rats over nine 
weeks (n=16 KD and 11 control rats). Despite a precipitous increase in plasma
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BHB levels and a moderate hypoglycemia that developed within one day of diet 
initiation, the pentylenetetrazole (PTZ) seizure threshold was not consistently 
elevated above controls until at least 13 days of diet treatment (Figure 50A-D). 
To determine if the observed decline in seizure threshold in the control group 
was due to kindling by repeated administration of PTZ (Han et al., 2000), 
separate groups of seizure-naive rats were fed the KD or control diets for three 
weeks and then tested once for seizure threshold against either PTZ (n=25) or 
flurothyl (n=20). In both tests, seizure threshold was elevated compared to 
controls after the same duration (20-21 days) of KD treatment (Figure 50E,F). 
These findings suggest that the decline in PTZ seizure threshold over three 
weeks in control rats was not due to a chemical kindling effect, but instead may 
reflect a developmental change. We conclude that chronic but not acute ketosis 
is associated with the anticonvulsant action of the ketogenic diet.
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Figure 50: The Anticonvulsant Effect of the KD Develops Slowly. (A) 
Pentylenetetrazole (PTZ) seizure threshold, (B) plasma levels of (3- 
hydroxybutyrate (BHB), (C) body weight, and (D) plasma levels of glucose were 
measured repeatedly for 65 days before, during, and after administration of a KD 
to rats. The bar (D) represents the time during which a KD was administered to 
the KD group (solid circles). Control (CON) animals were maintained on normal 
chow, ad libitum throughout the experiment (open squares). On day 31, KD-fed 
animals were reverted to a control diet (gray circles). Points represent the mean 
± standard error of the mean (SEM) of each diet group: KD-fed (n = 16) and 
control animals (n = 11). * p < 0.05, analysis of variance. Separate cohorts of 
seizure-naive animals exhibited similar elevations in seizure threshold as 
evaluated by either PTZ (E; n = 25) or flurothyl (F; n = 20) after 20 to 21 days of 
diet treatment. Bars represent group mean + SEM. * p < 0.05, unpaired t test.
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Metabolic Genes are Coordinately Upregulated after KD 
The updated CDF file (Dai et al , 2005) was used to assign probe pairs to 
accession numbers for the Affymetrix rat 230A GeneChip. The updated 
assignments resulted in a reduction of the number of transcripts available on this 
chip from 15,866 (reported by Affymetrix) to 10,179. Normalization and filtering of 
the signal intensities resulted in 5518 genes that were reliably expressed (i.e., 
“present") in either or both treatment groups. Statistical analysis at a 1% false 
discovery rate yielded 658 differentially-expressed genes in the hippocampus 
after KD, seven of which were expected to be false positives. Only 60% of these 
differentially expressed genes were identified using the original CDF file available 
through Affymetrix. A total of 384 transcripts were induced (297 with known 
functions), whereas 274 were repressed (199 identified genes) after KD (Fig 
51 A). A list of all differentially expressed transcripts is available in Table 3 of the 
Appendix. Differentially expressed genes occurred for transcripts exhibiting a 
100-fold range of control expression levels (Figure 51 A). Low variability was 
generally observed across arrays (Figs 51A-B) and resulted in the ability to 
identify transcripts with as little as a ±16% repression or induction. The mean 
coefficient of variation (CV) of the expression level was 9%.
Batch searches of the differentially-regulated genes produced a Gene 
Ontology (GO) biological process for about half of the named genes. Many of the 
remaining genes could be assigned to functional categories after searches of 
EntrezGene, Genecards, the Rat Genome Database or PubMed. In all, 462 
genes could be assigned to one of eight functional categories (Figure 51C). More
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than half of these genes were associated with one of three categories: 
metabolism (104 genes), signal transduction (101 genes), and transcription (77 
genes).
Transcripts in one functional category (metabolism) were coordinately up- 
regulated after KD, whereas those in the synaptic transmission category were 
down-regulated (* p < 0.02 in Fig 51C, Fisher’s exact tests). Within the 
metabolism category, three subcategories of transcripts involved in energy (34 
genes), lipid (17 genes), and protein (34 genes encoding proteolytic enzymes or 
proteasomes) metabolism predominated; 19 others were not members of these 
three sub-categories. Energy metabolism genes accounted for the coordinate 
induction of this transcript category after KD (p < 0.0001, Fisher’s exact test with 
Bonferroni correction, Fig 52A). All 34 of the transcripts in this category were 
upregulated. Hierarchical clustering of expression values for differentially- 
expressed energy metabolism genes showed that both transcripts associated 
with gIFycolysis, all six in the tricarboxylic acid (TCA) cycle pathway, and all 21 
encoding oxidative phosphorylation enzymes, were up-regulated after KD (Figure 
52B). The oxidative phosphorylation transcripts encoded protein subunits of 
complex I (five subunits of NADH dehydrogenase), complex II (subunits A and D 
of succinate dehydrogenase), complex IV (cytochrome C oxidase subunit V ia l), 
and five subunits of the Fo-F-i ATP synthase complex. Transcripts for creatine 
kinase, glycogen phosphorylase, glucose-6-phosphate dehydrogenase, and 
acetyl-coA synthase 2 were also upregulated.
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If the modest but concerted upregulation of transcripts encoding metabolic 
proteins were focused in a subpopulation of principal cells rather than distributed 
throughout the hippocampus, differential expression of these transcripts should 
be much larger in cells harvested by laser capture microscopy and assayed by 
quantitative RT-PCR. Based on estimates of the relative amounts of RNA in 
each neuron population compared with whole hippocampus, and assuming all of 
the change was concentrated within one cell population, one would predict a log2 
ratio for most of the differentially expressed transcripts >3, well within the limit of 
detection for quantitative RT-PCR. l_og2 ratios of >0.8 can be consistently 
detected in qRT-PCR (Greene et al., 2005). If on the other hand the modest 
upregulations observed were distributed evenly over various cell types in 
hippocampus, qRT-PCR should show no differences. This hypothesis was tested 
for dentate granule cells and CA1 pyramidal cells by assaying the levels of eight 
energy metabolism transcripts by qRT-PCR. In this experiment there was no 
measurable difference in energy transcript levels for neurons isolated from KD or 
control-fed rats. These findings suggest that the KD caused a widespread, 
coordinate up-regulation of energy metabolism transcripts across hippocampal 
cell types.
A coordinated upregulation of 19 proteasome -  related transcripts 
occurred in hippocampus after KD, compared with only four downregulated 
transcripts. A previous report (Sullivan et al., 2004) showed that proteasome 
inhibition was associated with reduction in the activity of complex I and II 
components of oxidative phosphorylation in hippocampal mitochondria, thus
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upregulation of proteasome transcripts is consistent with enhanced oxidative 
phosphorylation.
A total of 39 genes directly associated with ion channels or synaptic 
transmission changed after KD. Downregulated transcripts (n=23) predominated 
(Figure 51C, p < 0.01), which included two voltage-dependent calcium channel 
subunits (y4 and a1D), the CICN1 chloride channel, the KCNH3 and KCNE1-like 
potassium channels, P2X3 and P2X7 purinergic receptors, and synaptotagmins 6 
and XI. Upregulated transcripts (n=16) include the glutamate receptor subunits 
GluR2 and KA1, the KCNN2 potassium channel, the SCN1a type la sodium 
channel subunit, and the SLC1A1 glutamate transporter (EAAC1). No genes 
encoding GABAb receptors, metabotropic glutamate receptors, or subunits of 
NMDA receptors were induced or repressed after KD. Elucidation of the 
functional consequences of these changes requires further study.
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Figure 51: Changes in Gene Expression after KD. (A) Genes induced (gray 
circles) or repressed (white circles) after KD (1% false discovery rate; n = 658; 
see Materials and Methods). Each symbol depicts one transcript. Variability 
(dashed line) is represented by the mean coefficient of variation (CV) determined 
as in B. (B) The relation between CV and control expression level was calculated 
from the best fit of the plot of the mean CV versus mean expression for all 
differentially expressed probe sets (n = 6 arrays). (C) The number of genes 
induced or repressed in each functional category after KD. Functional categories 
were assigned to 462 differentially expressed known genes. Each bar represents 
the total number of genes per category. Two categories were significantly 
upregulated or downregulated after KD (* p < 0.02, Fisher's exact test). No 
differences in activities of selected energy metabolism enzymes.
In view of the microarray results, we determined whether a coordinate up- 
regulation in energy transcripts in the hippocampus was paralleled by an 
increase in metabolic enzyme activities after KD. We found that activities of 
glycolytic enzymes (hexokinase, glucose-6-phosphate dehydrogenase, and 
lactate dehydrogenase) and enzymes nvolved in the TCA cycle (citrate 
synthase, a-ketoglutarate dehydrogenase, and malate dehydrogenase) were not 
significantly altered after KD (Table 1). Except for malate dehydrogenase (Figure 
52B), transcripts for the other enzymes were unchanged after KD or below
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detection level. These data suggest that the modest increases in transcript levels 
observed (<35%, Figure 52B) were insufficient to cause significant increases in 
enzyme activities measured in vitro. At a = 0.05, the power to detect a 25% 
change in enzyme activity was 291% for all of these enzyme assays. Small, 
individually unremarkable increases in the activity of several sequential enzymes 
in a metabolic pathway can, however, cause a substantial increase in total flux 
through the pathway. Indeed, the increased glutamate level (Table 1) probably 
reflects a higher flux through the TCA cycle. The integration of glutamate, 
glutamine and alanine levels, all of which are energy metabolites, also shows a 
larger combined level in hippocampus of KD (17.7 ± 0.4 nmoles/mg wet weight) 
rats than controls (16.3 ± 0.2; p = 0.02).
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Figure 52: Metabolic Genes Changed after KD. (A) The 104 metabolism-related 
genes in Figure 52C could be further subcategorized into energy metabolism, 
lipid metabolism, protein (proteolysis and proteasome) metabolism, and a 
miscellaneous subgroup. Bars indicate the total number of genes per subgroup. 
Two categories showed coordinate regulation of the genes in the category (* p < 
0.0001 for energy metabolism, and p < 0.02 for lipid metabolism, Fisher’s exact 
test with Bonferroni correction). (B) Relative expression levels of 24 energy 
metabolism genes that were upregulated by KD. Each row corresponds to one 
gene. Genes associated with glycolysis, the tricarboxylic acid (TCA) cycle, or 
oxidative phosphorylation are grouped.
Increased Number of Mitochondrial Profiles in the Hippocampus after KD 
Ketosis and fasting result in loss of oxidative phosphorylation and 
mitochondrial function and numbers in muscle (Lecker et al., 2004, Yechoor et 
al., 2002). We next determined whether the concerted increase in expression of 
energy metabolism genes in hippocampus (Figure 52) was accompanied by
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mitochondrial biogenesis. By visually scoring electron micrographs taken from 
the dentate/hilar region of hippocampus, we found significantly more 
mitochondrial profiles in animals fed a KD compared to controls (Figure 53). Data 
were remarkably consistent across animals (CV=3% for both KD and CON), 
indicating a 46% increase in mitochondrial profiles for KD-fed animals versus 
controls (Figure 53B left panel). In the same micrographs there was no difference 
in the number of dendritic profiles (Figure 53B right panel). The large majority of 
mitochondria counted in both control and KD tissue appeared to be located in 
neuronal processes (dendrites or axon terminals). The finding of increased 
numbers of mitochondrial profiles was reinforced by our observation that 39 of 42 
differentially regulated transcripts encoding mitochondrial proteins were 
upregulated after KD (Figure 53C). In addition to 23 energy metabolism genes, 
up-regulated mitochondrial transcripts included two mitochondrial ribosome 
subunits (L20 and L53), the ANT3 and ANT4 nucleotide transporters, ornithine 
aminotransferase, acyl-coA synthase 3 and hydroxyacyl-coA dehydrogenase.
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Figure 53: Mitochondrial Biogenesis in Hippocampus of Rats Fed a KD. (A) 
Representative electron micrographs taken from control- (CON) or KD-fed 
animals (original magnification, X 20,000; calibration bar = 0.5 pm). Arrow 
indicates a mitochondrial profile. The number of mitochondrial profiles in each 
micrograph was counted. (B) There were significantly more mitochondrial profiles 
in the dentate gyrus of KD-fed animals than in control animals. Mitochondrial 
counts were taken from 4 KD-fed animals representing a total of 2,680 pm2 and 5 
control rats representing 3,080 pm2. Data are presented as mean of averaged 
counts ± standard error of the mean per 100 pm2 (n = 4 or 5). * p < 0.001, t test. 
By comparison, there was no difference in the density of dendritic profiles in the 
same micrographs, which guards against differential shrinkage of the tissue in 
KD versus control brains. (C) A total of 39 transcripts, assayed by microarray, 
encoding mitochondrial proteins were upregulated after KD (open bar), whereas 
only one transcript was downregulated (gray bar). ** p < 0.0001, Fisher’s exact 
test.
Energy Reserves are Increased after KD 
We next determined whether the coordinate induction of energy 
metabolism genes and mitochondrial biogenesis led to increased production of 
energy metabolites in hippocampus after KD. The (3-hydroxybutyrate level was 
significantly (p < 0.001) elevated. Glycogen was significantly (p = 0.01) 
decreased after KD as expected from the moderate hypoglycemia, whereas 
glutamate and glutamine were elevated (Table 1).
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Table 1: Levels of Energy Metabolites following Ketogenic Diet.
E nzym e o r  M etabo lite C O N  (m ean  — SD ) n K D  (m ean ±  S D ) tl P
Enzym es
H  exokinase 7 .2 0  ±  1.46 10 7 .19  ±  0.71 10 0 .9 8
G lucose 6 -phospha te  dehydrogc- 1.13 ±  0 .0 9 9 1.21 ± 0 .2 1 9 0 .2 9 6
nase
L actate dehydrogenase 2 6 .0  ±  1.32 6 23 .9  ±  2 .31 6 0 .0 8 7
p-H vdroxvbtitv race dehydrogenase 1.22 ±  0 .0 9 10 1.28 ± 0 . 1 6 10 0 .32
C itra te  synthase 2 4 .3  ±  2 .33 10 26 .2  ±  4 .8 9 10 0 .2 8
or -Kecoglutarate dehydrogenase 1 .54  ± 0 . 1 7 10 1.54 ± 0 . 2 4 10 0 .9 7
M aiacc dehydrogenase* 9 8 .6  ±  10.3 10 90 .8  ±  14.2 10 0 .1 7
M etabo lites
G lu tam ate 11.5 ±  0 .43 9 12.2 ±  0 .4 8 9 0 .0 3
G lu tam in e 4 .04  ±  0 .2 4 9 4 .5 3  ±  0.41 9 0.01
A spartate 1.98 ±  0 .1 7 9 1.99 ±  0 .1 8 9 0.84
G 1yd ne 2 .83  ± 0 .1 5 9 3.11 ±  0 .3 2 9 0 .0 3
T au rin e 5 .79  ±  0 .28 9 4 .6 3  ±  0 .3 7 9 < 0 .0 0 1
A lan ine 0 .7 4  ±  0 .03 9 0.81 ±  0 .0 7 9 0.01
C itra te 0 .0 9 2 3  ±  0.011 9 0 .0 8 5 6  ±  0 .0 1 2 7 10 0 .24
G lycogen 3 .68  ±  0 .2 2 8 2 .88  ±  0 .1 9 0 0.01
Procein/w et w e ig h t1* 0 .1 1 9  ± 0 .0 0 4 10 0 .1 1 9  ±  0 .0 0 7 10 0 .8 8
P C r:C t rario 1.32 ±  0 .038 ~T 1.48 ±  0 .0 4 5 9 0 .0 1 7
Glycogen measurements were performed on rats killed by head-focused, high- 
energy microwave irradiation to preserve in vivo nucleotide levels. The other 
analyses were from fresh-frozen tissue. Data were expressed as nmol/mg wet 
weight (metabolites) or nmol/mg wet weight/min (enzymes). An unpaired 
Student’s t test was used to compare statistical differences of the mean between 
groups.a Mitochondrial cytosolic.b Milligram protein/mg hippocampal fresh tissue, 
reported as a measure of potential protein catabolism or of hydration changes 
that might have affected analyses. CON = control; SD = standard deviation.
There was a significantly larger phosphocreatine to creatine ratio (Figure 
55C, p < 0.05, t-test) in rat hippocampus following three weeks on KD. ATP, ADP 
and AMP levels were not significantly increased in hippocampus after KD, 
although ADP level showed a 2-fold trend towards an increase. Other discrete rat 
brain regions were also assayed for adenine nucleotides, phosphocreatine and 
creatine and these findings support our published hippocampal data (Bough et 
al., 2006). There was a significantly (p < 0.01) elevated phosphocreatine to 
creatine ratio in hypothalamus (Figure 54C). Although levels of ATP were not 
changed in hippocampus, we observed levels elevated significantly in cerebral
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cortex (p < 0.05), hypothalamus (p < 0.001), and striatum (Figure 55A, p < 0.05). 
Levels of ADP and AMP were unaltered (Figure 55B & C). Dependent on levels 
of adenine nucleotides in a particular brain region in relation to each other, 
alternative measurements of brain energetics can be obtained by comparing 
either ATP/ADP ratios or the adenylate energy charge values. We observed a 
significantly (p < 0.001) elevated ratio of ATP to ADP in brain from rats fed a KD 
in hypothalamus and striatum (Figure 56A). Significantly increased adenine 
nucleotide energy ratios were demonstrated after KD administration in most 
regions examined; cerebral cortex (p < 0.01), hypothalamus (p < 0.01), striatum 
(p < 0.05), and cerebellum (Figure 56B, p < 0.05). Levels of adenosine were 
quantified for brain regions, excluding hippocampus, and no significant changes 
were observed although there was a trend toward increased adenosine levels 
(Figure 57). Because most of the tissue glutamate in the brain is used as an 
energy source rather than neurotransmitter (Walaas & Fonnum, 1980), our 
results are consistent with the notion that energy reserves are elevated in rat 
brain after KD. The magnitude and direction of change of metabolites measured 
here in hippocampal tissue after the KD are similar to those reported by DeVivo 
et al. (1978) for whole brain.
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P h o s p h o c re a tin e  C reatine
Phosphocreatine / Creatine Ratio
Figure 54: Effects of KD on Levels of Creatine and Phosphocreatine in Discrete 
Rat Brain Regions. (A) Compared with controls, levels of phosphocreatine were 
not statistically different in any of the tested brain regions following administration 
of an 8% KD for 3 weeks. (B) We did not observe any statistically significant 
differences in levels of creatine. (C) Statistically significant increases were 
observed for the ratio of phosphocreatine/creatine in hippocampus and 
hypothalamus compared to control rats. * p < 0.05 versus control. Values are 
mean ± SD. Sample sizes are indicated on respective bars.
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ATP ADP
AMP
Figure 55: Effects of KD Administration on Levels of Adenine Nucleotides in 
Discrete Rat Brain Regions. (A) Levels of ATP increased significantly in cerebral 
cortex (p < 0.05), hypothalamus (p < 0.001), and striatum (p < 0.05) after 
administration of an 8% KD for 3 weeks. (B) We observed statistically non­
significant elevations in levels of ADP in cerebral cortex, striatum, and 
cerebellum compared to control rats. (C) No statistically significant changes were 
observed for AMP levels in all tested brain regions compared to controls. * p < 
0.05 versus control, ** p < 0.01 versus control, *** p < 0.001 versus control. 
Values are mean ± SD. Sample sizes are indicated on respective bars.
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A T P /A D P  Ratio Adenylate Energy Charge
Figure 56: Effects of KD Administration on Energetic Ratios in Discrete Rat Brain 
Regions. (A) We observed statistically significant increases for the ratio of 
ATP/ADP after administration of an 8% KD for 3 weeks in hypothalamus and 
striatum compared to control rats (p < 0.001). (B) Statistically significant 
increases for the adenylate energy charge were all demonstrated in cerebral 
cortex and hypothalamus (p < 0.01), striatum and cerebellum (p < 0.05). * p < 
0.05 versus control, ** p < 0.01, *** p < 0.001. Values are mean ± SD. Sample 
sizes are indicated on respective bars.
Figure 57: Effects of KD Administration on Levels of Adenosine in Discrete Rat 
Brain Regions. Compared with controls, we observed statistically non-significant 
increases (p < 0.05) for levels of adenosine after administration of an 8% KD for 
3 weeks in cerebral cortex, striatum, and cerebellum. Values are mean ± SD. 
Sample sizes are indicated on respective bars.
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To verify our initial findings that brain energy levels in rats fed a KD were 
significantly elevated we repeated our experiments. Levels of phosphocreatine 
were elevated significantly in hippocampus (p < 0.05), cerebral cortex (p < 0.05), 
and striatum (Figure 58A, p < 0.05) following administration of KD. In KD-fed rats 
levels of creatine were increased significantly (p < 0.05) in cerebral cortex (Figure 
58B). No changes to the ratio of phosphocreatine to creatine were noted (Figure 
58C). ATP levels were elevated significantly in hippocampus (p < 0.05) and 
cerebral cortex (Figure 60A, p < 0.01). Cortical levels of ADP were increased 
(Figure 60B, p < 0.05) whereas AMP levels were not significantly increased 
(Figure 59C). Upon examination of ATP/ADP ratios and adenylate energy charge 
values we did not observed any changes (Figure 60A-B). Levels of adenosine 
were quantified and significant increases were noted in cerebral cortex (Figure 
61, p < 0.05), striatum (p < 0.05), and cerebellum (p < 0.05).
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P h o s p h o c re a tin e  C rea tine
Phosphocreatine / Creatine Ratio
Figure 58: Effects of KD Administration on Levels of Creatine and 
Phosphocreatine in Discrete Rat Brain Regions. (A) Compared with controls, 
levels of phosphocreatine increased significantly (p < 0.05) in hippocampus, 
cerebral cortex, and striatum following administration of an 8% KD for 3 weeks. 
(B) Levels of creatine were elevated significantly (p < 0.05) in cerebral cortex 
compared to control animals. (C) No statistically significant changes were 
observed for the phosphocreatine/creatine ratios in all brain regions compared to 
controls. * p < 0.05 versus control. Values are mean ± SD. Sample sizes are 
indicated on respective bars.
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ATP  AD P
Hippocampus Cortex Striatum Cerebellum
Figure 59: Effects of KD Administration on Levels of Adenine Nucleotides in 
Discrete Rat Brain Regions. (A) Compared with controls, levels of ATP increased 
significantly in both hippocampus (p < 0.05) and cerebral cortex (p < 0.01) 
following administration of an 8% ketogenic diet for 3 weeks. (B) Levels of ADP 
were elevated significantly (p < 0.05) in hippocampus compared to control rats. 
(C) No statistically significant changes were observed for AMP levels in all tested 
brain regions compared to controls. * p < 0.05 versus control, ** p < 0.01 versus 
control. Values are mean ± SD. Sample sizes are indicated on respective bars.
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A T P  /  AD P R a tio  A d e n y la te  E n e rg y  C harge
Figure 60: Effects of KD Administration on Energetic Ratios in Discrete Rat Brain 
Regions. (A) Compared with controls, no statistically significant differences were 
observed for ATP/ADP ratios after administration of an 8% KD for 3 weeks in all 
tested brain regions. (B) No significant differences were observed for adenylate 
energy charge in all measured brain regions. * p < 0.05 versus control. Values 
are mean ± SD. Sample sizes are indicated on respective bars.
A d e n o s in e
Figure 61: Effects of KD Administration on Levels of Adenosine in Discrete Rat 
Brain Regions. Compared with controls, adenosine levels were increased 
significantly (p < 0.05) after administration of an 8% KD for 3 weeks in cerebral 
cortex, striatum, and cerebellum. No statistical difference was observed for 
hippocampus. * p < 0.05 versus control. Values are mean ± SD. Sample sizes 
are indicated on respective bars.
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Synaptic Transmission is More Resistant to Low Glucose after KD 
Synaptic transmission is highly dependent on ATP availability (Attwell & 
Laughlin, 2001). In view of our findings of a diet-induced modest enhancement in 
brain energy reserves, we asked whether synaptic transmission in hippocampal 
slices from KD-fed animals is significantly more resistant to mild metabolic stress 
compared to controls (Figure 62). Paired stimuli (50 ms delay) were delivered to 
the medial perforant path and field excitatory postsynaptic potentials (fEPSPs) 
were recorded from the dentate granule cell layer (Figure 62A). Stimulus 
intensities required to evoke fEPSPs (30-70 pA) did not differ across experiments 
or treatment groups. Reducing the bath glucose concentration from 10 mM to 2 
mM for 7 to 10 min rapidly and reversibly depressed the slope of the fEPSP by 
53 ± 9% in controls, but only by 27 ± 8% in KD-fed animals (Figure 62B, upper 
panel; p < 0.001 difference between CON and KD, ANOVA). Paired-pulse ratios 
increased in response to low glucose in slices taken from control and KD rats 
(Figure 62B, lower panel; p < 0.001, ANOVA), which supports the notion that 
diminished energy supply leads to an increased failure of transmitter release.
The latency to onset of the effect induced by low glucose varied substantially 
from slice to slice in control rats (Figure 62C), but for each pair of slices studied 
simultaneously (i.e., one from a KD-fed animal and one from a control-fed 
animal), the onset of fEPSP reduction after low glucose always occurred more 
rapidly in control tissue than in KD tissue (Figure 62C, n = 9 slice pairs from 6 
pairs of rats). In slices taken from KD-fed animals, the latency to 25% inhibition of 
the fEPSP was 46 ± 10% longer than that of control slices (Figure 62C, p <
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0.002, paired t-test). This difference, however, waned after slices were incubated 
in normal glucose-containing artificial CSF at room temperature for greater than 
3.5 h (data not shown), as expected if brain metabolism could revert rapidly when 
excess glucose is supplied. Collectively, these findings support the notion that 
KD-induced enhancement in energy reserves can maintain synaptic transmission 
in the dentate gyrus for longer periods of time under metabolic stress.
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Figure 62: Synaptic Transmission is More Resistant to Metabolic Challenge in 
Slices taken from KD-Fed Animals than those from Control-Fed Animals. (A) 
Representative paired-pulse evoked responses from control (top set of traces) 
and KD-fed (bottom set of traces) animals before (baseline) and 10 minutes after 
perfusion with low glucose (2 mM). Responses are the average of five traces. 
Symbols denote stimulus artifacts. (B) Average response of hippocampal slices 
prepared from control (open squares; n = 5 rats, 9 slices) and KD tissue (filled 
circles; n = 5 rats, 9 slices) to challenge with low (2 mM) glucose. (Top) Symbols 
represent the mean slope of the field excitatory postsynaptic potential (fEPSP) 
slope ± standard error of the mean (SEEM). The peak reduction in fEPSP slope 
(averaged over measurements during the period shown by the bar) after 
challenge with low glucose was significantly greater in control animals (** p < 
0.001, analysis of variance [ANOVA]). (Bottom) Paired-pulse responses during 
low glucose (** p < 0.001 compared w th control period, ANOVA). (C) Failure of
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synaptic transmission during low glucose was delayed in slices taken from KD- 
fed animals compared with control slices. Mean latencies to 25% reduction in 
synaptic efficacy are shown for experimentally matched slices prepared from 
control (open squares) and KD (filled circles) rats. Bars represent the mean.
Exogenously Applied Adenosine Decreases fEPSP Amplitude after KD.
Adenosine is the brain’s endogenous anticonvulsant and an endogenous 
neuromodulator that is released during seizures, ischemia, and hypoxia (Berman 
et al., 2000; Fredholm et al., 1984; Olsson et al., 2004). It exerts both 
antiepileptic and neuroprotective effects (Ribeiro et al., 2003) that are mediated 
by adenosine receptors, of which the inhibitory Ai receptor subtype (AiR) is the 
most abundant in seizure prone regions, such as hippocampus (Fredholm et al., 
2001, 2005b). Since our previous experiments demonstrated that KD-fed brain 
has elevated energy metabolite and adenosine levels as well as a greater latency 
to low glucose levels, we examined in collaboration with Dr. Susan Masino at 
Trinity College, the effects of adenosine (50 pM) application to hippocampal 
slices on fEPSP amplitude from animals fed either a control or KD. We 
hypothesized that KD-fed animals would have reduced excitability in response to 
adenosine. We found that indeed KD fed brain has a reduction in excitability to 
exogenously applied adenosine (Figure 63). Collectively, these findings support 
the notion that adenosine has a greater propensity to inhibit excitability in this 
tissue and these effects, although still undetermined in our model system, are 
likely to occur through the A-|R because this adenosine receptor has a strong 
inhibitory effect on excitatory synaptic transmission (Cunha, 2005).
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Figure 63: Effect of KD on fEPSP Amplitude in Hippocampus. Application of 
adenosine (50 pM) differentially inhibited the baseline fEPSP in hippocampal 
slices obtained from KD-fed versus control animals (p < 0.05). The control slices 
showed greater inhibition than the slices from KD animals. Error bars are SD.
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There is considerable evidence suggesting that impaired energy 
metabolism, along with mitochondrial dysfunction plays a fundamental role in the 
pathogenesis and progression of neurodegenerative disorders as a primary 
and/or secondary mechanism in the neuronal death cascade (Beal, 2005). This 
not only comprises neurodegenerative disorders, but furthermore acute and 
chronic conditions of the central and peripheral nervous systems. Although other 
means may exacerbate bioenergetic dysfunction, for instance changed 
transcription and protein aggregation; blighted energy metabolism may elicit pro- 
apoptotic signaling, oxidative damage, excitotoxicity, and hinder nuclear and 
mitochondrial DNA repair. These pathologic messages can interact and 
potentiate each other and result in an unrelenting cycle of energy depletion. 
Energy is important to the biological and molecular regulation of multiple cellular 
functions and therefore diminished energy levels threaten cellular homeostasis 
and integrity.
While the notion of neuroprotection was first considered by Greek 
physicians using hypothermia to treat stroke, a modern-day therapeutic strategy 
inducing sustained ATP levels may have both direct and indirect importance in 
ameliorating the severity of many of the pathogenic mechanisms associated with
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neurological disorders. Indeed, if neuronal dysfunction and loss are caused by 
diminished energy stores, then therapeutic regimens that buffer intracellular 
energy levels may hinder progression or prevent the neurodegenerative process 
(Klein & Ferrante, 2007). A major store of energy in the brain is ATP, which is 
closely tied to creatine and phosphocreatine levels within cells. Creatine is 
shuttled across membranes via a creatine transporter, CreaT (Snow & Murphy, 
2001) and creatine kinase catalyzes the reversible transfer of a phosphoryl group 
from phosphocreatine to ADP, generating ATP. Creatine counterbalances energy 
depletion by forming phosphocreatine, providing a spatial energy buffer to re- 
phosphorylate ADP to ATP at sites of energy utilization and forming 
phosphocreatine and ADP from creatine and ATP at locations of high-energy 
phosphate fabrication (Tombes & Shapiro, 1985). Therefore, increasing creatine 
levels may replenish energy stores and hence improve neuronal function. 
Moreover, creatine is implicated in regulating glycolysis, stabilizing the 
mitochondrial variety of creatine kinase, and thus inhibiting the mitochondrial 
permeability transition pore (O’Gorman et al., 1997).
Cholesterol Fed Rabbits as a Model for Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of degenerative 
dementia, characterized by profound memory impairment, reduced self-care, 
behavioral and psychological symptoms, and emotional troubles (Mimura, 2008). 
Previous reports have demonstrated decreased energy levels in probable AD 
(Pettegrew et al., 1994) and this led to our hypothesis that energy levels in 
cholesterol-fed rabbit cortex will be reduced. Following a 12 week dietary
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administration of a 2% cholesterol diet we observed a trend toward lower levels 
of phosphocreatine and this is not surprising since hypercholesterolemia-induced 
ischemic myocardia in swine reduced levels of phosphocreatine by 50% (Skinner 
et al., 1973). As well, patients with AD have reduced levels of phosphocreatine 
(Pettegrew et al., 1994). Significantly lower creatine levels were observed and 
may be due to content of the diet and/or availability of creatine to the tissue. Most 
notably, we indeed observed that levels of ATP, ADP and AMP were decreased 
significantly when compared to standard chow fed rabbit. These findings support 
studies demonstrating that excessive cholesterol intake is a risk factor for AD as 
well as genetic analyses that have shown reduced expression of many genes 
encoding ETC proteins. An alteration to the oxidative phosphorylation process 
does reduce the capacity of ATP production and will promote generation of 
reactive oxygen species that in turn will further hinder function of the ETC. This 
process may hold true in cholesterol fed rabbit as a model for AD however we did 
not perform studies to measure ETC protein levels and mitochondrial reactive 
oxygen species production. Further studies examining these critical factors that 
strongly influence cellular energy production are necessary to determine if 
decreased levels of adenine nucleotides are responsible for the pathology 
observed in this model system. As well, performing these studies in young 
animals, before AD pathology manifestation, may provide information as to 
whether diminished cerebral energy metabolism precedes AD pathology or if 
changes to energy levels are merely a consequence of the disease.
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Upon examination of adenylate energy charge one can readily appreciate 
the vast energetic difference between traditionally sacrificed and head-focused 
microwave-irradiated animals. The energetic charge values for these particular 
experiments were incredibly low and are caused by a rapid post-mortem 
dephosphorylation of adenine nucleotides when brain enzymes are not snap- 
inactivated. However, these diminished levels are present in both treatment and 
control groups and therefore allow comparisons between groups. A worthy 
experiment would be to kill these animals with head-focused microwave 
irradiation to better determine adenine nucleotide levels. There are no accurate 
brain energy metabolite measurements in the literature for normal or cholesterol- 
fed rabbits to date. The major obstacle for this specific study is to acquire 
appropriate modifications to a microwave irradiation unit so that it can house an 
animal as large as a rabbit; to date, the largest commercially available microwave 
arms can only hold a two pound animal.
Adenine nucleotides were decreased significantly and therefore we 
hypothesize that cortical adenosine levels will be increased in these animals. 
From these rabbits, we did not perform adenosine measurements as the total 
amount of tissue available for this study was limited. In chronic 
neurodegenerative disorders, such as AD, the density of adenosine h i receptors 
(A-iR) is reduced (Decked et al., 1998; Angulo et al., 2003; Ulas et al., 1993) and 
this is likely due to receptor internalization following constant high-level 
stimulation. Likewise, several studies have shown that short periods of brain 
ischemia, which also trigger a robust increase in the extracellular levels of
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adenosine (Kobayashi & Millhorn, 1999), produce a long-lasting decrease in the 
density of AiRs in several brain regions (Nagasawa et al., 1994).
A potentially modifiable vascular risk factor for AD is hypercholesterolemia 
and dietary fat intake (Sjogren et al., 2006). Hypercholesterolemia is a precursor 
to atherosclerosis, cardiovascular disease and diabetes and lofty serum 
cholesterol levels have created a major market for lipid-lowering drugs prescribed 
to persons at risk of cardiovascular or cerebrovascular conditions. One of these 
classes of drugs that lower cholesterol levels, statins, have been suggested as 
useful in both prevention and treatment of AD (Wolozin et al., 2000; Zandi et al., 
2005). The mechanism by which statins may provide a benefit against 
cerebrovascular disease including AD remains speculative and is likely 
multifactorial.
ADSL Transgenic Mice as a Model for Autism
A mere 30 years ago, there was an overall lack of any biological 
understanding of autism spectrum disorders; we now know that defined 
mutations and genetic syndromes account for approximately 10-20% of cases. 
However, no single identified cause accounts for greater than 1-2% of cases. A 
genetic mutation that fits this criterion is adenylosuccinate lyase (ADSL) 
deficiency. ADSL deficiency is a defect in purine metabolism and causes severe 
neurological and physiological symptoms. The deficiency was first described in 
1984 as three patients with severe psychomotor delay and features of autism 
were found to have elevated levels of succinylpurines in their cerebrospinal fluid,
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plasma and urine; specifically adenylosuccinate and SAICAR (Jaeken & Van den 
Berghe, 1984).
We examined the effects of specific mutations to the ADSL gene in mice 
on brain energy levels from either cortex or cerebellum in collaboration with Dr. 
David Patterson’s group at the University of Denver, Eleanor Roosevelt Institute. 
The majority of genetically modified animals from discrete founder mice did not 
demonstrate significant differences from wildtype mice on measurements of 
phosphocreatine, creatine, adenine nucleotides, energetic ratios, SAICAR, and 
adenylosuccinate. However some of these groups did have alterations to 
energetic systems in these brain regions. Of the eight transgenic groups, only 
half of these groups showed significant differences on any of our biochemical 
measurements; D87E_M347, ADSL_P9383, ADSL_P9365, and R426H_M1036. 
There may have been important differences between some of the groups that we 
did not observe any change from wildtype control, as our sample sizes were too 
small to properly evaluate statistically in our preliminary experiments. These 
groups from our preliminary studies, with sample sizes less than three, had to be 
“forced” to ignore statistical assumptions in order to generate a p value that may 
or may not represent proper analyses for these groups. The reason for our small 
sample sizes is that ADSL animals are difficult to generate and we only had 
access to limited numbers of these animals as they are not available 
commercially. Luckily, our second set of received animals had a larger sample 
size thus allowing for proper statistical analyses to be performed. In addition, 
three of the five preliminary groups were present with proper sample size in
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these experiments and represented the only groups where differences were 
noted in the preliminary studies.
From our preliminary experiments on the ADSL deficient D87E M347 
group, we observed levels of phosphocreatine and creatine that were decreased 
significantly from control animals though we did not see any significant changes 
to these levels in our second set of animals. This may be an example where an 
incorrect usage of statistics generated a significant result that may not hold true 
with proper sample size.
The other ADSL deficient group that showed significant differences from 
preliminary studies was ADSL_P9383; we observed that levels of 
phosphocreatine, ATP, ADP, SAICAR were decreased significantly as well as the 
ratios of ATP/ADP and adenylate energy charge. Findings from the second set of 
ADSL_P9383 animals agree well with the preliminary studies in that we found 
levels of phosphocreatine, ATP, ADP and the ratio of ATP/ADP to be decreased 
significantly from wildtype control mice. Thus, these data provide an example of 
diminished high-energy brain metabolites as a result of ADSL deficiency 
presumably due to a reduced flux through the purine biosynthetic pathway. 
Typically, tissues that are deficient for ADSL maintain normal concentrations of 
adenine nucleotides and have elevated levels of SAICAR and adenylosuccinate 
(Van Den Bergh, 1993a) and our data do not support findings in humans. One 
potential trouble with mouse models to study purine metabolism is that the purine 
pathway is dissimilar in mice and humans. Humans are missing the enzyme 
uricase (Becker & Roessler, 1995), hence the end product of purine metabolism
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in humans is urate. Accumulation of urate in human provides a significant 
antioxidant capacity in human plasma and thus help to protect against oxidative 
stress (Rosell et al., 1999). It is possible that this difference in the purinergic 
pathways between species accounts for our discrepant findings. These data also 
suggest that SAICAR levels are decreased significantly in these ADSL deficient 
mice however this, as well as all other SAICAR measurements, should be 
interpreted with caution.
Normally, SAICAR is extremely difficult to measure in normal brain as its 
levels are very low. We measured what we believe to be SAICAR via HPLC, 
based on retention times and sample spiking. During our measurements we 
collected HPLC fractions that were to contain our compound of interest and 
performed mass spectrometry on half of the collected samples to verify that 
indeed the compound was SAICAR, the remaining samples were lyophilized and 
then analyzed by Dr. Erin Spiegel via Elratton-Marshall assay. All verification 
experiments were unable to conclusively demonstrate that the HPLC peak was 
SAICAR and not a separate compound with an identical retention time. Assuming 
that our HPLC analyses were correct, we did not expect levels of SAICAR to be 
lowered significantly in ADSL deficient animals but taken together with 
diminished adenine nucleotides and phosphocreatine levels it appears that this 
specific ADSL mutation leads to an overall repression of the purine synthetic 
pathway. Early work performed by our collaborator, Dr. Patterson, found that 
intermediate levels of AICAR lead to retrograde flux through the pathway and 
accumulation of SAICAR (Sabina et al., 1985). Higher levels of AICAR result in
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the pyrophosphorylation of AICAR at the expense of
phosphoribosylpyrophosphate (PRPP) and a reduction of flux through the de 
novo pathway (Sabina et al., 1985).
The group R426H_M1036 is also ADSL deficient due to swapping arginine 
at position 426 to histidine. These mice displayed multiple energetic alterations 
when compared to wildtype mice. Levels of ATP and ADP, as well as these 
animals’ adenylate energy charge were increased significantly in R426H_M1036 
mice whereas the levels of AMP were decreased significantly in ADSL deficient 
mice. As well, adenylosuccinate levels were reduced significantly as well. These 
findings were surprising to observe in mice with the R426H mutation as this 
specific mutation has been commonly reported to cause moderate to severe 
autism in humans (see Table 5 in the Appendices). Typically, tissues that are 
deficient for ADSL maintain normal concentrations of adenine nucleotides and 
have elevated levels of SAICAR and adenylosuccinate (Van Den Bergh, 1993a); 
however we did not observe any of the expected levels. A lack of another purine 
could lead to the phenotype of ADSL deficiency apart from the compounds we 
measured. For example inosine, a nucleoside that can stimulate extensive axon 
outgrowth in goldfish and rats (Benowitz et al., 1999; Benowitz et al., 1998; 
Petrausch et al., 2000) or one of its metabolites may be altered. It is possible that 
exchanging an arginine for a histidine residue at position 426 does not produce 
the same phenotype in rodents as it does in human or it may be that this 
modification has important developmental consequences that are undetectable 
with energetic measurements by adulthood as homeostatic mechanisms may
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have corrected adenine nucleotide, SAICAR, and adenylosuccinate levels to 
normal. Performing these energetic measurements on very young or embryonic 
mice may provide insight for whether our observed levels hold true during 
development or if there are critical developmental events that transiently occur.
Cerebral tissues from ail other ADSL deficient groups did not demonstrate 
alterations to adenine nucleotide, SAICAR and adenylosuccinate levels. These 
data supporting the null hypothesis for adenine nucleotides are in agreement with 
human ADSL deficiency studies (Van den Bergh, 1993a, Van den Berghe et al., 
1993a, Van den Berghe et al., 1993b). Experiments on cultured fibroblasts from 
ADSL deficient patients demonstrated that the rate of de novo purine synthesis 
and nucleotide concentrations is not significantly different from individuals without 
the deficiency and that flux through the two ADSL catalyzed steps still occurs in 
these cells (Van den Berghe et al., 1993a; Van den Berghe et al., 1993b). 
Furthermore, these fibroblasts displayed standard growth rates and levels of ATP 
in the presence of purine bases (Van den Bergh et al., 1993a). Mammalian cells 
can synthesize purines via the adenine salvage pathway when cultured in the 
company of purine bases and this is adequate to sustain synthesis of adenine 
nucleotides in fibroblasts (Van den Bergh et al., 1993b). Normal physiological 
levels of adenine nucleotides were observed in liver, kidney, and muscle of ADSL 
deficient patients (Van den Berghe & Jaeken, 1986). One explanation is that the 
ADSL deficiency is overcome in these tissues by a contribution of purines from 
non-affected cells (e.g. erythrocytes, granulocytes) through purine salvage 
enzymes (Van den Berghe et al., 1997). Taken together these studies indicate
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that ADSL deficiency causes negligible changes in specific tissues when 
unaffected cell-types are capable of contributing purines.
Ts65Dn and GART Transgenic Mice as Models for Down Syndrome
Down syndrome (DS), or trisomy 21, is the most common genetic basis of 
considerable intellectual disability that occurs in approximately one in 733 live 
births (Centers for Disease Control and Prevention, 2006) with complete trisomy 
of the chromosome in roughly 95% of cases. DS can also be caused by partial 
trisomy of chromosome 21 (HSA21) but this occurs less frequently. Increases to 
levels of enzymes, resulting from trisomy, are of particular interest in the de novo 
purine metabolic pathway. There are many mitochondrial metabolism genes 
located on HSA21 and of these genes a large proportion are trisomic in the 
Ts65Dn mouse. With resultant increases to metabolic enzymes, it is extremely 
difficult to predict how these changes will ultimately affect energy and 
mitochondrial reactive oxygen species production. These mitochondrial protein 
alterations could lead to two possible outcomes; increased ETC proteins could 
facilitate either increased or decreased energy production. We hypothesize the 
latter outcome to be more probable since evolutionary processes have likely 
selected for the most advantageous arrangement and levels of metabolic 
proteins. Any change to the mitochondria’s homeostatic environment could 
potentially offset the proton gradient, generation and control of reactive oxygen 
species, and ultimately energy production. For example, even though metabolism 
genes are elevated in the Ts65Dn mouse, adenine nucleotide levels are 
decreased. We observed diminished levels of ATP, ADP along with the ratio of
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ATP/ADP and adenylate energy charge in mice either three or six months of age. 
We also observed that phosphocreatine levels decreased significantly. These 
results taken together suggest that trisomy of mitochondrial metabolism genes on 
chromosome 21 is sufficient to decrease brain energy.
A second model system used in our experiments was the GART 
transgenic mouse that expressed a GART gene that solely fabricates the GARS- 
AIRS-GART protein but not the single GARS protein. Since the purine pathway 
differs in humans and mice it is difficult to predict whether increases to an 
enzyme responsible for catalyzing three steps in the biosynthetic pathway would 
increase, decrease, or not affect energy levels. This model system is less 
complex than the Ts65Dn model as only a single gene was modified and 
therefore there are fewer modifications to the de novo purine biosynthetic 
pathway. We hypothesized that increasing GART would lead to a greater flux 
through the purine pathway; however it is possible that endproduct inhibition 
could restrain the pathway. In our experiments on these transgenic mice from 
two separate founders we observed an increase to high energy adenine 
nucleotides such as ATP and ADP, as well as elevations to the ratio of ATP/ADP 
and adenylate energy charge meanwhile we observed diminished levels of AMP 
and adenosine in these animals. Taken together it appears as though expression 
of human GART in mice results in increased energy levels without endproduct 
inhibition. From these studies it is impossible to determine if overexpression of 
mouse GART will cause these same effects and if it does cause the same effect 
why the effect is not observed in Ts65Dn mice. One explanation for why trisomy
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of GART does not increase energy levels in mouse is that factors decreasing 
energy outweigh the effects of GART alone.
In addition to our metabolite measurements in three and six month old 
animals we also examined old mice, between the ages of 12 and 18 months. In 
agreeance with increases to the cerebral metabolic rate of glucose data 
commonly reported in the literature, we found that levels of ATP were elevated 
significantly in Ts65Dn mice compared to wildtype controls. Furthermore, when 
comparing across age groupings of our trisomic mice we found that levels of 
phosphocreatine and ATP as well as the ratio of ATP/ADP and adenylate energy 
charge were increased significantly in old animals. These data suggest that the 
cerebral brain energy increases in our model system for DS with age and could 
potentially indicate a compensatory response in these mice prior to the 
progression of AD pathology. However, compensatory responses may eventually 
become pathological or unsuccessful to offset progressive degeneration 
(Mesulam, 1999). Prior to energy metabolite measurements, behavioral tests 
should be performed on these animals to determine whether or not these mice 
have developed AD and this will determine if increased energy levels is truly a 
compensatory response to dementia in this model system. Attaining a better 
understanding for the relationship between energy levels and dementia may 
provide insight for alternative therapeutic approaches to impede AD onset.
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Treatment of Rat Cerebral Cortical Neurons with HIV-1 Protein Tat as a Model for
HIV-1 Dementia
The advent of effective highly active anti-retroviral therapeutics has 
resulted in increased longevity of HIV-1 infected individuals, and an increased 
prevalence of HIV-1 associated dementia (Bouwman et al., 1998). This increased 
prevalence has renewed efforts not only to determine mechanisms underlying 
this neurological disorder that is the most common cause of dementia in people 
less than 60 years of age, but also to identify effective therapeutic strategies. 
Implicated in the neuropathogenesis of HIV-1 associated dementia is the non- 
structural protein Tat (Sabatier et al., 1991; Nath & Geiger, 1998; Perry et al., 
2005). Our study was focused to determine the extent to which HIV-1 protein Tat- 
induced neurotoxicity involved mitochondrial bioenergetic crisis and/or redox 
catastrophe, as well as the extent to which and the mechanisms by which 
creatine protected against this neurotoxicity. The major findings of the present 
study are that creatine protected against HIV-1 Tat-induced neuronal cell death 
through mitochondrial mechanisms including blocking decreases in ATP levels, 
depolarization of mitochondrial membrane potentials, and mitochondrial 
permeability pore opening. These findings are important because it provides 
further evidence for the involvement of mitochondria in HIV-1 Tat-induced 
neuronal cell death and identifies creatine as a potential therapeutic intervention. 
HIV-1 Tat of shorter and longer sequences including amino acids 31-61, 1-72 
and 1-86 are neuroexcitatory and neurotoxic (Chauhan et al., 2003; Kruman et 
al., 1998; Bonavia et al., 2001; Bonavia et al., 2001; Nath et al., 1996;
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New et al., 1997; Shi et al., 1998). Tat depolarizes and kills neurons by activating 
cell surface NMDA and non-NMDA glutamate receptors (Chandra et al., 2005; 
Cheng et al., 1998; Haughey et al., 2001; Magnuson et al., 1995; Self et al.,
2003; Song et al., 2003; Song et al., 2003). Tat-induced excitotoxicity may be 
further enhanced because Tat has been shown to decrease glutamate uptake in 
astrocytes (Zhou et al., 2004) and this may increase further activation of 
glutamate receptors on nearby neurons. Intracellularly, endoplasmic reticulum 
and mitochondria both contribute to Tat-induced neurotoxicity even though, for 
example, Tati.72 is internalized by cells to only a limited extent (Ma & Nath,
1997). Increased levels of intracellular calcium through activation of excitatory 
amino acid receptors and IP3-regulated stores of endoplasmic reticulum calcium 
clearly contribute to Tat-induced neurotoxicity (Haughey et al., 1999; Mayne et 
al., 2000; Haughey et al., 2001; Self et al., 2003; Fotheringham et al., 2004). 
Mitochondrial dysfunction has also been shown to be involved in Tat-induced 
neuronal cell death, and the implicated mechanisms include alterations in 
bioenergetics (Perry et al., 2005), mitochondrial membrane potential (Perry et al., 
2005; Aksenov et al., 2006), reactive oxygen species (Perry et al., 2005;
Aksenov et al., 2006; Wallace et al., 2006), mitochondrial permeability transition 
pore opening (Kruman et al., 1998), and caspase activation (Kruman et al., 1998; 
Singh et al., 2005). Moreover, the neurotoxic properties of Tat are exaggerated 
by glutamate and drugs of abuse (Haughey et al., 2001; Aksenov et al., 2006). 
Our findings that exogenous Tat treatment resulted in mitochondrial dysfunction 
through hypopolarization of mitochondrial membrane potential, production of
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reactive oxygen species, opening of the mitochondrial permeability transition 
pores and decreasing cellular bioenergetics help elucidate further the 
mechanisms by which Tat causes neurotoxicity.
Tati-72 with amino acids 31 to 61 deleted (mutant Tati.72), is not neurotoxic 
when applied directly to neurons or to hippocampal slices and consequently has 
been used by others and us as a control peptide for the actions of Tat (Gurwell et 
al., 2001; Prendergast et al., 2002; Self et al., 2004). However, recent results of 
others and us indicate that mutant Tati-72 is biologically active; it can increase 
cytokine and chemokine expression (Flora et al., 2003; Pu et al., 2003; Toborek 
et al., 2003). Indeed, we showed recently that Tati.72 and to a greater extent 
mutant Tati-72 increased the release of TNF-a from monocytes, macrophages 
and microglia, and that media from Tat-stimulated monocytes caused 
neurotoxicity that was TNF-a mediated (Buscemi et al., 2007). Therefore, while 
mutant Tati.72 was without effect in most of the current studies reported here, it 
was not totally surprising when we observed increased levels of reactive oxygen 
species following treatment of neurons with mutant Tati-72-
Tat has been shown to induce mitochondrial permeability transition pore 
opening in lymphoid cells (Macho et al., 1999) and cyclosporine A, a known 
inhibitor of mitochondrial permeability transition pore opening, inhibits Tat- 
induced neuronal apoptosis (Kruman et al., 1998). Here, we showed directly that 
Tati-72 opened mitochondrial permeability transition pores in neurons. Opening of 
the mitochondrial permeability transition pore results in rapid decreases in proton 
gradients across the inner mitochondrial membrane and this may explain
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reductions in mitochondrial membrane potential and cellular levels of ATP; all of 
which may result in the release of pro-apoptotic factors such as cytochrome c, 
apoptosis inducing factor, and caspases (Zoratti & Szabo, 1995). Creatine was 
shown in the current study to block mitochondrial permeability transition pore 
opening and neurotoxicity and further studies are warranted to determine the 
extent to which creatine prevents the release of implicated pro-apoptotic factors. 
The present data and results from other studies have shown that Tat increases 
oxidative stress in neurons (Kruman et al., 1998; Langford et al., 2004; Perry et 
al., 2005). Moreover, oxidative stress has been demonstrated in the brain and 
CSF of patients with HIV-1 associated dementia (Chauhan et al., 2003; Turchan 
et al., 2003). However, although creatine can act as a direct antioxidant by 
quenching superoxide anions, hydrogen peroxide, and peroxynitrite (Lawler et 
al., 2002), here creatine did not protect against Tat-induced increases in reactive 
oxygen species. With the caveat that protection may have been observed under 
different conditions, creatine neuroprotection did not appear to be due to the 
antioxidant actions of creatine.
In this study, Tat decreased significantly levels of intracellular ATP. These 
decreases may have been due to the hypopolarization of mitochondrial 
membrane potentials observed, loss of proton gradients across mitochondrial 
membranes, reduced ATP synthase activity, and subsequent depletion of 
intracellular levels of ATP. However, the inability of Tat to induce changes in 
either the adenylate energy charge or ATP/ADP ratio is indicative of only mild 
effects of Tat on cellular bioenergetics as they relate to adenosine nucleotides
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and suggest that the role of the creatine/creatine phosphate system as a high- 
energy phosphate donor could only play a minor role in the neuroprotective 
properties of creatine in this model.
The most robust neuroprotective mechanisms through which creatine 
appears to function in our model was through stabilization of mitochondrial 
membrane potential and keeping closed permeability transition pores. In this 
manner, creatine would prevent the redox catastrophe and resulting 
neurotoxicity. The readily available dietary supplement creatine might prove 
useful in preventing or lessening the severity of HIV-1 associated dementia.
Ketogenic Diet as a Treatment for Epilepsy 
The molecular mechanisms underlying regulation of energy metabolism in 
the brain are not as well defined as those described for muscle. Indeed, chronic 
ketosis with caloric restriction appears to affect metabolism quite differently in 
skeletal muscle and brain. In muscle, ketonemia and/or fasting is accompanied 
by down-regulation of oxidative phosphorylation, fewer mitochondria, less 
efficient mitochondrial respiration, and a fall in glutamate and glutamine levels 
(Hammarqvist et al., 2005; lossa et al., 2003; Lecker et al., 2004; Sparks et al., 
2005). By comparison, in the hippocampus chronic ketosis with caloric restriction 
results in upregulation of transcripts encoding oxidative phosphorylation and 
other mitochondrial proteins, mitochondrial biogenesis, elevated phosphocreatine 
to creatine ratio, and elevated glutamate and glutamine levels. Some of the 
energy transcripts were reported in a previous microarray study of KD (Noh et al., 
2004), but their use of only one sample each in KD and control groups makes
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interpretation difficult. In muscle PGC1a, y and A are powerful regulators of 
mitochondrial biogenesis and are downregulated during high fat diets (Mootha et 
al., 2003; Sparks et al., 2005). However, transcript levels for these proteins in 
both control and KD rats were below detection level in whole hippocampus and 
also in dentate granule cells, CA1 and CA3 pyramidal cells harvested by laser 
capture microscopy (Borges et al., 2007). Our results suggest significant 
differences in how brain and muscle respond to high fat diets.
The ketogenic diet (KD) is a high-fat, calorie-restricted diet used to treat 
childhood epilepsies that do not respond to available drugs. Despite its clinical 
use for nearly 100 years, how the KD controls seizures remains unknown. 
Transcriptional profiling of rat hippocampus after KD showed a concerted 
upregulation of numerous transcripts encoding energy metabolism proteins and 
mitochondrial proteins. The most striking finding of this study was a 46% 
increase in the density of mitochondrial profiles in the dentate gyrus of KD-fed 
rats, most of which were in neuronal processes. The increased phosphocreatine 
to creatine ratio and increased level of amino acid alternative energy sources, 
together with the improved resistance to low glucose, are consistent with an 
increased capacity to sustain ATP production in hippocampus in the face of 
increased physiological need. These findings collectively point to an enhanced 
energy production capacity in the hippocampus of rats fed a ketogenic diet.
Limitations
We studied the effects of a KD on the hippocampus of non-epileptic, 
adolescent rats, whereas this dietary treatment is often used in children with
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epilepsy originating outside the hippocampus. The validity of this model should 
therefore be carefully considered, and several points are relevant. First, the KD is 
effective in a variety of epilepsies including temporal lobe epilepsy (TLE), which 
involves the hippocampus (Freeman et al., 1998). Second, the rat model faithfully 
reproduces at least four key aspects of KD treatment observed clinically -  
maintained ketonemia, maintained hypoglycemia, reduced weight gain, and 
increased resistance to seizures. Third, hippocampal sclerosis may coexist with 
non-temporal focal epilepsy (Pan et al. 2004) or cortical dysplasia, a more 
common cause of childhood epilepsy (Bocti et al., 2003). Moreover, Lundberg et 
al. (1999) reported a high frequency of hippocampal asymmetry or sclerosis in 
benign childhood epilepsy with centrotemporal spikes, a common cause of 
childhood epilepsy. Therefore, although not involved in all childhood epilepsies, 
the hippocampus is a relevant structure. Finally, previous in vivo 
electrophysiological studies showed a robust anticonvulsant effect of the KD 
within the DG of the hippocampus in a rat model (Bough et al., 2003). KD-fed 
(and calorie-restricted) animals required greater stimulus intensities to evoke the 
same network excitability as compared to ad lib-fed controls. Enhanced paired- 
pulse inhibition was observed, consistent with enhanced functional, fast 
GABAergic inhibition, and electrographic seizure threshold was elevated in a 
kindling-like protocol. Thus, we decided to focus on a well-defined region of the 
brain, known to exhibit these KD-induced effects, and known to be importantly 
involved in the development and maintenance of epileptic phenotypes.
We and others (Appleton & DeVivo, 1974) found that an elevation in
152
roduced with permission of the copyright owner. Further reproduction prohibited without permission.
seizure threshold required two weeks or more of the KD to fully develop in rats; 
this effect waned slowly upon reversion to a high carbohydrate diet. By contrast, 
Freeman and Vining (1999) reported that in five children with Lennox-Gastaut 
syndrome who were experiencing more than 20 myoclonic or atonic seizures per 
day, seizure frequency was drastically reduced one or two days after initiation of 
the KD. Aside from this report there are only anecdotal comments about how 
rapidly the KD becomes effective in epileptic patients, although typical practice is 
to assess efficacy after several weeks on the diet. The speed with which the 
anticonvulsant effect of the KD develops might well depend on age, physiological 
status, and how the effect is measured (seizure threshold vs. seizure frequency) 
The Affymetrix GeneChip has been the most popular microarray 
platform, yet over the past few years there has been a growing gulf between the 
historical assignment by Affymetrix of oligonucleotide sequences to genes, and 
modern assignments. Dai et al. (2005) resolved this problem by reassigning 
sequences to transcripts based on the most up-to-date Unigene build. These 
assignments significantly simplify analysis of microarray experiments as 
described in Methods, and Results. Several reviews have highlighted issues of 
particular importance to microarray studies of the brain (Cao & Dulac, 2001; Luo 
& Geschwind, 2001; Mimics & Pevsner, 2004). Chief among these are cellular 
heterogeneity within a brain region, low expression levels of many transcripts in 
neurons, and the short supply of neuron-specific genes on most cDNA 
microarrays. Beyond the technical challenges of identifying differentially 
expressed low abundance genes in identified neurons that are relevant to
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epilepsy, a number of interpretational pitfalls must be recognized. Microarrays 
report the relative expression of mRNAs and thus have the major limitation of not 
directly measuring protein levels themselves. Moreover, post-translational 
processing that alters protein function is hidden from microarray studies. 
Experience has shown that even subtle alterations in a cell’s environment can 
change gene expression, so model-specific effects are also expected. The 
consequence of these limitations is that, from the standpoint of changes in 
protein function, both false positive and especially false negative signals are 
expected to be common in microarray studies of RNA expression. Experimental 
designs must include strategies (e.g., replication, follow-up confirmation of 
signals) to minimize the impact of these deficiencies.
An Energy Preservation Hypothesis for the Anticonvulsant Effect of the KD 
Several mechanisms for the anticonvulsant action of the KD have been 
proposed, including acidosis, enhanced GABA production, change in electrolyte 
balance or energy metabolism, activation by free-fatty acids (FFAs) of potassium 
or other channels, or dehydration (Schwartzkroin, 1999). One of the oldest 
theories stems from the idea that an increased production of ATP should 
enhance neuronal stability by stabilizing the resting membrane potential, perhaps 
via enhanced operation of the Na+/K+ ATPase (DeVivo et al., 1978).
Taken together, our findings suggest a modification of the energetic 
hypothesis for the anticonvulsant effect of the ketogenic diet (Figure 64, * 
denotes findings in the present study). We propose that chronic but not acute 
ketosis activates a genetic program that leads to mitochondrial biogenesis in the
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hippocampus, which results in enhanced energy stores. The half-life of liver 
mitochondria is three to four days (Lipsky & Pedersen, 1981). If that of brain 
mitochondria were similar, five half-lives (15-20 days) would be approximately 
the time required to achieve an anticonvulsant action of the KD, consistent with 
the model presented in Figure 64. We suggest that mitochondrial biogenesis 
increases ATP production capacity, with excess high-energy phosphates stored 
as phosphocreatine. Glutamate and glutamine formed from the ketone-boosted 
TCA cycle provide an important second energy store that, in concert with 
phosphocreatine, can be drawn upon to sustain ATP levels in times of need (i.e., 
during hyperexcitability leading to a seizure). The ability to sustain ATP levels 
during metabolic or physiological stress should allow neurons to fuel Na+/K+ 
ATPase and other transporters that stabilize membrane potential in neurons and 
thus maintain ionic homeostasis for longer periods of time. Under low glucose 
conditions, transmitter release from perforant path terminals could be maintained 
about 60% longer in hippocampal slices taken from KD compared to control-fed 
rats, a likely consequence of enhanced energy stores.
The enhanced resistance to metabolic stress could thus elevate seizure 
threshold, if seizure initiation results from a crescendo barrage of neuronal 
impulses that eventually causes ATP levels to decline, leading to sustained 
membrane depolarization and runaway neuronal firing. The Na+/K+ATPase 
inhibitor, ouabain, lowers seizure threshold to kainate (Brines et al., 1995), as 
expected if oxidative metabolism opposes seizure initiation. It is noteworthy that 
the KD increases seizure threshold, but cannot terminate a breakthrough seizure
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and may actually provide a greater energy supply that exacerbates spread of 
seizures once initiated (Bough et al., 2000b), consistent with our model. Although 
the degree of glutamate and phosphocreatine elevation is modest in KD-fed rat 
hippocampi, a similar elevation in PCr/Cr ratio has been observed previously in 
total brain after KD (DeVivo & Leckie, 1978). Both glutamate and 
phosphocreatine are present in approximately 10-fold higher concentrations than 
ATP, befitting their role as energy buffers. Thus, small absolute adjustments 
should be effective. Phosphocreatine opposes an acute activity-dependent fall in 
ATP levels by donating its phosphoryl group to ATP (Rango et al., 1997).
There is an established role for diminished ATP production capacity in both 
patients with epilepsy (Antozzi et al., 1995; Kunz et al., 2000) and pilocarpine- 
treated rats (Kudin et al., 2002). In a recent study of human epileptic tissue, the 
rate of recovery of the resting membrane potential following an evoked stimulus 
train was positively correlated with the PCr/ATP ratio, but inversely correlated 
with granule cell bursting (Williamson et al., 2005). It is interesting to speculate 
whether GABAergic inhibitory interneurons, which tend to have a greater 
energetic requirement to maintain high-frequency modes of firing (Atwell & 
Laughlin, 2001), are particularly advantaged by improved energy levels 
associated with the KD. Electrophysiological evidence collected in vivo showed 
that KD decreases hippocampal network excitability in part by enhancing 
GABAergic inhibition (Bough et al., 2003). Enhanced cellular metabolism might 
be expected to prolong activation of inhibitory interneurons, diminish network 
excitability, and thus improve seizure control. A critical test of this hypothesis will
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require the development of a method for selectively interrupting mitochondrial 
biogenesis in the brain.
Whereas glycogen was elevated in total brain (DeVivo & Leckie, 1978), 
we observed reduced levels of glycogen in hippocampus. It is doubtful, however, 
that reduced glycogen level plays a particularly important role in seizure 
resistance because hypoglycemia can rapidly reduce levels of brain glycogen 
(Choi et al., 2003; Garriga & Cusso, 1992), and KD-induced hypoglycemia 
occurred well before the anticonvulsant effect appeared. It is thus unlikely that 
glycogen, the largest energy store in brain, is regulating seizure threshold 
directly.
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Figure 64: Hypothesis for Anticonvulsant Effect of KD. Chronic ketosis in the 
brain is proposed to trigger mitochondrial biogenesis and associated induction of 
transcripts encoding proteins in the oxidative phosphorylation and tricarboxylic 
acid (TCA) pathways. Mitochondrial biogenesis increases ATP production 
capacity, but under resting conditions, excess ATP is converted to 
phosphocreatine, leading to increased phosphocreatine/creatine ratios. Ketones 
also serve as a substrate for glutamate synthesis via the TCA cycle, and some 
glutamate is reversibly converted to glutamine. Both glutamate and PCr act as 
energy buffers that can be drawn on to synthesize ATP when needed to fuel
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Na+/K+-ATPase and other pumps, which serve to stabilize neuronal membrane 
potential. The resulting enhanced resistance of hippocampal tissue to metabolic 
stresses accompanying hyperexcitability results in an elevated seizure threshold. 
Asterisks indicate results observed in this study.
Relevance to Childhood Epilepsies 
We studied the effects of a KD in the hippocampus of nonepileptic, 
adolescent rats. Because this dietary treatment is often used in children with 
epilepsy originating outside the hippocampus, the validity of this model should be 
considered carefully and several points are relevant. First, the KD is effective in 
adolescents and adults, if tolerated (Bough et al., 1999b; Sullivan et al., 2004). 
Second, the KD has efficacy in a variety of epilepsies including temporal lobe 
epilepsy, which involves the hippocampus. Third, the rat model faithfully 
reproduces at least four key aspects of KD treatment observed clinically; 
maintained ketonemia, maintained hypoglycemia, reduced weight gain, and 
increased resistance to seizures. Fourth, hippocampal sclerosis may coexist with 
nontemporal focal epilepsy (Yudkoff et al., 2005) or cortical dysplasia, a more 
common cause of childhood epilepsy (Bocti et al., 2003). Moreover, Lundberg 
and colleagues (Blumcke et al., 1999) reported a high frequency of hippocampal 
asymmetry or sclerosis in benign childhood epilepsy with centrotemporal spikes, 
a common cause of childhood epilepsy. Therefore, although not involved in all 
childhood epilepsies, the hippocampus is a relevant structure. Finally, previous in 
vivo electrophysiological studies showed a robust anticonvulsant effect of the KD 
within the dentate gyrus of the hippocampus in a rat model (Sparks et al., 2005). 
KD-fed (and calorie-restricted) animals required greater stimulus intensities to
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evoke the same network excitability compared with ad libitum-fed control 
animals. Enhanced paired-pulse inhibition was observed, consistent with 
enhanced functional fast GABAergic inhibition, and electrographic seizure 
threshold was elevated in a kindling-like protocol. For these reasons, we decided 
to focus on a well-defined region of the brain, known to exhibit these KD induced 
effects and known to be involved importantly in the development and 
maintenance of epileptic phenotypes. We and others (Appleton & DeVivo, 1974) 
found that an elevation in seizure threshold required two or more weeks of the 
KD to fully develop in rats; this effect waned slowly following reversion to control 
or even high carbohydrate diet (Appleton & DeVivo, 1974). By contrast, Freeman 
and colleagues (Prins et al., 2005) reported that in five children with Lennox- 
Gastaut syndrome who were experiencing more than 20 myoclonic or atonic 
seizures per day, seizure frequency was drastically reduced one or two days 
after initiation.
Implications for Neuroprotection
Mitochondrial dysfunction contributes to reperfusion injury, congestive 
heart disease, type 2 diabetes, and neurodegenerative disorders. Adaptive 
responses that induce mitochondrial biogenesis and enhance oxidative 
phosphorylation could therefore limit the progression of these disorders. The 
notion that mitochondrial biogenesis plays a role in neuronal survival in epilepsy 
is supported by the observation that surviving dentate hilar neurons in humans 
with epilepsy contain more mitochondria than normal (Blumcke et al., 1999). 
Several studies have shown that the KD can be neuroprotective. In mice treated
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with the KD for several weeks (Noh et al., 2003) reported that kainate-induced 
status epilepticus caused less hippocampal cell death and less caspase-3 
activation than control-fed mice. Whereas KD-fed mice exhibited a delay in 
seizure onset (increased seizure resistance), seizure severity was comparable to 
controls. In rats, the KD is neuroprotective in models of controlled cortical injury 
(Prins et al., 2005) or hypoglycemia (Yamada et al., 2005), but, unlike mice, not 
status epilepticus produced by either kainate (Muller-Schwarze et al., 1999) or 
lithium-pilocarpine (Zhao et al., 2004).
Proteasome inhibition leading to mitochondrial dysfunction appears to 
contribute to several neurodegenerative disorders (Jana et al., 2001; Sullivan et 
al., 2004). Mitochondrial biogenesis, a coordinate increase in 19 proteasome 
transcripts, increased production of the UCP2 uncoupling protein, reduced 
reactive oxygen species generation, enhanced respiration rate of isolated 
mitochondria (Andrews et al,. 2005; Sullivan et al., 2004), and enhanced 
alternative energy stores, all point to a myriad of potential neuroprotective 
mechanisms induced after KD. The enhanced ability to maintain energy levels 
was demonstrated by our biochemical analyses, we observed elevated 
phosphocreatine levels ATP levels, ATP/ADP ratio, adenylate energy charge 
should improve calcium homeostasis and limit synaptic dysfunction after 
metabolic challenges (Yamada et al., 2005). The strong trend towards higher 
ADP levels may additionally protect against seizure-induced neuron death by 
inhibiting opening of the mitochondrial transition pore (Gizatullina et al., 2005), 
and/or facilitating opening of K a t p  channels, which should reduce neuronal
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excitability (Babenko, 2005).
The purine, adenosine, was demonstrated to have a non-statistically 
significant trend toward increases levels following a KD in our preliminary studies 
however we subsequently observed that levels were increased significantly in KD 
fed rat (Figure 61). During epilepsy, adenosine kinase (ADK) is upregulated. For 
example, kainic acid-induced status epilepticus led to a significant increase in 
ADK activity and spontaneous seizures (Gouder et al., 2004). Pharmacoresistant 
seizures in this mouse model (Gouder et al., 2003) could be suppressed by 
application of the ADK inhibitor 5-iodotubercidin (3.1 mg/kg, i.p.). These results 
suggest that upregulation of ADK in epilepsy is implicated in epileptogenesis 
through a reduced adenosine tone at the AiR. ADK was also upregulated in 
kindled rats and in the rat pilocarpine model of epilepsy (Boison, 2008). 
Upregulation of ADK in epilepsy is paralleled by downregulation of A ^ s  (Rebola 
et al., 2003; Rebola et al., 2005).
Cellular energy charge is a primary consideration that defines the status of 
metabolism. The intracellular concentration of ATP is much greater than that of 
adenosine. Thus, minor alterations to the concentration of ATP will cause 
several-fold changes to the intracellular concentration of adenosine (Cunha, 
2001). In fact, there is a tight relation between the levels of adenosine and the 
energy charge as it is expected that adenosine levels are amended by injurious 
stimuli. As a result, stimuli varying from elevated neuronal firing to hypoxia or 
ischemia can cause extracellular levels of adenosine increases (Cunha, 2005). A 
study conducted by our collaborator Dr. Susan Masino found that exogenous
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application of adenosine to KD fed hippocampal tissue resulted in less inhibition 
to fEPSPs and this suggests that tonic adenosine levels are raised. Together 
with our biochemical analyses it is likely that these elevated levels of adenosine 
are providing a neuroprotective effect through the AtR.
We conclude that diet can dramatically affect neuronal function within 
hippocampus. In response to a high-fat, calorie-restricted diet, the hippocampus 
responds by inducing mitochondrial biogenesis, enhancing metabolic gene 
expression, and increasing energy reserves. We also observed increased energy 
reserves in other brain regions in seizure naive rat. Our findings support an 
energy preservation hypothesis for the anticonvulsant effects of the KD, which 
might be particularly important for GABAergic interneurons. Because the 
enhanced ability of neurons to manage metabolic challenges after KD likely 
improves neuronal survival as well as function under stressful conditions, the 
benefits of dietary therapies such as KD might also be extended to the treatment 
of other neurodegenerative disorders such as Alzheimer’s or Parkinson’s 
diseases.
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APPENDICES
Table 2: Dietary Constituents for Standard Rodent Chow (2018 Harlan-Teklad).
1 P rox im a te  A na lys is |  F a tty  A c id s 1
Crude Protein % 18.90 SATURATED
Crude Oil % e.oo C 4:0 Butyric 9*2 000
Dude Fiber % 3.30 C6.0 Caproic 0.00
Ash % 5.90 r 8 0 Caprylic 352. 000
NFE % "  “ 55'40 " C10:0Caprlc o m 0.00
Carbohydrate % 57 33 C12 0 laurlc 9*9 026
Starch % 41.24 C14:0 Myrt Stic 9*9 006
Sugar % 4.93 C15.0 Ptntadecanoc 9*9 000
Digestible Energy Krol/giM.i.kgS 3 4(14 03) CIO 0 Palmitic 9*9 7 .64
Metabofeatie Energy Kca!/q iMJ/kq)
....
C17 0Maro*r?c 9*9 0.00
C 18:0 Stearic (Wa 1.50
Am ino A cid s C20:0ArocbkHc 3 '2 i_
Aspartic Acid % 1 4i!












Tyrosine % 0 61
Phe + Tyr % 1.60
Methionine % 0.35
Cystine % 0.33
Met ♦  Cyst % 0.69
Lysine % 092
POLYUNSATURATED
C220 Behenic 9*9 003
C?4 0 Ugnoceric q/kQ 000
MONO-UN SAT URATE D
C16:1oj7 PofnstDfcfc a a a _____________ 007
C17:1 w8 Heptadecenoic __________ sits_____________ 000
C18.lw9 Oleic 8*9 12.59
C20 1«>S Gadoiek. 9*9 0.17
C22: 1uj9 EfUClC 9*9 0.01
C162o>6 Unoleic 9*9 31.35
C10.3<ii3 Linotenlc 9*9 2.76
C1fl’4co3 Octadecatetraenolc 9*9 0.00
C20:2oj6 Efcosadtertole 0.00
C20:3w6 D»homo-qaminn-Hnoienic 9*9 0.00
C20;4to6 Arochidonic g'*Q 0.00
C 20.50*3 Eicosopeutancic 9*9 0.00
C22 5co3 Ckipanodonic g/kg 0.00
C226to3 Docosahexaenolc 0*9 0.00
Arginine % 1.06
Tryptophan % 0.20 Vitamin A iu/cj 15.40
AvalaWe Lysine % 0.83 Retinol mg/kg 4.65
Vitamin D-. iu/q 1.54
, ' - CRoiecQtcSfsroi »9*3________ 38.39
Calcium T(?1 Vitamin E ia-tocopherof) mq/kq 101OO
Phosphorus % 065 Vitamin Kt  (menadione) mg/kg 51.00
Soowm % 023 Vitomm B-. (thiamine? mg'kg 16.50
Potassium % 0.68 Vitamin B; (riboflavin) mgrteg 14.00
Chloride % 0.40 Avail. Niacin (rvcotbiic acid) 9*3*9 41.20
Magnesium % 020 Vitamin 6* (pyndoxine) _____ E2*a________ 18.50
Zinc mg-kg 77 00 Pantothenic Acid mq/kg 33.00
Manganese mo*9 118 CO Vitamin B - (cyanocobalanrin) mg/kg 0.08
Cooper iTK̂ kg 15.21 Avail. Biotin mg/kg 0.30
iodine (added) 193*2. 11.55 Folate mg/ko 3.34
hon mg/kq 226.00 Vitamin C mq/kg 0.00
Selenium J53* 9 020 Choline mg/kg 1120.00
Cobalt nig/kg 063 B Carotene mg.'kg 2,47
Chromium rng/Kg 0.53 inositol n*J*q 1455.00
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Table 3: Dietary Constituents for Bio-Serv Ketogenic Diet (F3666 Bio-Serv).
PROXIMATE PROFILE < %) C ALORIC PROFILE (Kcal/gm
Protein 8,36 Carbohydrates 0.76 Protein 0334
Fat 78.80 Fiber 5.00 Fat 7.092
Ash 3.80 Moisture <5.00 Carbohydrate 0030
Total 7 456
AMINO ACID PROFILE (gm/kg)
Alanine 2.26 Lysine 5 94
Arginine 3.01 Methionine 0 43
Aspartic Acid 5.18 Phenylalanine 3,68
Cystine 0.25 Proline 8 19
Glutamic Acid 16.30 Serine 4 60
Glycine 2 .01 Threonine 3.60
Histidine 2.26 Tryptophan 1.25
Isoleuciue 4.43 Tyrosine 4.60
Leucine 669 Valine 5.28
CARBOHYDRATE PROFILE (gm/kg 1
Monosaccharides 7.60 Trisaccliarides 0
Disaccharides 0 Polysaccharides 0
FATTY ACID PROFILE (gm/kg)
C4  Butanoic 4.59 C is Palmitic 1S9.03
C6  Hexanoic 3.19 C l6 :l cis-9-Hesadecenoic 28,18
Cg Octanoic 2.99 t '1 7  Heptadecanoic 2.38
Cjo Decanoic 4.39 C1 7 3  Heptadecenoic 1.43
Cjo i Decenoic 0.80 Cig Stearic 84.79
Cj 2 Laurie 6.41 C1 8 .I Oleic 298.34
Ci2;l cis-9-Dodeeenoic 040 C is :2 Linoleic 319.44
Cj4  Myristic 24.43 Cig ;3 Linolenic 6.33
Ci4 ;i cis-9-Tetradecenoic 6.14 C? 0  Eicosanoic 1.18
C15 Peatadecanoic 0.48 C2 0 :1 cis-il-Eicoseuoic 380
MINERAL PROFILE 1 gm/kg)
Aluminum 0 0 0 Manganese (mg/kg) 70.00
Calcium 5.60 Pliosphorus 4.32
Clilorine 1 .68 Potassium 4.09
Copper (ma/kg) 6.51 Selenium (mg/kg) 0  12
Chromium (mg/kg) 3.85* Sodium 1 13
Iodine (tng/kg) 0 .22 * Sulfur 037
Iron (mg/kg) 40.00 Zinc (mg/kg) 30.00
Magnesium 0.55
VITAMIN PROFILE < mg/kg)
Ascorbic Acid - Pvndoxine 14.63
Biotin 0.42 Riboflavin 12 54
Cal. Pantothenate 40.00 Thiamine 12,54
Choline 0 .0 0 Vitamin A (IU/kg) 10450
Folic Acid 4.18 Vitamin D-. (IU/kg) 2090
Inositol Vitamin E (IU'/kg) 209
Menadione 2.09 Vitamin Br 0 .0 2
Niacin 60.00
164
■oduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 4: Ketogenic Diet affects Expression of Metabolism Genes




CB584892 Aga pr 0 34 Aspartylglucosaminidase
AA998065 Crmpl 0 35 Collapsin response mediator protein 1
J02657 Cyp2c -0.53 Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase)
AI045511 — 0 53 Dehydrogenase E1 and transketolase domain containing 1
AM 04245 Dhrsx_pr 0.41 Dehydrogenase/reductase (SDR family) X chromosome
AI411270 — 0.38 EPM2A (laforin) interacting protein 1
AA943554 Gstm3 0.25 Glutathione S-transferase. mu type 3
CB693436 Hamp -0.55 Hepcidin antimicrobial peptide
U06273 Ugt2b5 -0.74 Hypothetical gene supported by U06273; NM 031980
NM 017351 Itih3 0.65 Inter-alpha trypsin inhibitor, heavy chain 3
NM 053902 Kynu -0.58 Kynureninase (L-kynurenine hydrolase)
AF287268 Lepr -0.38 Leptin receptor
CB314275 Nagk_pr -0.36 N-acetylglucosamine kinase
AI175212 Neu2 -0.53 Neuraminidase 2
Al 170683 Oat 0.42 * Ornithine aminotransferase
A! 236089 Rbks_pr -0.41 Ribokinase
AA996886 — -0.32 Ribose 5-phosphate isomerase A
AI172579 — -0.46 Similar to cDNA sequence BC023151
CR458478 — -0.38 Transcribed locus
Metabolism - energy
XM 215897 Acas2l pr 0.39 * Acetyl-Coenzyme A synthetase 2 (AMP forming)-like
CK842246 Acypl pr 0.39 Acylphosphatase 1. erythrocyte (common) type
AI177136 Atpaf2_pr 0.66 * ATP synthase mitochondrial F1 complex assembly factor 2
CV118235 Atp5d 045 * ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit
CR754443 Atp5c1 0.40 * ATP synthase. H transporting, mitochondrial F1 complex, gamma 1
D13127 Atp5o 0.44 * ATP synthase, H4 transporting, mitochondrial F1 complex, O subunit
BQ780988 Atp6ap1 0 26 ATPase, H* transporting, lysosomal (vacuolar proton pump), subunit 1
BI278866 Atp6v0a1 0 27 ATPase, H transporting, lysosomal V0 subunit a isoform 1
CB781621 Atp6v0e2 0 24 ATPase, H4 transporting. V0 subunit E isoform 2
BI293306 Atp6v1c1 pr 0.55 * ATPase, H transporting, V1 subunit C, isoform 1
AA874909 Atp6v1e1 0.27 * ATPase, H transporting, V1 subunit E isoform 1
AI599960 Atp6v1f 0 21 * ATPase, H* transporting, V1 subunit F
CN540790 Pygb 0.19 Brain glycogen phosphorylase
M14400 Ckb 0.35 Creatine kinase, brain
AA892167 Cox6a1 0.31 * Cytochrome c oxidase, subunit Via, polypeptide 1
CV116832 Cyc1 pr 0.34 * Cytochrome c-1
AI102441 G6pdx 0.41 Glucose-6-phosphate dehydrogenase
AA892808 Idh3g 0.33 * Isocitrate dehydrogenase 3, gamma
AI229468 Mdh1 0 25 Malate dehydrogenase 1, NAD (soluble)
AI010480 Mori 032 * Malate dehydrogenase, mitochondrial
AI171476 Ndufa6 pr 0.22 * NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14)
CB725067 Ndufa8_pr 0.38 * NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8
CF976612 Ndufb9_pr 0 34 * NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9
CB781739 Pfkp 021 Phosphofructokinase, platelet
AI410824 RGD. 1303292 0.30 RE70703p-like
CF976253 RGD:1303259 0.25 * Similar to CG6105-PA (component of ATP synthase, F0 complex)
CR468174 LOC361596 0.27 Similar to NADP*-specific isocitrate dehydrogenase
CB327643 Slc25a4 0.23 * Solute carrier family 25 (mitochondrial adenine nucleotide translocator 4)
CA340524 Slc25a3 0.35 * Solute carrier family 25 (mitochondrial adenine nucleotide translocator 3)
AW922020 Sdha 0.34 * Succinate dehydrogenase complex, subunit A, flavoprotein (Fp)
BC059160 Sdhd 0.22 '  Succinate dehydrogenase complex, subunit D, membrane protein
0.26 * similar to NADH-ubiquinone oxidoreductase 18 kDa subunit
BC085339 RIS1 0.38 * Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
AM 75483 Ndufbl 1 0 43 * NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11
Metabolism - lipid
AA800237 Acadm -0.39 * Acetyl-Coenzyme A dehydrogenase, medium chain
BM390148 Acsl3 0.40 * Acyl-CoA synthetase long-chain family member 3
BF284062 — -047 Arylsulfatase A
Al 176264 Dei 0.46 • Dodecenoyl-coenzyme A delta isomerase
AA891699 Elovl5 -0 41 ELOVL family member 5, elongation of long chain fatty acids (yeast)
CB324831 Ech1 0.50 Enoyl coenzyme A hydratase 1. peroxisomal
CK840087 Gpam -0.41 * Glycerot-3-phosphate acyltransferase, mitochondrial
AM 02615 Hadhb 0.35 * Hydroxyacyl-Coenzyme A dehydrogenase (trifunctional protein), beta
AB048790 Ltc4s -0.53 Leukotriene C4 synthase
CK839714 Lrp10 pr -0.53 Low-density lipoprotein receptor-related protein 10
AF166100 Pla2g10 -0.54 Phospholipase A2, group X
AW253977 Bach 0.52 Similar to RIKEN cDNA 4122402022
AW921955 Scap pr 0.34 SREBP cleavage activating protein
AI102817 Sc4mol -0 32 Sterol-C4-methyl oxidase-like
AI412229 Hexb_pr 0.35 Transcribed locus
AM 02097 — -0 20 Transcribed locus
CN542598 Dgatl -0.28 Transcribed locus
Metabolism - protein
AW254234 — -0.41 Ariadne ubiquitin-conjugating enzyme E2 binding protein homolog 1
AI317864 Rnpep 0 19 Arginyl aminopeptidase (aminopeptidase B)
AA848349 — -0 55 Calpain 7
AA944580 Ctsb 028 Cathepsin B
L03201 Ctss 050 Cathepsin S
L07315 Dpepl -0.50 Dipeptidase 1 (renal)
AA891897 Dpp7 -0.19 Dipeptidylpeptidase 7
L19694 Gzmk -0.69 Granzyme K
BF409872 Phr1 pr 0.41 Pam, highwire, rpm 1
BM383854 Psmc5 0.44 Peptidase (prosome, macropain) 26S subunit, ATPase 5
AA893190 Pgcp -0.67 Plasma glutamate carboxypeptidase
D32249 Pja2 0.28 Praja 2, RING-H2 motif containing
BQ780887 Psmcl 0.40 Protease (prosome, macropain) 26S subunit, ATPase 1
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CB325790 Psme2 0.09 Protease (prosome, macropain) 28 subunit, beta
CR465648 Psmd7_pr 0.40 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 7
AA801204 Psma2 0.37 Proteasome (prosome, macropain) subunit, alpha type 2
BQ079060 Psma5 0.31 Proteasome (prosome, macropain) subunit, alpha type 5
CK840954 Psmbl 0.30 Proteasome (prosome, macropain) subunit, beta type 1
AI172162 Psmb4 0.36 Proteasome (prosome. macropain) subunit, beta type 4
BU759790 Rbaf600 0.44 Retinoblastoma-associated factor 600
CB324548 Rpn2 0.28 Ribophorin II
AI177765 Rnf146_pr 0.26 Ring finger protein 146
AI011368 — -0.52 Ring finger protein 44
CR469025 — 0.39 Ring finger protein 8
CF975601 Skp1 a 0.23 S-phase kinase-associated protein 1A
CR472274 Fbxo7_pr -0.28 strongly similar to XP_576203.1 F-box only protein 7
AI231460 — -0.28 Transcribed locus
BM391877 Prss15 0.24 Transcribed locus
CB612042 LtchU 0.46 Ubiquitin carboxy-terminal hydrolase L1
CB327486 — 0.34 Ubiquitin specific protease 24
AI412007 Usp5_pr 0.45 Ubiquitin specific protease 5 (isopeptidase T)
Al 177522 — 0.41 Ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast)
BC086980 Ube2g1 0.26 Ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C elegans)
CN542760 Vcp 0.32 Valosin-containing protein
CB557665 Pcsk2 0.52 WW domain binding protein 4
Functional categories of differentially expressed metabolism genes after KD. A 
complete list of altered genes is available in Supplementary Material in Bough et 
al., 2006 (http://www.mrw.interscience.wiley.com. ezproxy.und 
medlibrary.org/suppmat/0364-5134/suppmat/ana.20899.html).
* Denotes transcripts that encode mitochondrial proteins. “_pr” appended to 
symbols indicates a predicted sequence.
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Table 5: List of ADSL Mutations.
Base and amino acid numbers corresponding to full length nucleotide sequence 
of human ADSL cDNA deposited in the EMBL database under accession number 
X65867 by E.A. Fon. * Denotes siblings, ** Denotes splice site.
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Table 6: Genes on Chromosome 21 Important for Mitochondrial Metabolism
IjK'gg In Ts65Dn Mil ochondrial
1 ;7;. Mitochondrial ribosomal protein L39 V 7. t  Yes : , Yes V '
2 Mitochondrial coupling factor 6 (ATP synthase F0 subunit 6) Yes Yes
3 . \ Nuclear respiratory factor Yes No
4 APP Yes No
5 Bachl f y ' ; ' - ' '  V : Yes No
6 GART Yes No
7 SOD1 ' -'V T  v Yes No
8 NADPH quinine reductase-like Yes Yes
9 ATP synthase OSCP unit . : Yes Yes
10 Mitochondrial ribosomal protein S6 Yes Yes
11 Calcipressin T  . iv? :■ Yes No
12 Carbonyl reductase 1 (NADPH dependent oxidoreductase) Yes Yes
13 Carbonyl reductase 3 (NADPH dependent oxidoreductase) Yes : ■ Yes ■ 7  : :
14 Thioredoxin-like protein (SH3BGR) Yes No
15 Mitochondrial NADH oxidoreductase : No Yes
16 CBS No No
17 AMP protein kinase-like (SNF1LK) .No' A'
18 C21orf2 mitochondrial protein No Yes
All 18 genes listed are involved in mitochondrial metabolism and are located on 
chromosome 21 with all of these genes expressed in the mouse and the first 14 
trisomic in the Ts65Dn mouse (Akeson et al., 2001; Gardiner et al., 2002; Gitton 
et al., 2002; Reymond et al., 2002a; Reymond et al., 2002b).
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